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Abstract 
Background: Neuroinflammation is common to many neurodegenerative conditions and is 
principally mediated by microglia. Microglia maintain homeostasis, respond to 
trauma/infection and can promote repair. This is achieved by switching between surveillance 
(M0), pro-inflammatory (M1) and pro-repair (M2) phenotypes. However, inappropriate 
phenotype switching contributes to neurodegeneration, through failure to clear harmful 
substances or even direct tissue damage. How inappropriate switching occurs is not fully 
understood. Therefore, identifying a model for assessing phenotypic changes would provide 
a powerful tool to investigate the roles of microglia in disease, and develop therapies based 
on microglial immunomodulation. Nanoparticles (NPs) may be key to delivering 
immunomodulatory drugs to the brain, but it is unknown whether NPs will provoke 
inflammatory microglial responses.  
Methods: RT-qPCR was used to detect differences in gene expression for primary rat 
microglia, in response to various culture conditions and stimuli, including differently 
formulated NPs (e.g., PEGylated ‘stealth’ NPs and dextran ‘control’ NPs). 
Results: Three microglia reference genes were validated for qPCR (Gapdh, Usp14 and 
Rpl32). The presence of serum did not alter microglial activation state, compared to two 
commercially-available serum-free media. Cardinal M1 markers (Il-6, Il-1β and Tnf-α) were 
well-characterised in response to a wide range of lipopolysaccharide (LPS) concentrations, 
and at three different time points (2, 6 and 24 h). Unexpectedly, several pro-M2 stimuli (Il-
4, Il-13 and Tgf-β) failed to alter M2 markers, even with multiple changes to the protocols. 
Microglia exhibited uptake of several NP types without inflammatory responses.  
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Conclusions: An in vitro model of microglial switching has been refined and validated for 
M1 responses. Further refinement is necessary for study of M2 switching. The NP data 
suggest that NPs could be used without unintended inflammatory responses.  
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Chapter 1 : General introduction 
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1.1 Neurodegenerative disease: need to model and develop therapies 
A major societal and economic concern for the world is the increasing prevalence of 
neurodegenerative diseases (e.g. dementia) as shown in Figure 1-1 for Europe (Prince et al. 
2013). This represents a substantial burden for healthcare systems, estimated to cost $1 
trillion worldwide, requiring expensive long-term treatment and personal care (WHO & 
Alzheimer’s 2012). There are no cures, and current treatments are palliative and often needed 
until death (Alzheimer’s Association 2018). So, better treatments are required to ease these 
burdens and ideally cure/reverse these diseases.  
 
Figure 1-1: Prevalence of dementia in Europe. Adapted from Winblad et al. (2016) 
Neuroinflammation is a term used to describe inflammation in the central nervous 
system (CNS; brain and spinal cord). It may be triggered by pathological events such as 
infection, trauma or disease associated molecules: e.g., amyloid β (Aβ) or α-synuclein 
misfolding/aggregation. Similar to peripheral inflammation, neuroinflammation can be 
acute or chronic. Acute neuroinflammation (e.g., CNS injury/trauma) is defined by brain’s 
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immune cells response, production of inflammatory mediators (e.g., chemokines and 
cytokines) and phagocytic activity. Even though acute inflammation may lead to the 
production of destructive molecules, such as reactive oxygen and nitrogen species, this is 
usually short-lived and unlikely to damage healthy tissue (Buckley et al. 2001). Acute 
neuroinflammation is essential for minimising the adverse effects of injury and promoting 
recovery of the injured tissue. 
In contrast, chronic neuroinflammation can cause neural tissue damage, and is a 
major feature of traumatic brain injury (TBI) and neurodegenerative diseases, such as 
multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD). Acute 
inflammation should resolve itself through anti-inflammatory signalling, restoring 
homeostasis to the tissue (Medzhitov 2008). However, failure to resolve, results in chronic 
pro-inflammatory activation. The destructive features of this can ultimately damage healthy 
neural tissue, which causes more release of pro-inflammation cytokines, continuing a 
feedforward loop. As opposed to the acute neuroinflammation, chronic neuroinflammation 
can have harmful outcomes in the brain.  
Studies have provided a lot of evidences that chronic neuroinflammation has roles 
in the development and progression of many neurodegenerative diseases. For example, AD 
is usually associated with chronic neuroinflammation and increased levels of many pro-
inflammatory cytokines (Qiao et al. 2001). In AD, it has been suggested that 
neuroinflammation might be a crucial link between Aβ deposits, tau pathology and clinical 
symptoms (Boon et al. 2018). In another study, results from analysis of the cerebrospinal 
fluid (CSF) sample of patients with AD indicated a high level of inflammatory markers being 
strongly associated with Aβ-positive individuals (Janelidze et al. 2018) (discussed in section 
1.7.1). The inappropriate expression or overexpression of these pro-inflammatory cytokines 
can lead to neuronal dysfunction and death in neurodegenerative disease (Modi et al. 2010). 
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 Neuroinflammation in neurodegenerative diseases has been suggested to be 
mediated at least in part by the microglia, as evidence suggested an increased accumulation 
of these cells in neurodegenerative tissue (Ransohoff, 2016). Microglia have important roles 
in maintaining CNS homeostasis, however a change in activation state in neurodegeneration 
from proactive helpful to harmful state, might ultimately play a critical role in disease 
pathogenesis (Dorothée 2018). Therefore, microglia could provide an attractive therapeutic 
target for the treatment of neurodegenerative diseases. 
1.2 The role of microglia in brain homeostasis and proteopathy  
 Microglia are specialised form of immune cells in the CNS (Stollg & Jander 1999). 
In healthy tissue, microglia are similar to macrophages that scan their environment and 
engulf invading pathogen, therefore, microglia are considered the brain’s first line defence 
and are essential for its homeostasis (Hefendehl et al. 2014). The initial understanding of 
microglia came from macrophages. Therefore, a growing body of evidence suggests that like 
macrophages, microglia can be activated to adopt different states/phenotypes depending on 
challenging stimuli (Carson et al. 2007; Hanisch & Kettenmann 2007; Colton 2009; Varnum 
& Ikezu 2012; Tang & Le 2015). Macrophages are activated in response to microbial 
infection or innate danger signals by producing toxic substances (e.g., nitric oxide, NO), this 
activation state typically called M1 (mirroring T-helper cell 1, Th1) (Italiani & Boraschi 
2014). The M1 activation state is typically followed by the repair state, typically called M2 
(mirroring T-helper cell 2, Th2) (Mantovani et al. 2004). The repair action could be 
explained by arginine/NO pathway since this pathway would decrease the amount of 
arginine available for NO synthesis and the pathway itself produces ornithine which feeds 
into the downstream of polyamine and proline syntheses pathways. Polyamine and proline 
are important for proliferation and tissue repair (Rath et al. 2014). As originally established 
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in macrophages, the initial microglial pro-inflammatory M1 phenotype may converts to 
repair-orientated activity profiles (alternatively activated microglia; M2) (Liu et al. 2012). 
Under normal conditions, microglia should eventually return to the resting state M0 
(Blaylock & Maroon, 2011) (Figure 1-2). 
 
Figure 1-2: Schematic diagram illustrating proposed microglia phenotype switching: activation and expected return 
to ‘resting’ or ‘surveillance’ state. This illustrates population-level changes, not an individual cell. For example, 50 
% the microglia may exhibit an M1 phenotype, while the other 50 % may exhibit an M2 phenotype.  
Appropriate changes between phenotypes are important for coping with disease. 
For example, M1 activation in injury produces pro-inflammatory responses to kill damaged 
cells, preventing damage from propagating neighbouring cells, but should typically be 
followed by the M2 phenotype to phagocyte cell debris, enhance tissue repair, and produce 
anti-inflammatory factors that end the neuroinflammation (Tang & Le 2015). Sometimes, 
cells fail to resolve back to M0 state, as a result of lost specific function (e.g., ineffective 
phagocytosis) or undergoing inappropriate activation (e.g., aggregated α-synuclein in PD or 
Aβ plaques in AD, which could induce a chronic M1 activation, that eventually leads to an 
irreversible neuronal death (Lee et al. 2013)). Therefore, developing a therapy that has the 
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ability to resolve the activation, restore microglial function and/or phenotype switching 
would be of great benefit in this field. 
1.3 Microglial origins and phenotypes 
Although microglia are developed from different progenitor cells and within a unique 
environment compared to other innate immune cells, microglia are frequently called ‘brain 
macrophages’. Furthermore, microglia share functional similarities with macrophages 
resident in peripheral tissues. Early histological observations noted that microglia could 
exhibit ramified or amoeboid morphologies (Figure 1-2). A wider variety of phenotypes have 
been described, based on markers and behaviours similar to those of macrophages. This led 
to the adoption of similar terminology for both. The inactivated (default) microglial 
phenotype, present throughout the ‘healthy’ CNS, is often described as ‘resting’. However, 
this term failed to reflect the high levels of activity displayed by these cells, which actively 
survey their local microenvironment using highly motile processes (video file submitted with 
thesis, Video 1; internet link: youtube.com/watch?v=OVE1AL7xmwE). Here, this 
phenotype will be termed M0, with the activated phenotypes being referred to as M1 (also 
known as ‘classically activated’) or M2 (‘alternatively activated’). These major phenotypes 
would be described in the sections 1.4.1, 1.4.2 and 1.4.3.  
1.3.1 Microglial development: features unique to parenchymal microglia 
While all other resident cells in the CNS are derived from the neuroectoderm (Kang et al. 
2010), microglial precursors are developed from myeloid progenitors in the yolk sac and 
make a journey into the brain early in embryonic development (Figure 1-3) (Kierdorf et al. 
2013). Although sharing similarities with macrophages from other sources, microglia are a 
distinct population, with properties that differentiate them from other tissue-resident immune 
cells (Figure 1-4). In the mature CNS, microglia are not typically replenished from bone 
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marrow cells (as peripheral immune cells are) but can self-renew from mature microglia as 
required (Bruttger et al. 2015).  
 
Figure 1-3: Microglial precursors originate in the yolk sac, and express similar markers to peripheral macrophages 
during development. (a) Microglia are specialised immune cells found throughout the CNS parenchyma. (b) Some 
brain macrophages (e.g., pericytes, which are associated with blood vessels) are proposed to be generated by 
infiltration from the periphery, although this is likely limited to perivascular areas, including the choroid plexus 
and meninges. AGM, aorta gonad mesonephros; CD45, cluster of differentiation; CSF1R, colony stimulating factor 
1 receptor; CX3CR1, fractalkine receptor; E, embryonic day; EMP, erythromyeloid progenitor; HSCs, 
haematopoietic stem cells; IL-34, interleukin-34; IRF8, interferon regulatory factor 8; MMP, matrix 
metalloproteinase; MPs, myeloid precursors; MYB, transcriptional activator MYB; PU.1, transcription factor 
PU.1; RUNX1, runt-related transcription factor 1. Adapted from Prinz & Priller (2014). 
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Figure 1-4: Development of resident macrophages in different tissues . Tissue-resident macrophages in the brain 
are predominantly microglia, derived from the yolk sac. Immune cells from both yolk sac and ‘definitive 
haematopoiesis’, which occurs in the foetal liver, typically populate other tissues. This difference contributes to the 
unique profiles and behaviours of microglia compared to other macrophages. For example, microglia have greater 
longevity and capacity for self-renewal. E, embryonic day; EMP, erythromyeloid progenitor; HSCs, haematopoietic 
stem cells; MPs, myeloid precursors. Adapted from Prinz & Priller (2014)  
Although microglia are considered to be macrophages, with similar immune 
regulatory functions (surveillance and debris removal), and share macrophages-specific 
markers such as ionized calcium binding adaptor molecule 1 (Iba1) and fractalkine receptor 
(Cx3cr1) (Prinz & Priller 2014). Studies have identified a number of signature genes 
expressed only in microglia and not in other macrophages, such as Sall1, P2ry12 and 
Tmem119 (Hickman et al. 2013; Bennett et al. 2016; Koso et al. 2016). Parenchymal 
microglia have a self-renewal ability, but most other tissue-resident macrophages (Figure 
1-3) can be renewed from monocytes (immune cells from bloodstream) which in turn are 
constantly replenished by the differentiation of hematopoietic stem cells (HSCs). This 
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explains why microglia are more prone to becoming senescent than peripheral macrophages, 
the same pool of cells makes new microglia throughout life, and they are not renewed from 
bone marrow. So, microglia and macrophages can be represented as two distinct populations 
(Prinz et al. 2011). Therefore, it is important to study microglia, not just assume literature 
on peripheral immune cells will predict microglia behaviour. 
1.4 Microglial activation is poorly understood (M1/M2 model system) 
Microglia exhibit a wide variety of behaviours mainly intended to destroy foreign 
matter and remove debris, with roles in brain development and remodelling, infection and 
trauma. To achieve these effects, microglia can reversibly alter their phenotypes between an 
‘inactivated’ state and various ‘activated’ states including a pro-inflammatory phenotype 
that induces neuroinflammation. Microglia are activated in response to different pathological 
states within the CNS including injury, ischemia and infection. The subsequent 
neuroinflammation produces pro-inflammatory cytokines such as interleukin (Il)-1β, Il-6 
and tumour necrosis factor alpha (Tnf-α), although this pro-inflammatory response is 
important in fighting infections and removing damaged “self” cells, it could be toxic to other 
healthy neural cells (Smith et al. 2012). Tnf-α may directly mediate apoptosis by interaction 
with tumour necrosis factor receptor (TNFR). The actions of Il-1 in inducing apoptosis are 
less clearly defined but appear to be dependent on the presence or absence of additional 
cytokines and signalling molecules. For example, Il-1 has been shown to promote cell death 
when combined with either interferon gamma (IFN-γ) or TNF-α in primary human neuron 
cultures (Chao et al. 1995). Pro-inflammatory cytokines can also contribute to damage of 
neurons and glia by promoting the transfer of peripheral immune cells into the CNS.  
Some markers have been reported for the identification of microglial activation 
state, but it has become obvious that more detailed analyses are required. As different 
microglial phenotypes can perform different functions, an assessment that involves the 
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identification of specific microglial phenotypes is required. Inactivated M0 microglia have 
few unambiguous markers/hallmarks. Activated microglia have been classified broadly into 
M1 and M2 phenotypes, but a number of M2 subtypes have also been proposed, based on a 
wide variety of markers. Although considerable researches have been devoted to establishing 
which markers most reliably identify each phenotype, M1 and M2 are in vitro phenotypes 
and the in vivo situation is not fully clear cut. 
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Table 1-1: Microglial phenotypes, roles and proposed markers. 
Subtype Induced by Cytokines Chemokines Phenotypic 
markers 
References 
M0 Cd200  Cx3cr1 Cd200R 
 
(Ponomarev et al. 2005; Li et al. 2007; 
Zhang et al. 2011) 
M1 Ifnγ, 
LPS–TLR4 
signalling 
Il-1, 
Il-6, 
Il-12, 
Il-15, 
Il-23, 
Tnf-α. 
Ccl8,  
Ccl15, 
Ccl19, 
Ccl20, 
Cxcl9, 
Cxcl10, 
Cxcl11, 
Cxcl13. 
Il-6, 
Il-1β, 
Tnf-α, 
Cox-2, 
iNos. 
(Kaneko et al. 1989; Masliah et al. 1991; 
Letiembre et al. 2009; Chhor et al. 2013; 
Kobayashi et al. 2013; Brites & Vaz 
2014; Szulzewsky et al. 2015; Walker & 
Lue 2015) 
 
 
M2a Il-4 or Il-13 Tgf-β, 
Il-10, 
Il-1Ra, 
fibronectin 1, 
Igf-1. 
Ccl13, Ccl14, 
Ccl17, Ccl18, 
Ccl22, Ccl23, 
Ccl24, 
Ccl26. 
Arg1,  
Ym1, 
Fizz1. 
( Martinez et al. 2006; Chhor et al. 
2013; Lisi et al. 2014; Peferoen et al. 
2015; Walker & Lue 2015) 
M2b Immune complexes 
(binding of fcγR) 
and 
Il-1β or LPS 
Il-10, 
Tnf-α, 
Il-1 β, 
Il-6. 
Ccl1, 
Ccl20, Cxcl1, 
Cxcl2, Cxcl3. 
Il-10high, 
Il-12low, 
MHC II, 
Cd86. 
 
(Chhor et al. 2013; Lisi et al. 2014; 
Gensel & Zhang 2015) 
M2c Il-10, Tgf-β or 
glucocorticoids 
None known Ccl16, Ccl18, 
Cxcl13. 
Tgf-β, 
Arg1, 
Cd163, 
Cd206. 
(Mantovani et al. 2004; Chhor et al. 
2013; Novak & Koh 2013; Pey et al. 
2014; Mecha et al. 2015) 
Arg1, Arginase 1; Ccl, Chemokine (C-C motif) ligand; Cd86, Cluster of differentiation 86; Cd163, Cluster of 
differentiation 163; Cd200, Cluster of differentiation 200; Cd200R, Cluster of differentiation 200 receptor; Cd206, Cluster 
of differentiation 206; Cox-2, cyclooxygenase 2; Cx3cr1, fractalkine receptor; Cxcl, Chemokine (C-X-C motif) ligand; 
FcγR, Fc receptor for immunoglobulin G; Fizz1, Resistin-like molecule alpha; Ifn-γ, interferon-γ; Igf-1, insulin-like growth 
factor 1; Il-, interleukin-; iNos, inducible nitric oxide synthase; LPS, lipopolysaccharide; MHC II, Major 
Histocompatibility Complex Protein II; Tgf-β, transforming growth factor β; TLR, Toll-like receptor; Tnf-α, tumour 
necrosis factor; Ym1, chitinase 3-like protein 3. Table adapted from David & Kroner (2011). 
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1.4.1 Resting microglial (M0) 
1.4.1.1 Actions of M0 microglia 
The resting/quiescent microglial phenotype M0 is also called ‘ramified microglia’, 
because it is characterised by a small soma with many fine branched (ramified) cellular 
processes (Brites & Vaz 2014). Although described as ‘inactive’ or ‘resting’, M0 microglia 
are physiologically active, showing pinocytosis (uptake) activity and a high degree of 
process motility (Fetler & Amigorena 2005). The classical thought was that the main purpose 
of this phenotype is to provide a constant amount of microglia to sense and fight infection 
(Aloisi 2001), with their processes screening the environment, making them the monitor of 
the CNS (Vinet et al. 2012). However, the published evidence reports that M0 microglia 
have active roles in development, homeostasis and brain remodelling. For example, 
microglia can secrete neurotrophic factors (Saijo & Glass 2011) and also play an important 
part in neuronal activity, including structural and functional plasticity (Tremblay et al. 2010).  
1.4.1.2 Mediators and markers characteristic of M0 microglia 
The M0 phenotype has a fewer reported markers than other phenotypes. Bertolotto 
et al. (1995) reported that keratan sulphate epitope is expressed by ramified microglia in 
adult rats (recognised by monoclonal antibody 5D4) on their surface, unlike peripheral 
macrophages and other microglial phenotypes. Thiamine pyrophosphatase is another 
selective marker for ramified microglia (Glenn et al. 1992). Major histocompatibility 
complex protein II (MHC II) is present in M0 microglia, but as co-stimulatory molecules are 
not present, M0 microglia cannot function as antigen presenting cells (Li et al. 2007) 
(microglia antigen presentation is discussed in section 1.6). Although few markers have been 
suggested to be M0 markers, from my review of the literature nobody has attempted to 
characterise this phenotype. 
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1.4.1.3 Presence of M0 phenotype 
M0 microglia are present in a normal healthy condition, and so are considered to be 
the default phenotype, rather than an ‘activated’ form (Vinet et al. 2012). In vitro, untreated 
microglia are often considered to be M0, but this should be investigated in greater detail, as 
the derivation process can be expected to provide activating stimuli, and culture conditions 
may also lead to activation (Butovsky et al. 2014). Microglia maintain the M0 state through 
cluster of differentiation 200 (Cd200), which is expressed by neurons and acts on the Cd200 
receptor (Cd200R) (Zhang et al. 2011). This Cd200-Cd200R signalling may play an 
important role in keeping the microglia in the resting state, as neuronal loss leads to loss of 
this signal and subsequent microglial activation (Gorczynski et al. 2004). Similar to Cd200-
Cd200R signalling, signals such as fractalkine (Cx3cl1), which is expressed by neurons, and 
interacts with microglial fractalkine receptors (Cx3cr1) to maintain them in the M0 
phenotype (Verge et al. 2004). 
1.4.1.4 Controlling M0 microglia 
In healthy conditions, M0 is the dominant microglial phenotype (Nimmerjahn et al. 
2005). M0 changes to other microglial phenotypes in response to various stimuli, e.g., 
neuronal ‘distress’ signals, trauma, injury, neurodegenerative diseases (Haynes et al. 2006). 
It has been suggested that resting microglia do not convert to an active state directly, but 
they might pass through a ‘primed’ M0 stage first (Blaylock 2013). Furthermore, resting 
microglia can be stimulated through damage-associated molecular patterns (DAMPs) 
(DAMPs are endogenous molecules released from cells into cytoplasm after CNS injury) or 
pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS), which 
interact with adenosine triphosphate (ATP) receptors or Toll-like receptors (TLRs) (Mosser 
& Edwards 2008). Upon receiving these signals, microglia direct their processes towards the 
site of injury then retract the processes and become motile cells travelling to that location 
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(Davalos et al. 2005), often adopting an amoeboid morphology (Hailer et al. 1999). 
Depending on which signal is received, microglia can shift to either M1 phenotype (e.g., in 
response to LPS) or M2 phenotype (e.g., in response to interleukin 4, Il-4) (Gordon & 
Martinez 2010).  
1.4.2 Activation microglial (M1) 
1.4.2.1 Actions of M1 microglia 
Microglia in classical activation state (M1 microglia) are an important player in 
defence against most foreign substances (Ridolfi et al. 2013). M1 microglia produce redox 
molecules such as reactive nitrogen species (RNS) (e.g., NO and inducible nitric oxide 
synthase, iNos) and reactive oxygen species (ROS) (Liao et al. 2012). However, an excessive 
amounts of these substances could damage cell membranes of neuron and other glia cells. 
 M1 response also includes an expression of pro-inflammatory cytokines such as Tnf-
α, Il-1β, Il-12, Il-1α, Il-6 and Il-23. These cytokines play an important roles; Tnf-α plays a 
role in the control of neuronal survival (Gururaja et al. 2007). Collectively, Il-1β, Il-6 and 
Tnf-α impart neuroprotection both in vivo and in vitro (Carlson et al. 1999). However, the 
mechanism of action of these proinflammatory cytokines is not fully clear and there is 
increasing evidence to suggest that pro-inflammatory cytokine might have a role in neuronal 
degeneration (Smith et al. 2012). 
Furthermore, M1 microglia have the ability to produce inflammatory chemokines 
(C-C motif) ligand e.g., Ccl8, Ccl20 and Ccl15 (Orihuela et al. 2016), which are produced 
during infections or as a response to an inflammatory stimulus and facilitating immune 
response. Chemokines attract microglia to the infection site to destroy the pathogens 
(Ramesh et al. 2013). 
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Additionally, M1 microglia can act as antigen presenting cells (APCs) due to their 
expression of co-stimulatory molecules (e.g., Cd86) on the surface of the cell (Taylor & 
Sansing 2013). Together, MHC II and Cd86 expression in M1 microglia can activates T-
cells (discussed in section 1.6).  
M1 microglia are proposed to exhibit phagocytosis (discussed in section 1.5), 
enabling the engulfment of dead cells, debris and pathogens, which is critical in 
reconstruction and reorganisation of neuronal networking, e.g., in the case of brain injury 
(Mantovani et al. 2002). Other reports suggested that phagocytosis is also performed by M2 
phenotypes, making phagocytosis less useful as a phenotype marker (Fumagalli et al. 2015).  
1.4.2.2 Mediators and markers characteristic of M1 microglia 
Despite a wealth of literature describing microglia M1 phenotype markers (e.g., 
Cd86 (Kobayashi et al. 2013), Il-1β, Il-6 and Tnf-α (Brites & Vaz 2014)) however, the most 
reliable marker seems to be iNos (Chhor et al. 2013) (see section 5.1.2 which further explains 
the role of these markers). The significance of these contradictory reports might reveals the 
limitations of the current discrete classification system; therefore, it has been proposed that 
activated microglia can adopt phenotypes along a spectrum, and so simultaneously display 
‘markers’ of multiple phenotypes (Chhor et al. 2013). 
1.4.2.3 Activation of the M1 phenotype 
Physiologically, M1 is associated with ageing, infections and neurodegenerative 
diseases (Harry 2013). In the laboratory, M1 activation is reliably induced by exposure to 
LPS and/or Interferon gamma (Ifn-γ) (Walker & Lue 2015), which leads to activation of 
TLR4 or Ifn-γ receptors 1 and 2, respectively. For both stimuli, this causes stimulation of 
NF-κB and signal-transducers and activators of transcription 1 (STAT1), increase in iNos, 
secretion of pro-inflammatory cytokines, chemokines, and overflow of ROS and RNS 
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(Orihuela et al. 2016). These responses can recruit other immune cells (including by antigen 
presentation) and destroy foreign pathogens (Orihuela et al. 2016). 
1.4.3 Alternative activation microglial (M2) 
The M2 microglial phenotype is usually referred to as ‘alternatively activated’, and 
broadly described as anti-inflammatory. However, it has recently been proposed that M2 
microglia could be divided into several subtypes: M2a, M2b and M2c. Each subtype is 
reported to perform different functions and express a different combination of 
genes/proteins, although there is substantial overlap between these. Many published articles 
continued to refer to M2 microglia, without distinguishing between these subtypes. 
Microglia routinely adopt M2 phenotypes upon resolution of inflammatory events, and 
possibly under other circumstances such as in early stage of AD (Tang & Le 2015). 
1.4.3.1 M2a 
1.4.3.1.1 Actions of M2a microglia 
M2a is an alternate activation phenotype. M2a microglia secrete a range of anti-
inflammatory molecules (e.g., Il-1Ra and Tgf-) (Chhor et al. 2013). Therefore, the main 
function of this phenotype is inflammatory suppression (Cherry et al. 2014) by decreasing 
M1 microglia cytokines and other pro-inflammatory mediators (Mosser & Edwards 2008). 
Furthermore, M2a microglia have the ability to promote tissue repair (Walker & Lue 2015) 
via production of repair-promoting molecules such as Arginase-1 (Arg1), Chitinase 3-like 
protein 3 (Ym1) and Resistin-like molecule alpha (Fizz1). The proline and polyamine 
produced in Arg1 pathway has a high impact in tissue repair . Ym1 has an important roles 
in the protection of the extracellular matrix (ECM) especially during injury (Hung et al. 
2002). M2a also produces insulin-like growth factor 1 (Igf-1) that helps in the resolution of 
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inflammation and enhances neuronal survival and phagocytosis (see section 1.5) (Cherry et 
al. 2013; 2014). Furthermore, M2a could be a neuroprotective phenotype (Chhor et al. 
2013). There are some evidences to suggest that M2a microglia function may be impaired 
with age (as discussed in section 6.1.2), and this may have consequences for late-onset 
metabolic and neurodegenerative diseases (Fenn et al. 2014). 
1.4.3.1.2 Mediators and markers characteristic of M2a microglia 
Reports showed that Arg1, Fizz1 and Ym1 can be considered as a M2a microglia 
markers (Chhor et al. 2013; Orihuela et al. 2016). Furthermore, M2a microglia have been 
reported to produce macrophages mannose receptors: Cd206 and Cd209 (Peferoen et al. 
2015), and chemokines Ccl22, Ccl13, Ccl17 and Ccl23 (Martinez et al. 2006). However, 
Arg1 is the most commonly used marker for M2a phenotype identification (Lisi et al. 2014). 
1.4.3.1.3 Activation of M2a phenotype 
M2a microglia are activated in response to extracellular stimuli such as spinal cord 
injury (SCI), and potentially play a role in survival, repair and growth processes (David & 
Kroner 2011). Walker & Lue (2015) in vitro study, showed that M2a microglia are reliably 
induced in response to Il-4 or Il-13. Both Il-4 and Il-13 interact with Il-4R to induce several 
processes that lead to effective anti-inflammatory functions, such as Arg1 up-regulation, 
inhibition of NF-κB isoforms and production of scavenger receptors for phagocytosis 
(Cherry et al. 2014). 
1.4.3.2 M2b 
1.4.3.2.1 Actions of M2b microglia 
M2b is an immune regulatory phenotype (Chhor et al. 2013). M2b microglia are 
unique in their ability to produce high levels of anti-inflammatory cytokine Il-10 and low 
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level of Il-12 (Mosser 2003). Furthermore M2b microglia have the ability to produce pro-
inflammatory cytokines such as Tnf-α, Il-6 and Il-1β (David & Kroner 2011). This suggests 
that M2b expresses the same genes as M1 and M2c, and explains their ability to adopt 
complex function of both inflammation and tissue repair (Fenn et al. 2012). 
1.4.3.2.2 Mediators and markers characteristic of M2b microglia 
Available evidence indicates that no specific markers for M2b exists since this 
phenotype is capable of producing both pro- and anti-inflammatory cytokines (e.g., Il-1, Il-
6, Tnf-, MHC II, Cd86, Il-10 and Cd163; see Table 1-1) ( Chhor et al. 2013; Lisi et al. 
2014; Gensel & Zhang 2015). Therefore, it has been suggested that a high cytokine Il-10 
with low Il-12 might be a M2b marker.  
1.4.3.2.3 Activation of the M2b phenotype 
Although, few studies have reported the induction of M2b, it has been suggested that 
a combination of either immunoglobulin G (IgG), TLR agonists and Il-1R or 
immunoglobulin Fc gamma receptor (FcγRs: Cd16, Cd32 or Cd64) ligands can be used to 
generate M2b microglia in vitro (Chhor et al. 2013). Furthermore, only one study has 
suggested that adult microglia adopt M2b (as indicate by high level of Il-10 and low level of 
Il-12) (Fenn et al. 2012).  
1.4.3.3 M2c 
1.4.3.3.1 Actions of M2c microglia 
The acquired-deactivating (M2c) phenotype has an immunosuppressive function 
(Gensel & Zhang 2015). Microglial morphology in this phenotype has been suggested to be 
“round with multiple microspikes” (Mecha et al. 2015). The M2c microglia are sometimes 
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referred to as deactivated , however this description seems to be unhelpful, since M2c 
appears to be associated with tissue remodelling, matrix deposition after inflammation 
(Cherry et al. 2014), involved in the innate immune response suppression (Mandrekar-
Colucci & Landreth 2010) and debris scavenging (David & Kroner 2011). Additionally, M2c 
microglia can increase neural stem cell (NSC) proliferation (Kiyota et al. 2012), down-
regulate pro-inflammatory microglia (Varnum & Ikezu 2012), up-regulate cytokine Tgf- 
(Appel et al. 2010) and down-regulate factors that contribute to APC function, such as MHC 
II (Gordon 2003). 
1.4.3.3.2 Mediators and markers characteristic of M2c microglia 
Reports have shown that M2c have several markers such as Cd206 (Gensel & 
Zhang 2015), Cd163 (Pey et al. 2014), scavenger receptor A and B and Cd204 (Table 1-1) 
(Varnum & Ikezu 2012). But the key marker in this phenotype is Tgf-β (Novak & Koh 2013). 
1.4.3.3.3 Activation of the M2c phenotype 
Physiologically, apoptotic cells are capable of increasing microglial Tgf-β expression 
and secretion and shift the microglia phenotype toward M2c (Spittau et al. 2015). Il-10, Tgf-
β and glucocorticoids are used to induce M2c microglia in vitro by downregulating STAT1 
and NF-B (Chhor et al. 2013; Mantovani et al. 2004). 
1.4.4 Microglia and resolution of neuroinflammation 
The loss of M1 microglia, and reversion to M0 microglia, is described as the 
resolution of inflammation. The general assumption was that inflammatory (M1) microglia 
should convert to the anti-inflammatory/wound healing M2 phenotype, and then the same 
cells would revert to the M0 phenotype. But even from in vitro data, it is not clear that this 
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is the case. Some studies do suggest that M1 microglia alter their phenotype to become M2 
(same cells) (Polazzi & Monti 2010). Other studies suggested that M1 inflammatory state 
might undergo apoptosis, with different M0 microglia generating a replacement population 
of M2 cells (Lobo-Silva et al. 2016). Furthermore, there is some indication that after M1 
activation, an individual microglial cell may not fully resolve to the M0 phenotype. Rather, 
it could retain a low level of ‘activation’, or at least remain long-term/permanently altered 
(e.g., in the literature some theories suggested a ‘primed’ microglial phenotype: M0') 
(Torres-Platas et al. 2014). M1 microglia is the most widely studied phenotype, but its 
resolution is not fully understood. 
As M2a is the disease/injury resolved phenotype it could be expected that it 
following the resolution of inflammation, M2a microglia revert to the M0 phenotype 
(Varnum & Ikezu 2012). However, it has been suggested that resolution may involve 
phenotype switching of some microglia from M1 to M2a and then M2c, since M2c is the 
wound healing phenotype, playing important roles in further deactivating of microglial 
inflammation (Mantovani et al. 2004).  
M2b microglia are the least understood phenotype, and its existence in vivo is 
controversial. In vitro, it has been suggested that this phenotype might be associated with 
M1 as it works on removal of ROS and RNS during M1 activation, as M2b could be induced 
by combination of immune complexes (IC)+LPS (Mantovani et al. 2004). However, Mosser 
(2003) study showed that M2b cells had protected mice against LPS toxicity. Furthermore, 
another study showed that, in the last proliferative stage of M2b microglia, there is as 
increase in the production of both Il-10 and Tgf-b, and this signal converts M2b microglia 
to M2c phenotype (Novak & Koh 2013). Also, an in vivo study showed that adult mouse 
microglia have been switched from M2b to M2c, 24h after LPS injection (Fenn et al. 2012). 
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Although, few authors have described the M2 subtypes (as discussed previously), 
these reports were contradictory with a lot of overlaps between these subtypes. Therefore, 
this thesis will study M2 in general. 
In summary, the resolution of microglial inflammation needs further study both in 
vivo and in vitro. Understanding why neuroinflammation fails to resolve, and how resolution 
may be triggered, will be of great benefit for developing treatments for neurodegenerative 
diseases. In particular, how microglia switch between appropriate phenotypes should allow 
modulation of microglial function. 
1.5 Microglia are the principal phagocytic cells in the brain 
Phagocytosis is the ability of cells (usually specialised phagocytises, including 
microglia) to identify, engulf and degrade invading organisms, debris and apoptotic cells 
(Mukherjee et al. 1997). Active microglia play an important role in maintaining the 
homeostasis of the brain through phagocytosis (Neumann et al. 2009). In the phagocytosis 
process, first microglia recognise surface signals (so-called eat-me signals) (Zitvogel et al. 
2010) such as phosphatidylserine (PS), which is a component of the inner surface of the 
cellular membrane and is everted when cells undergo apoptosis (Sambrano & Steinberg 
1995). Secondly, microglial receptors interact with eat-me signals to initiate phagocytosis. 
Microglial phagocytosis depends mainly on two receptors: TLRs, which have a high affinity 
for foreign microbial pathogens (Veerhuis et al. 2011); and PS receptors (Green & Beere 
2000), which identify apoptotic cells. There are several other phagocytosis-related receptors 
such as: complement receptors, pyrimidinergic receptor (P2Y), scavenger receptors (SR) 
(Lucin & Wyss-Coray 2009), LPS receptor CD14 (Liu et al. 2005), and low-density 
lipoprotein receptor-related protein (LRP) receptor, which also take part in microglial 
clearance of apoptotic cells and dead neurons in both acute and chronic brain injury (Smith 
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1999). So, microglia sense eat-me signals, engulf cells by binding to these signals and 
forming vesicles called phagosomes, which then go through a series of events leading to 
digestion of the pathogen/debris when phagosomes merge with lysosomes (vesicles 
containing degradative enzymes at low pH; Figure 1-5) (Fu et al. 2014). 
 
Figure 1-5: Microglia-signalling pathway in phagocytosis. Microglia membrane recognises the apoptotic cell, then 
microglia processes surround the target and engulf it. The target will be internalised and merged with the lysosome. 
This process could lead to an antigen presentation and M1 activation of other cells. Adapted from Sierra et al. (2013).  
1.6 Microglia can engage in antigen presentation  
Antigen presentation may be defined as the process that takes place in the immune 
cells to generate T-cell protective responses against pathogens or other foreign structures. 
The APCs must have the ability to phagocytose the foreign body and express MHC II on the 
cell surface. The T-cells recognise the MHC II, which leads to activation of T-cell and 
initiates the immune response (Becher et al. 2006). 
Studies have shown that in normal brain, microglia have the ability to be APCs by 
having MHC II and co-stimulatory molecules (e.g., Cd40 and Cd86) on their surface 
(Williams et al. 1995), which bind to CD4+ (T-cell receptor) (Almolda et al. 2011). Antigen-
presenting microglia can cause CD4+ T-cells to differentiate into helper T-cells (either Th1 
or Th2 subtypes), which modulates their activity, for example by increasing production of 
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pro-inflammatory cytokines such as Ifn- in Th1 or anti-inflammatory cytokines such as Il-
4 in Th2 (Aloisi et al. 1998). Furthermore, it has been suggested that MHC II upregulation 
in microglia is an early sign of microglial activation in CNS injuries (Kreutzberg 1996). In 
early MS lesion, increased MHC II expression in microglia suggest that microglia are 
responsible cells for presenting the myelin to CD4+ T-cells and sustaining the inflammatory 
process (Li et al. 1996). An in vitro study on both primary microglia and microglia cell line, 
showed a timed response of MHC II gene expression when microglia were treated with Ifn-
γ and that expression decreased when the cells further treated with Tgf-β, Il-4 or Il-10 
(O’Keefe et al. 1999). 
It has been suggested that T-cells might promote M1 microglial activation, as part of 
CD4+ Th1 cells response; these cells start to produce Ifn-γ, which induces M1 microglial 
activation (Mount et al. 2007). Furthermore, studies suggested that activated microglia and 
CD4+ T-cells might play a role in neuroinflammatory disease progression (e.g., PD and 
amyotrophic lateral sclerosis) but probably not in disease initiation (Appel et al. 2010). 
1.7 Microglial roles in neurodegenerative diseases 
1.7.1 Microglia in Alzheimer's disease 
Alzheimer's disease is characterised by accumulation of Aβ plaques (Ballard et al. 
2011). Aβ is a fragment of a protein known as amyloid precursor protein (APP), which can 
be cleaved to produce amyloid protein, and the Aβ fragment. The main function of amyloid 
protein is neurotrophic factor in undifferentiated neurons and it is neurotoxic to mature 
neurons (Lorenzo et al. 1994). Aβ function depends on two factors: the concentration of Aβ 
and the age of the neurons so high concentrations of the protein in mature neurons could 
cause neuronal degeneration as in AD (Yankner et al. 1990). 
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Normally, Aβ are soluble proteins but insoluble Aβ are characteristic of several 
neurological conditions including: AD. Amyloid plaques do not seem to have a definite 
pattern of deposition, perhaps due to the many mechanisms able to clear these extracellular 
proteins, including microglial phagocytosis (Webster et al. 2000). Microglia have a role in 
degrading Aβ. But failure to either degrade / misfolding / aggregation (still unclear) leads to 
insoluble aggregates, associated with AD.  
In the early stage of AD, microglia are present in increased numbers, and may delay 
disease progression through clearance of Aβ before senile plaque formation (Webster et al. 
2000). But, increased Aβ accumulation even in the presence of microglia suggests that 
microglial ability/capacity to phagocytose Aβ may diminish with increasing age and 
progression of AD (Hickman et al. 2008). In a human study, evidence has shown increased 
numbers of pro-inflammatory M1 microglial markers (e.g., IL-1β, IL-6 and TNF-α) (Sastre 
et al. 2006), and similar observations have been made in mouse models (Sarlus & Heneka 
2017). Several studies have confirmed that Aβ can interact with TLR4 and suggested that 
TLR4 mediates microglial-induced neurotoxicity both in vitro and in vivo (Lehnardt et al. 
2003; Carty & Bowie 2011). 
Healthy neurons express CD200 at the cell membrane, which interacts with CD200R 
(in microglial membrane), to maintain an M0 phenotype (Lynch 2014). Age-dependent 
decline of CD200 leads to the activation of microglia (Varnum & Ikezu 2012). In AD, 
evidences from both human and rodent brain tissue suggested that there is more rapid 
decrease in CD200 expression (Lyons et al. 2007). Sudduth et al. (2013) showed that in early 
stage AD, there are two distinct patient populations, based on analysis of microglia in brain 
tissue. One-half of the early AD cases showed a bias toward a pro-inflammatory, M1 
phenotype, whereas the other half of the early AD cases show a bias toward the M2 
phenotype (Sudduth et al. 2013). In contrast, the late-stage AD patients were more 
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homogeneous, and all of them showed a similar complex neuroinflammatory state, with 
markers of M1 and M2 all being elevated (Sudduth et al. 2013). It would be fascinating to 
know the role of different microglia phenotype in AD as in normal healthy brain, microglia 
phagocytose Aβ which may suggest the presence of M2. It is not clear why microglia lose 
this ability and increasingly exhibit an M1 phenotype. However, to investigate this a better 
in vitro model with known phenotype characteristic should be developed. 
It is important to unravel the factors that contribute to the apparent inability of 
microglia to phagocytise Aβ aggregates. Many studies suggested different mechanisms, e.g., 
Hickman et al. (2008) in their mouse model, indicate that microglia promote Aβ clearance 
in early AD, but as the disease progresses, pro-inflammatory cytokines produced (i.e. M1) 
in response to Aβ deposition down-regulate genes involved in Aβ clearance. A second study 
demonstrated that microglial activation in AD can, in turn, activate astrocytes, which can 
inactivate microglial phagocytosis, which could be through down-regulation of microglial 
scavenger receptors or altered levels of phagocytosis related trophic factors (Liddelow et al. 
2017). A third study on AD brain showed that microglial Aβ phagocytosis dysfunction may 
be caused by high mobility group box protein 1 (HMGB1), a chromosomal protein that 
inhibits phagocytosis. HMGB1 may bind to Aβ and inhibit Aβ degradation by microglia 
(Takata et al. 2012). Given these and other reports, it remains unclear how effective 
microglial phagocytosis of Aβ is, and how a loss of this capability may contribute to AD 
pathophysiology. 
A really well-defined model will allow better understanding at an in vitro level; this 
allows the generation of hypothesis which can be tested in more complex models. 
1.7.2 Microglia in Parkinson's disease 
Parkinson's disease is characterised by degeneration of dopaminergic neurons in the 
substantia nigra pars compacta and development of Lewy bodies (a pathologic hallmark) in 
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dopaminergic neurons (Lue et al. 2001). The most important molecule in PD is α-synuclein 
(Papadopoulos et al. 2018). Although α-synuclein has been suggested to be neuroprotective, 
there are abundant data implying its role in the regulation of presynaptic secretory function 
(Chandra et al. 2005). In PD, α-synuclein levels are changed by overexpression, mutations, 
or chemical modifications (such as increased dopamine quinone formation, oxidation, 
nitration, phosphorylation and exposure to metal ions or toxins) (Sulzer 2007). These 
conditions can lead to an increased oxidative environment around dopaminergic neurons, 
which ultimately leads to neuronal death (Obeso et al. 2010). 
In post-mortem analyses of the brains of PD patients, high numbers of activated 
microglia are found near the degenerating dopaminergic neurons (Ferreira & Romero-
Ramos 2018). Also, in vivo positron emission tomography (PET) imaging of patients 
diagnosed with PD showed increased microglial numbers in the substantia nigra (Sulzer et 
al. 2017). This is to be expected, as damaged and dying dopaminergic neurons would 
produce pro-M1 signals (such as α-synuclein aggregates, ATP, matrix metallopeptidase 3 
(MMP-3) and neuromelanin), which activate microglia (Kim et al. 2007). However, it is not 
clear whether microglial activity slows disease progression, or whether chronic over-
activation contributes to the pathology, causing further damage through the release of 
neurotoxic factors (Manocha et al. 2017). Some animal model studies suggested that 
microglia play an important role in the disease process at an early stage (Liu 2006).  
The role of microglia in PD is not entirely understood; but their potential modes of 
participation might include cell death (that produces DAMPs which interacted with ATP 
receptor inducing M1 microglia phenotype as discussed in 1.4.2), increased α-synuclein 
levels (α-synuclein M1 microglia phenotype through NF-κB, and alters microglia 
phagocytosis (Zhang et al. 2017)) and loss of neuronal signals, such as CD200 and 
fractalkine, which are known to be important in the maintenance of the M0 phenotype; and 
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increased protease production, which is thought to activate microglia by outline mechanism 
(Moehle et al. 2012). Disorder of CD200-CD200R signalling might increase microglial 
activation during PD, as this removes a stimulus that usually induces the M0 phenotype 
(Nayak et al. 2014). Zhang et al. (2011) reported that inhibition of this pathway increased 
inflammation, neuronal cell death and neurological dysfunction in a rat model of PD. 
Because CD200-CD200R signalling physically couples microglia and neurons in the healthy 
CNS, helping maintain an inactivated microglial state, disruption of this pathway during a 
neurodegenerative disease such as PD could result in chronic microglial activation (Zhang 
et al. 2011). A study showed that the chronic production of ROS and pro-inflammatory 
molecules (e.g., Tnf-α, Il-1β and Ifn-γ) from microglia in the brains of PD patients (Brochard 
et al. 2009), can subsequently cause damage to midbrain neurons, including dopaminergic 
neurons (Lysle et al. 1999), which feeds this vicious cycle.  
M1 and M2 Microglia phenotype has been poorly studied in PD. Autopsy of PD 
brain showed cytokine markers of both M1 and M2 (Rojo et al. 2010), however, other study 
suggested that α-synuclein induces M1 microglia phenotype (Zhang et al. 2017). 
Furthermore, some study suggested that different M1/M2 polarisation state depends on the 
stage and severity of the disease. Therefore, understanding stage-specific switching of 
microglial phenotypes could be beneficial for PD therapy (Subramaniam & Federoff 2017). 
A well-defined in vitro microglia system will allow better understanding of PD 
multiple factors on microglial activation state and the role of each phenotype in PD 
progression; this allows the generation of hypothesis which can be tested in more complex 
models. 
1.7.3 Microglia in traumatic brain injury 
It has been suggested that microglial activation plays an important role in the 
neuroinflammation and secondary injury after TBI (Loane & Kumar 2016). A good 
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understanding of microglia phenotype/function could contribute to the treatment of 
neuroinflammatory brain injury.  
One of microglia’s important function (as discussed in section 1.5) is to remove the 
debris through their phagocytic ability. In the case of brain injury with damaged neurones, 
microglia play neuronal protective roles through phagocytosis, production of neurotrophic 
factors and anti-inflammatory cytokines (Witcher et al. 2015). Which might suggest that 
microglia in the early stage of TBI are adopting M2 phenotype (Loane & Kumar 2016). 
However, TBI causes neuronal death, in turn these damaged cells release DAMPs, ROS, 
pro-inflammatory chemokines and cytokines, which suggests that these signals might drive 
microglia toward M1 phenotype. As discussed in section 1.4.2, M1 microglia produce 
important pro-inflammatory markers that are essential in host defence mechanism via ATP 
release and activation of purinergic receptors. Therefore, it has been suggested that both M1 
and M2 microglia work together after TBI, although their roles in brain injury progression 
and repair were not fully determined. 
However, experimental and clinical studies showed that chronic M1 
phenotype lasts for months to years after TBI with low tissue repairing ability, mainly in 
moderate and severe TBI ( Nagamoto-Combs et al. 2007; Smith et al. 2013; Loane et al. 
2014). In vivo studies, using animal models of spinal cord and brain injury have shown that 
within the site of injury, there were mixed M1 and M2 phenotypes. But M2 phenotype 
response is short-lived and there is a phenotypic shift towards M1 microglia phenotype 
within 7 days of injury (Kigerl et al. 2009; Hu et al. 2012). Which decreases the 
microglia phagocytic ability, and increased pro-inflammatory production that could 
contribute to the injury and pathology (David & Kroner 2011). Furthermore, it has been 
suggested that after one month of brain injury, microglia show priming phenotype (there is 
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further discussion on this phenotype in section 1.8) with hyper M1 response to second stimuli 
(LPS) (Fenn et al. 2014).  
It has been suggested that M2 microglia have important roles in neuronal repair and 
regeneration after TBI (Loane & Kumar 2016). Therefore, a better understanding of M1/M2 
mechanisms in TBI might help in developing a future therapeutic targeting microglia 
phenotypic switching to enhance functional recovery after TBI (Figure 1-6). 
 
Figure 1-6: M1 and M2 microglia phenotype/ function in TBI. DAMPs produce by injured neuron could lead to 
microglia activation, microglia phenotype depends on the extracellular signals released by injured neurons. M1 
microglia produce pro-inflammatory markers such as IL-1β, TNFα, IL-6 and iNOS, chemokines and free radicals. 
In contrast, M2 microglia upregulate markers such as CD206, CD163, FCγR, arginase 1, Ym1, and TGFβ and 
produce neurotrophic factors, anti-inflammatory cytokines, enhance protease production and phagocytosis ability. 
DAMPs, danger-associated molecular patterns; PRR, pathogen recognition receptors; TLR, toll-like receptors. 
Adapted from Loane & Kumar (2016). 
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1.8 The theory of microglial ‘priming’ 
It has been proposed that the extent and type of microglial activation in response to 
a given stimulus might be altered by the environment in which these microglia have pre-
existed (Wolf et al. 2017). It has been suggested that some M1 microglia do not go back to 
M0 but instead adopt a ‘primed’ phenotype. The definition of primed (M0’) microglia, is 
that they exhibit an exaggerated inflammatory response (hypersensitive pro-inflammatory 
phenotype) to a second stimulus, after prior exposure to an initial (priming) stimulus. The 
initial stimulus could be a systemic illness or infection (i.e. not necessarily in the brain), but 
still lead to modified microglial responses to subsequent disease or injury, adversely 
affecting disease outcome (Haley et al. 2017) see Figure 1-7.  
 
Figure 1-7: Schematic diagram illustrating the priming theory. Low level of inflammatory signal may not be enough 
to induce full M1 activation, but it could put microglia in the primed state. M0’ microglia ‘over-react’ to subsequent 
activation with prolonged pro-inflammatory activation. 
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One of the first studies done on the priming of microglia was by using an animal 
model of prion disease where it was shown that microglia from animals with prion disease 
produce more pro-inflammatory cytokines when treated with LPS in comparison with naïve 
microglia (Combrinck et al. 2002). Later on, similar work has been done using prion disease 
and LPS (Cunningham et al. 2005; Cunningham et al. 2009) or polyinosinic:polycytidylic 
acid (poly I:C) (Fielda et al. 2010). Also, clinical and pre-clinical studies have shown that 
aged microglia are primed and present an exacerbated response to acute inflammatory 
challenge (Wolf et al. 2017; Godbout et al. 2005). In a recent study, d’Avila et al. (2018) 
showed that aged microglia produced a higher levels of pro-inflammatory cytokines (Il-1β 
and Il-6) in comparison with younger microglia when both young and aged mice have been 
treated with systemic inflammation (LPS). This might be due to the less sensitivity of 
microglia – neuronal signal such as fractalkine–CX3CR1 and CD200–CD200R1 with aging 
(Hanisch & Kettenmann 2007). However, the real mechanism behind priming microglia is 
not fully understood.  
It has been suggested that peripheral infection might contribute to neurodegenerative 
disease, and the link between peripheral and neuronal disease might be through priming 
microglial cells in the brain. It is well known that peripheral viral or bacterial infection 
usually associate with sickness behaviour (controlled by the brain) such as loss of appetite, 
depression and loss of concentration (Dantzer et al. 2008). Peripheral infection and chronic 
disease are associated with increased production of pro-inflammatory markers (Il-6, Il-1β, 
Tnf-α, RNS and ROS) by peripheral immune cells. These markers might reach the brain and 
cause the sickness behaviour (van Dam et al. 1992). The actual mechanism that explains 
how these markers enter the brain is not fully explored, however there are different 
suggestions. Vitkovic et al. (2000) suggested that cytokines might affect neurons, which in 
turn affect microglia. While Dantzer et al. (2008) suggested that cytokines overflow in 
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systemic circulation can cross the blood-brain barrier (BBB) to the brain through transport 
system. The presence of these markers could partially activated or primed microglia. 
M0’ microglia theory provides a molecular and cellular pathway on how the systemic 
inflammation could contribute in neurodegenerative disease progression. Furthermore, the 
increase in pro-inflammatory marker expression could damage neurons, M0’ microglia may 
respond to the further stimulation by altering the receptor properties in ways which have 
highly important consequences. In mouse models of neurodegenerative disease, peripheral 
inflammation led to increased microglial Fc-type immunoglobulin receptor expression 
higher than these with neurodegenerative or systemic inflammation alone. 
Many preclinical studies provide evidence that M0’ microglia and their subsequent 
inflammatory response might lead to damage the tissue in animal models of prion disease 
(Perry 2010), AD (Kitazawa et al. 2005), PD (Pott Godoy et al. 2010), stroke (McColl et al. 
2007) and MS (Moreno et al. 2011). 
1.8.1 Systemic inflammation can influence neuroinflammation  
Systemic inflammatory signals can travel through the bloodstream, reaching the 
majority of tissues, except some ‘immunoprivileged’ sites, such as the eyes, testicles or 
placenta (Padrós et al. 2018; Ramos Robles et al. 2018; Schooten et al. 2018). For a long 
time, the brain was also considered immunoprivileged, due to the presence of the BBB. 
However, it is now clear that immune related molecules such as inflammation factors can 
cross the BBB, for example receptors for Il-1β, Il-6 and Tnf-α are expressed on 
cerebral endothelium and systemic Il-1β and Tnf-α cause cerebral endothelial 
activation (Skelly et al. 2013). Also, cells can cross the BBB to some extent such as 
lymphocytes in response to systemic inflammation (Banks et al. 2012). Ultimately, they 
influence neuroinflammation (Galea et al. 2007). The BBB does greatly limit the levels of 
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cytokines and antibodies within the brain, compared to the blood, and neuroinflammation is 
not a guaranteed consequence of systemic inflammation. 
The mechanisms by which systemic inflammation may lead to neurodegeneration or 
neuroinflammation have been studied in many rodent models, by using administration of a 
peripheral stimulus (i.e. LPS) and/or pro-inflammatory cytokines (such as Il-1β, Il-6 and 
Tnf-α) (Dantzer et al. 2008; Andersson & Tracey 2012). Results showed that systemic 
inflammation (low doses of LPS) can cause microglial activation in both humans and animal 
models (Brydon et al. 2008; Harrison et al. 2009; Hannestad et al. 2012). The systemic 
effects seem to be mediated by increased production of NF-κB (Li et al. 2012), which is first 
observed in the microglia, but is later also observed in neurons (Zhang et al. 2013).  
Findings from both humans and animal models of obesity support the idea that a 
high-fat diet and obesity are associated with neuronal damage in the hypothalamus and this 
is associated with altered microglial activation (Thaler et al. 2012). Age-related activation 
of microglial cells within the hypothalamus could, therefore, partly explain the relationships 
between chronic systemic inflammatory conditions, such as diabetes and obesity and the 
development of the age-related neurodegenerative disease (Balakrishnan et al. 2005; Donath 
& Shoelson 2011). 
In summary, there are some circumstances in which systemic inflammatory signals 
can affect the CNS, including microglial phenotype switching in particular. These effects 
may influence disease onset and progression and warrant further study. 
1.9 Immunomodulation as a therapy 
Although it is not yet fully understood which events lead to inappropriate microglial 
activation, their roles in neurodegenerative conditions, such as AD, PD and TBI, are clearly 
important. It has been shown previously that microglia adopt different phenotypes in the 
different stages of neurodegenerative disease. In fact, in the early phase of some 
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neurodegenerative disease, microglia may adopt a neuroprotective M2 state and later 
become pro-inflammatory (M1), contributing to neurodegeneration (Kempuraj et al. 2016). 
Therefore, some strategies aimed to use immunosuppressive drugs to reduce microglial 
numbers, and/or convert M1 microglia to M0. However, it could be argued that a more 
effective approach could be used. Instead of immunosuppression, immunomodulation could 
be used to switch the microglial phenotype from M1 to M2, offering a better solution to treat 
neurodegenerative diseases. In this case, the unwanted M1 activity would be reduced, but 
also protective M2 activity would be promoted. Immunomodulatory drugs have been tested 
in in vitro and in vivo models of neurodegenerative diseases and showed some promising 
results. 
Fingolimod (Gilenya®) was the first Food and Drug Administration (FDA) approved 
MS treatment, based on its ability to modulate microglia phenotypes. In vitro, fingolimod 
modulates microglial activation, by increasing neurotrophin production and decreasing Tnf-
α, Il-6 and Il-1β release, which switch microglia towards a neuroprotective phenotype (Noda 
et al. 2013). Two independent phase-III clinical trials have approved its effectiveness 
(NCT02139696, NCT00340834) (Pawate & Bagnato 2015; Peña-Altamira et al. 2016). 
Glatiramer acetate (GA) (Copaxone®), is another immunomodulatory drug to treat 
MS, approved by FDA in 2014 (English & Aloi 2015). In vitro and in vivo studies have 
demonstrated that microglia are the key mediator in the neuroprotective effect of GA in MS, 
mainly by inducing the M2 phenotype (Giunti et al. 2014). In vitro study showed that GA 
leads to reduced release of pro-inflammatory cytokines by microglia (Chabot et al. 2002). 
Also, GA causes an elevated Il-10 levels and promotes phagocytic activity in microglia (Pul 
et al. 2011). 
 Many other possible cellular and molecular targets have been identified such as 
HMGB1, AMPK, GSK3β, HDACs and peroxisome proliferator-activated receptor γ (PPAR-
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γ) for their potential role to immunomodulate microglia (Table 1-2) (Peña-Altamira et al. 
2016). This is an interesting therapeutic target, however further studies are needed. 
Therefore, the development of an in vitro microglia system will allow better understanding 
of these mechanisms and allow the generation of hypotheses which can be tested in more 
complex models. 
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Table 1-2: Potential molecules and targets for microglia immunomodulation.  
Immunomodulatory 
molecule 
Potential targets for 
immunomodulation 
The modulation effect References 
Ethyl pyruvate (EP) 
High-mobility group 
box-1 (HMGB1) 
Dopaminergic neurons are protected 
by regulating microglial activation 
 (Huh et al. 2011) 
Inflachromene (ICM) HMGB1 
Blocks microglial-mediated 
inflammation and stimulate 
microglial-mediated neuroprotection 
(Lee et al. 2014)  
5-amino-4-imidazole 
carboxamide riboside 
(AICAR) 
AMP-activated protein 
kinase (AMPK) 
Inhibits the expression of pro-
inflammatory cytokines and iNos in 
microglia, by reducing NF-κB 
activation 
(Giri et al. 2004)  
Metformin AMPK 
Promotes functional recovery and 
tissue repair after stroke through the 
switch of microglia phenotype from 
M1 to M2  
 (Jin et al. 2014) 
GSK-3β inhibitors 
Glycogen synthase 
kinase-3 β (GSK3β) 
Reduces microglial M1-like 
activation, without affecting M2-like 
activation 
(Prati, De 
Simone, et al. 
2015) 
HDAC inhibitor 
trichostatin A (TSA) 
Histone deacetylases 
(HDACs) 
Decreases histone acetylation, 
modulating chromatin condensation 
and gene expression driving 
microglial phenotypic shift 
(Suuronen et al. 
2003; Suuronen et 
al. 2006) 
Pioglitazone 
Peroxisome proliferator-
activated receptor γ 
(PPAR-γ) 
Modulates microglia towards a more 
neuroprotective phenotype 
(Masciopinto et 
al. 2012; Barbiero 
et al. 2014)  
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1.10 Drug delivery to the CNS is hindered by the blood-brain barrier 
Developing therapies for modulating neuroinflammation with high specificity and 
low side effects may be critical to treating neurodegenerative diseases. As described in 
section 1.9, there is a substantial evidence that immunomodulatory drugs have a high 
therapeutic potential. However, many immunomodulatory drugs cannot currently be used to 
treat CNS conditions, because of the presence of the BBB, preventing or severely limiting 
drug delivery to the brain (Löscher & Potschka 2005). 
1.10.1 Blood brain barrier structure and functions  
The main function of the BBB is the regulation of transport of molecules and cells 
into and out of the CNS (Saraiva et al. 2016). The neurovascular unit is the functional unit 
of the BBB, comprising astrocytes, pericytes (the smooth muscle-like cells), endothelial cell, 
neurons and microglial cells (Figure 1-8) (ElAli et al. 2014). The BBB is a physical and 
enzymatic barrier (Lalatsa & Butt 2018). It inhibits the passage of many drugs and 
biomolecules (proteins, carbohydrates and insoluble lipid) from the endothelial capillaries 
to the brain parenchyma (Upadhyay 2014). The BBB function comes from : 
• Tight junctions between the endothelial cells that are responsible for providing a 
physical barrier between the brain–blood compartments, and the selective transport 
of important ions (Abbott et al. 2010). 
• Efflux/influx transporters that are responsible for the transport of nutrients and 
hormones, and the removal of metabolic waste, foreign substances and 
excess neurotransmitters via the ATP-binding cassette (ABC) transporters (Thurgur 
& Pinteaux 2018). 
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• Detoxifying and scavenging enzymes that are responsible for supplying trophic 
factors and hormones for brain maturtion, and the protection of the brain fluid 
environment (Abbott & Friedman 2012).  
 
Figure 1-8: Blood brain barrier functional unit (neurovascular). Comprises of astrocytes, pericytes, endothelial cells, 
neurons and microglial cells. Adapted from ElAli et al. (2014) 
In summary, the BBB is a major challenge to immunomodulatory therapies 
targeting microglia. It may be necessary to identify novel drugs with the ability to cross the 
BBB and reach microglia. However, an alternative approach would be to modify microglial 
activity, but the inability to cross the intact BBB, so that the modified form reaches the brain 
parenchyma. Various approaches are being investigated and may involve drug modification 
(conjugating particular molecules), or packaging of the drug within a delivery system so that 
it can cross the BBB. 
1.10.2 Strategies to cross the blood brain barrier 
There are different transport methods for substances to cross the BBB (Table 1-3). 
The strategies to cross the BBB either through the paracellular pathway (between adjacent 
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cells) such as ions, which could cross the BBB by simple diffusion, this usually occurs from 
the high to the low concentration side (Gjedde & Crone 1983) alternatively there is a 
transcellular pathway (through the cells) which includes mechanisms such as receptor-
mediated transport and transcytosis (Dong 2018). Despite the nature of the BBB, the 
transport of substances across the BBB depends on different factors such as their lipid 
solubility, molecular size, electrical charge and affinity for a carrier molecule (De Lange 
2012). 
Table 1-3: Representation of known transport mechanisms at the blood brain barrier. 
Type of transport Sub-type  Mechanism of action References 
Paracellular Simple diffusion Transport of the substances depends on their concentration 
on each side of the barrier 
(Gjedde & Crone 
1983) 
Transcytosis Influx transport Transport gradient by carriers from the blood into the brain (Ohtsuki & 
Terasaki 2007) 
Efflux transport Transport gradient by carriers from the brain into the blood (Scherrmann 
2005) 
Vesicular transport Receptor-mediated 
endocytosis 
Transport of the substance occurs by endocytosis of the 
materials out of the plasma membrane at the blood side of 
the BBB, then, moving through the cytoplasm of the 
endothelial cell, followed by exocytosis in the brain  
(Temsamani & 
Vidal 2004) 
Absorptive-
mediated 
endocytosis 
Transport of the substances depends on electrostatic 
interactions with anionic sites of the plasma membrane 
surface that trigger adsorptive endocytosis  
(Hervé et al. 
2008) 
  
Although the BBB used to be a major problem for treating CNS diseases effectively because 
of its selective permeability (as discussed previously), methods to cross the BBB and deliver 
therapy to the brain are being investigated currently such as cell-mediated delivery, cell-
penetrating peptides (CPPs), receptor-mediated transport (RMT) and hyperthermia 
techniques (Pandey et al. 2016). Although all of these techniques have promising results and 
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are now under clinical trials, they still have some disadvantages (Table 1-4). Therefore, 
another way has been proposed that is ‘nanotechnology’.  
Table 1-4: Pros and cons of different strategies to cross the blood brain barrier. Adapted from Pandey et al. (2016). 
Strategy Pros  Cons 
 Clinical 
trial 
Cell penetrating peptides 
(CPPs) 
Excellent penetrating ability Fast Removal Phase II 
Low cellular toxicity Non-specificity 
Immunoresponsive 
Hyperthermia Easy to perform Increase intracranial pressure Phase II 
Drug compatible Necrosis 
Tissue damage 
Cell-mediated delivery Low cytotoxicity Require high cell quantity Phase I 
Controlled drug release Cell injury 
Targeted transport 
Receptor-mediated 
transport (RMT) 
Site-specific Low dissociation rate Phase III 
 
Rapid cargo degradation 
Possible toxicity 
 
1.10.3 Nanotechnology to cross the blood brain barrier  
Nanotechnology is a material or a device that has at least one dimension on the 
nanometer scale range from a few to about 1000 nm. Nanoengineered materials and devices 
aimed at biological applications and medicine in general, and neuroscience in particular, are 
designed fundamentally to interact with cells at the molecular level. One particularly 
important area of nanotechnology application to CNS is the development of approaches for 
delivering drugs, genes, and contrast agents across the BBB. The ability to cross the BBB to 
deliver the drugs to the target site may face several challenges. First, the nanodelivery drug 
should avoid the clearance by the immune system in the body as the mononuclear 
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phagocytise system (MPS) (Dobrovolskaia et al. 2008). Second, they should be able to cross 
the BBB. Finally, they should be able to reach the target cells. 
A body of work has been aimed to overcome these challenges to cross the BBB by a 
specific mechanism such as opening the tight junctions between the endothelial cells 
(Borlongan & Emerich 2003), disrupting the tight junctions by using the osmotic shock 
which leads to shrinking the endothelial cells (Doolittle et al. 2000). However, these methods 
might cause extra damage since they may lead to the presence of unwanted blood 
components in the brain which could lead to neuronal damage/death. Therefore, using 
nanotechnology s facilitator to cross the BBB (Lipinski et al. 2001). 
Another challenge for the drug to reach the CNS is that most of these drugs are 
intravenously (i.v.) administered which leads to recognising them by the MPS in the body, 
causing a major loss of the injected dose (>50 %) within a few hours after an i.v. injection 
(Li & Huang 2010). Therefore, a modification to the surface of the drug/ drug carrier should 
be made to avoid the clearance by the MPS and increase the half-life of the drug in the 
circulating system which increase the changes to reach the CNS, and that is why some drugs 
have been coated with poly(ethylene glycol) (PEG) (Verrecchia et al. 1995; García et al. 
2014). Nanotechnology also used the PEGylated coating especially in term of treatment and 
imaging CNS cancers (Malam et al. 2009; Bae & Park 2011). PEGylated nanoparticles (NPs) 
are often mentioned as “stealth” NPs, because of their ability to escape the surveillance of 
MPS better than the non-stealth nanoparticles.  
Research is focusing on using PEGylated nanoparticles for the delivery of drugs that 
have poor solubility under physiologic conditions and require specific carriers. In a MS 
model, PEGylated nanoparticles showed the ability to cross the BBB and accumulate at high 
concentration in the brain (Calvo et al. 2002). In a rat model of PD, a tyrosine hydroxylase 
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expression plasmid was delivered to the striatum of adult rats using PEGylated NPs to 
normalise tyrosine hydroxylase (TH) expression levels. By using specific antibodies to 
transferrin receptors conjugated to the nanoparticles, TH plasmids were shown to be 
expressed throughout the striatum (Zhang et al. 2003). 
There are increasing number of researches interested in using PEGylated NPs in 
treatment and diagnosis, and an increasing body of work indicates that PEGylated NPs could 
escape clearance by the MPS (Zhu et al. 2017; Shen et al. 2018), and increased crossing of 
the BBB, but even after entering the CNS there is another immune cell with phagocytosis 
ability (microglia). Microglia could engulf NPs, which may or may not be useful, depending 
on the intended target of the drug payload. If drugs are intended to activate surface receptors, 
it would be preferable to avoid cellular uptake. But if intracellular delivery to microglia is 
intended, then this uptake may be beneficial. However, there is limited research into the fate 
of NPs within the brain, and also with respect to interactions between NPs and microglia, in 
particular. 
1.10.4 Microglia response to nanoparticles  
Some studies have evaluated microglial response to NPs, including these that may be 
encountered accidentally (e.g., through pollution), or these intended for research of 
therapeutic purposes. These studies will be discussed here. 
The effect of NPs’ toxicity on microglia have been studied using NPs with different 
composition such as SiO2, TiO2, Fe3O4, Ag and Au NPs, although none of these NPs used 
as drug-delivery vehicles, none of these NPs cause any toxic effect on microglia especially 
in the low to moderate concentration (Xue et al. 2012; Söderstjerna et al. 2014). Although 
NPs did not cause a direct toxic effect on microglia, further studies have been performed to 
understand their effect on microglial activation state. 
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In vitro studies regarding the inflammation caused by NPs used to treat microglia 
have primarily suggested an increased ROS and RNS in NPs treated microglia (Long et al. 
2006; 2007; Choi et al. 2010; Wang et al. 2011). Fe3O4- and TiO2-NPs have been shown to 
induce ROS and RNS generation in BV-2 microglia cell line (Long et al. 2007; Wang et al. 
2011), and similar observation has been made when primary microglia culture have been 
treated with Si-NPs (Choi et al. 2010). However, Xue et al. (2012) reported no increase in 
RNS production or iNos gene expression by microglia when treated with SiO2-NPs or Fe3O4-
NPs. 
Few studies have tried to understand the effect of NPs on pro-inflammatory factors 
produced by microglia such as Tnf-α and Il-1β (Choi et al. 2010; Wang et al. 2011; Xue et 
al. 2012). Choi et al. (2010a) reported that silica NPs (ranging from 150 to 200 nm in 
diameter) induced the expression of Tnf-α, Il-1β and cyclooxygenase 2 (Cox-2) in primary 
microglia. Xue et al., (2012) reported that Fe3O4-NPs also induced the protein production of 
Tnf-α, Il-1β and Il-6 in primary microglia. In contrast, Wang et al. (2011) observed that 
microglia treated with Fe2O3 NPs did not lead to elevation of the levels of inflammatory 
cytokines Tnf-α, Il-1β and Il-6. 
In summary, microglia can internalise a variety of NPs, with no obvious toxic 
effect. These NPs could lead to alternative microglial response. A better understanding of 
microglial response will be necessary, if NPs are to be considered as a drug delivery method 
for manipulating microglial functions. 
1.11 Greater understanding of microglial phenotype switching is required 
An understanding of neurodegenerative diseases will be greatly enhanced by a full 
understanding of microglial phenotype switching. As discussed above, it is widely 
speculated that events such as inappropriate M1 activation, loss of phagocytic function or 
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microglial priming are key to disease onset or progression (Gao & Hong 2008). If this is 
true, then determining the stimuli that lead to these events could offer valuable insight into 
currently untreatable and devastating diseases. Such insights could inform the development 
of effective therapies based on neuroimmunomodulatory drugs and harnessing the 
protective/regenerative abilities of microglia.  
Studying microglial phenotype switching is important, since microglial response 
varies to different stimuli, refined phenotypes (M0, M1, M2) were proposed. Microglia 
phenotype identification is usually based on the different markers that these phenotypes 
produce, for example M1 microglia are associated with pro-inflammatory cytokines, while, 
M2 microglia produce anti-inflammatory markers. Microglia phenotype will depend on CNS 
environment which is complex and hard to define precisely. The mechanism behind the in 
vivo phenotype switching is not fully understood. However, some reports suggested the 
ability to drive microglia from one phenotype to another, which could be a good target for 
treating neurodegenerative diseases. 
While the in vivo environment is too complex to study, in vitro models may be 
viewed as overly reductionist. However, such models will allow the mechanisms crucial to 
switching of microglial phenotype to be defined to develop hypotheses with regards these 
mechanisms, which can be tested in more complex models.  
The available researches on microglia phenotype often lack to full 
characterising the model. These studies usually depend on using only one concentration of 
the stimuli, which makes it difficult to know if the microglia response is the highest response. 
Also, they depend on only one-time point. Such limitations in the current studies make these 
models not the best option to study microglial phenotype switching in disease and on testing 
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different treatments. Therefore, increasing the knowledge in these areas will require suitable 
models to study microglial phenotype switching. 
1.11.1 Gene expression studies require greater rigour 
Gene expression is of interest to microglial researchers (Bennett et al. 2016Plastira 
et al. 2016; Rey et al. 2016; Yang et al. 2017), and is likely useful for identifying phenotypic 
changes (Satoh 2017). Furthermore, characterising an exclusive gene expression signature 
of different microglia state would be of great importance for both understanding microglia 
biology behaviour in healthy brain and developing microglia-targeted therapy for different 
neurodegenerative diseases. 
There are different assays for gene expression analysis such as quantitative 
polymerase chain reaction (qPCR), microarray and RNA sequencing (RNA-seq). qPCR 
(referred to as real-time PCR) is a widely used assay to determine relative transcript numbers 
in biological samples. qPCR is a robust, highly reproducible and sensitive method to 
quantitatively study gene changes across varying environmental or experimental conditions. 
Furthermore, reverse transcription analyses are now combined with qPCR methods (RT-
qPCR), offering a powerful tool for quantifying gene expression (in terms of relative 
quantities of mRNA transcripts). Microarray is used to measure DNA expression levels of 
thousands number of different genes at the same time. RNA-seq also has the abilty to look 
at differential expression at the same time and even discover new genes or alternative splice 
variations; however RNA-seq is expensive and represents a challenge in the planning stage. 
qPCR has a wide dynamic range and low quantification limits in comparison to microarrays 
or RNA-seq. 
Most microglial RT-qPCR studies have used glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) or ACTB as the sole reference gene. However, their suitability as 
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reference genes is questionable, because of their potential involvement in a wide range of 
physiological conditions. Furthermore, the minimum information for publication of 
quantitative real-time PCR experiments (MIQE) guidelines highly recommend using 
multiple reference genes for reliable qPCR data (Bustin et al. 2009). Therefore, it is 
surprising that, to date, no study has been performed to identify the reference gene(s) for 
normalisation of transcript levels in microglia. 
1.12 Modelling microglial phenotype switching 
Models for studying microglial phenotype switching that offer greater control are 
needed, and the ability to measure phenotype-relevant changes. But, widely-used microglial 
models have various drawbacks. 
Human data for live microglia are limited due to the difficulty to study the 
microglia in human before death. Although, there has been some progress in in vivo imaging 
of microglia, it is impossible to study phenotypes in detail in living patients. Although 
neuroinflammation could be detected, implying M1, current techniques cannot reliably 
identify microglial phenotype.  
Human tissue samples are available with some limitations such as ethical approval 
and high biosafety requirement to deal with such samples. There is no regular source of live 
microglia from humans that could be studied in vitro. Furthermore, cells sometimes are 
available, but not on a regular basis, that make it possible to study microglia phenotype in 
neurodegenerative diseases. Post-mortem samples are available from tissue banks; from 
patients with neurological diseases. However, characterising microglia phenotype in fresh 
brain is more challenging than assessing fixed brains or fixed blocks. 
Furthermore, the fixation and storage of these tissues may not always be perfect 
for preserving markers. Also, it is difficult to reliably get mRNA/gene expression data for 
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human microglia and to have control groups. In addition, access to the patient’s disease 
history is limited and it is difficult to definitively know whether the human source had or 
was developing specific diseases. 
Live animal models offer some advantages, including the presence of the BBB, 
all cell types being present, …, etc. But microglia are difficult to monitor in live animals; it 
is more difficult to control experimental conditions in vivo, with experiments being time 
consuming, low throughput and requiring more training, compared to cell culture. 
Furthermore, animal models are limited due to the legal restrictions on their availability and 
use, particularly for therapy development projects. 
Therefore, in vitro microglial cultures can overcome many of these problems, 
representing a valuable tool to study microglial phenotypes. In vitro studies enable 
assessment of secreted factors, cell motility, allow testing of more concentrations/times and 
other important components that characterise microglia, which cannot be appropriately 
studied in vivo. 
Microglial cell line has been widely used in studying microglia, but one of big cell 
line’s problem is the immortalised cell lines ability to genetically drift or select for certain 
phenotypes, as they are passaged many times over. This may explain why the same treatment 
(stimuli) lead to different response. Cheepsunthorn et al. (2001) and Horvath et al. (2008) 
studies showed different results when treated highly aggressively proliferating immortalised 
cell line (HAPI; microglia cell line) with LPS. Cheepsunthorn et al. (2001) found an increase 
in Tnf-α release in the culture media, while, Horvath et al. (2008) found no release of Tnf-α 
into the media at either 24 or 48 h.  
Ultimately, it would be of high value to the research community to develop an in 
vitro microglial model that reliably predicts/measures phenotype switching. Such a model 
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would allow the study of pathological stimuli, and the screening of immunomodulatory 
drugs. This may be particularly useful in the context of drug delivery systems that employ 
novel biomaterial-based technologies. 
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1.13 Aims and objectives of the experimental Chapters 
This thesis will describe studies to develop an in vitro model of microglial 
phenotype switching, focussed on gene expression analysis. 
1.13.1 Objectives  
• To develop an in vitro microglial culture system, to study phenotype switching. 
Identify and validate multiple reference genes for microglial qPCR studies. 
• To collect detailed gene expression changes in response to a widely-used M1 
stimulus. 
• To collect detailed gene expression changes in response to a widely-used M2 
stimulus.  
• To assess whether nanoparticles alter the expression of M1 and M2 markers genes 
and the activity of inducible nitric oxide synthase system. 
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1.13.2 Experimental studies descriptions 
Chapter 3: Validating culture system and methods for microglial studies 
Validation of primary microglial culture and qPCR methods was the aim of this 
Chapter. The purity of microglia derived from primary mixed glial culture was assessed. 
qPCR primers for multiple reference genes and genes of interest were designed and 
validated. Yield of mRNA from microglia was assessed. Sex-dependent differences in 
microglial gene expression were studied. 
Chapter 4: Characterising primary microglia culture in serum-free media 
The possibility that serum may alter ‘baseline’ microglial activation, or maximum 
response, was tested in this Chapter. Serum-free media were tested for maintaining 
microglial cultures. 
Chapter 5: Characterising microglial responses to pro-inflammatory activation 
The primary aim for this Chapter was to characterise microglial responses to a range 
of concentrations of an M1 stimulus, and at different time points. These data would permit 
the calculation of the maximum response and EC50 values, which will be useful in 
understanding microglial behaviour in disease. These data would allow the comparison 
between different stimuli, including pathology-associated molecules. They would also be 
useful for determining the effects of potential microglia-targeted drugs. The secondary aim 
was to investigate whether microglia may exhibit behaviours consistent with ‘priming’, in 
this in vitro model. 
Chapter 6: Characterising microglial responses to anti-inflammatory activation 
The aim for this Chapter was to characterise microglial responses to a range of 
concentrations of M2 stimuli. Calculating the maximum response and EC50 values, as 
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previous chapter, would be useful in understanding microglial responses in different 
phenotypic states, and potentially aid development of immunomodulatory therapies 
targeting microglia. 
Chapter 7: Microglial response to different nanoparticle formulations, including 
‘stealth’ coat  
The primary aim of this Chapter was to study whether NPs induce inflammatory 
responses in M0 microglia, and whether a ‘stealth’ coating may limit any such responses. A 
‘control’ NP was compared to a stealth NP, identical except for the coating. NP toxicity and 
levels of uptake were compared for both. The secondary aim was to investigate if M1 (pre-
activated) microglia have their inflammatory responses exacerbated by interaction with NPs, 
including stealth NPs.  
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Chapter 2 : Materials and methods 
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2.1 Experimental design  
In comparison with in vivo, in vitro studies provide methodological benefits for 
high-throughput screening of microglial response, including greater experimental control 
(e.g., direct application of treatments, with identical local concentrations), and ease of 
monitoring. In vitro experiments also use fewer animals and produce larger numbers of 
microglia with high purity (Schmid et al. 2009). Multiple doses and time points can be 
studied with cells derived from the same source, reducing noise due to biological variation 
between animals. Rodents were chosen as a model organism because their genetic and 
biological characteristics closely resemble these of humans (Galatro et al. 2017). Also, there 
is evidence that the immune system in rat shares many characteristics with that of human 
(Guerrero & Reiter 2002; Azizi et al. 1998). 
2.2 Reagents and equipment 
Unless otherwise stated, culture plastics, media and reagents were from SLS, 
Sigma-Aldrich and Fisher, UK. End-point PCR used a thermocycler (Bibby Scientific, UK), 
qPCR was performed using a PrimePro48 machine (Techne, UK).  
2.3 Primary microglial culture  
The care and use of all animals in the production of cell cultures were in accordance 
with the Animals Scientific Procedures Act of 1986 (UK) with approval by the local ethics 
committee. 
Primary mixed glial cultures were prepared from the cortices of postnatal day 0-3 
rat (McCarthy & de Vellis 1980). Briefly, the cortices have been dissected in 1 M HEPES 
with HBSS and 2 % penicillin–streptomycin and removal of the meninges, the cortices were 
chopped into small pieces and subsequently mechanically dissociated. Dissociated cortices 
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were maintained in D10 media [Dulbecco’s modified Eagle’s media (DMEM) supplemented 
with 10 % fetal bovine serum (FBS), 50 U/ml penicillin, 50 µg/ml streptomycin, 1 mM 
sodium pyruvate and 2 mM Glutamax] in poly-D-lysine (PDL) coated flasks until confluent 
(37 °C; 5 % CO2; 95 % humidified air; 7-10 days). Cultures were maintained in D10 media 
with a 50 % D10 refresh every 2-3 days. Microglia were isolated by mechanical shaking 
(ThermoScientific, USA) (200; 37 °C; 90 min; Figure 2-1). Medium enriched with microglia 
was collected, cells pelleted by centrifugation (300 g, 5 min), counted then plated in D10 (6 
x 105 cells/cm2; PDL-coated coverslips or 12 well plates or 24 x 105 cells/cm2; PDL-coated 
T25 flasks). The plating density have been increased from 6 to 24 x 105 cells/cm2 to increase 
the amount of RNA extracted from microglia cells. The day after plating, cultures were 
treated. 
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Figure 2-1: Schematic diagram illustrating the main procedures for the preparation of purified microglia from 
mixed glial cultures. Neonatal cortex is dissociated and cultured in flasks until confluent. Once confluent, astrocytes 
force microglia and oligodendrocyte precursors to form an upper layer of cells. Simple shaking can then release 
microglia, which can be plated in high purity culture. After experimental treatment (e.g., LPS to induce M1 
phenotype), cells can be imaged live or fixed and stained. In parallel, mRNA can be extracted from cultures for 
qPCR analysis. Finally, culture media can be collected to assess what cytokines have been secreted and/or detect 
products of reactive nitrogen species. Adapted with permission from Dr Stuart Jenkins (Keele University) Jenkins 
(2013).  
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2.4 RNA extraction and quantification of gene expression by qPCR  
2.4.1Selecting genes of interest and reference genes 
The literature search identified several genes that could serve as markers for 
different microglial phenotypes (Table 2-1). A panel of three reference genes (Gapdh, Usp14 
and Rpl32) was used for the quantitation of changes of gene expression (see section 3.1.3). 
Table 2-1: List of microglial phenotypic markers. Upregulation or down–regulation of each gene (marker) helps in 
the distinction between different phenotypes. 
Phenotype Genes (markers) with altered 
expression  
References 
M0 Cd200R  (Zhang et al. 2011; Butovsky et al. 2015) 
M1 Il-1β, Il-6, Tnf-α and iNos  (Ling & Wong 1993; Chhor et al. 2013; FreILich et al. 
2013; Orihuela et al. 2015) 
M2 Fizz1, Arg1, Il-10, Tgf- and 
Ym1 
 (Chhor et al. 2013; Kobayashi et al. 2013; Cherry et al. 
2014; Orihuela et al. 2015) 
 
2.4.2 RNA extraction and RNeasy columns 
Total RNA was purified according to Qiagen RNeasy instructions. Before RNA 
extraction, supernatant (conditioned media) was collected and stored at -80 °C until analysis 
of nitrite levels. Cells were washed twice with diethylpyrocarbonate (DEPC; used to inactive 
RNase enzyme) containing phosphate buffered saline (PBS), homogenised in lysis buffer 
and transferred to eliminator spin columns to remove gDNA (genomic DNA). Then, three 
wash steps (RW1 and RPE buffers) removed salts and biomolecules (e.g., carbohydrates, 
proteins, fatty acids, …, etc.). RNA was eluted using RNase-free water, then the RNA 
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concentration and purity level was quantified using Nanodrop (NanoDrop Technologies, 
USA) then stored (-80 °C). 
2.4.3 Reverse transcription 
Total RNA was reverse transcribed into complementary DNA (cDNA) using the 
iScript™ cDNA synthesis kit (BIO RAD, UK), according to kit instructions. 1-2 μg of RNA 
was combined with reaction mix and reverse transcriptase in a thermal cycler (Prime thermal 
cycler, Bibby Scientific) (5 min, 25 °C; 30 min, 42 °C; 5 min, 85 °C). Negative controls 
(RT; this control assesses the amount of DNA contamination present in an RNA preparation) 
omitted the reverse transcriptase enzyme. 
2.4.4 Primer design 
Primer pairs were designed to generate amplicons between ~75 and 300 base pair 
(bp) since short PCR products are typically amplified with higher efficiency than longer ones 
(Ma & Chung 2014). An amplicon should be at least 75 bp to easily distinguish it from any 
primer-dimers that might form (primer dimers are short non-target PCR products, formed 
from partial complementarity of the primers with non-target templates, or among the primers 
themselves) (SantaLucia 2007) and to cross at least one intron so that products amplified 
from gDNA will be a different size to these amplified from mRNA. The search algorithm 
was set to keep guanine cytosine (GC) content between 50-60 % (for optimum PCR 
efficiency as clusters of G’s or C’s can cause non-specific priming) and melting temperatures 
close to 60 oC (because primers with melting temperatures above 65 oC have a tendency for 
secondary annealing). The primers designed with NCBI Primer Blast software. Table 2-2 
lists the sequences and NCBI references of used primers for RT-qPCR (SantaLucia 2007; 
Ma & Chung 2014).  
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Table 2-2: List of primers used for real-time reverse transcription polymerase chain reaction (RT-qPCR). 
References to literature indicate sequences derived from published papers. All other primer pairs were designed as 
part of this project. bp = base pairs. 
Gene NCBI references Forward primer Reverse primer Amplicon 
length (bp) 
Arg1 NM_017134.3 TCGGAGCGCCTTTCTCTAAG ATCCCCGTGGTCTCTCACAT 125 
Arg1 
(Louveau et 
al. 2015) 
NM_017134.3 CCAACTCTTGGGAAGACACCA GTGATGCCCCAGATGACTTT 173 
ATP6AP2 NM_001007091.1 CGCCAGGGTCTGTTGTTTTC GGAATAGGTTGCCCACAGCA 138 
Gapdh NM_017008.4 CAGGGCTGCCTTCTCTTGTG GGTGGTGAAGACGCCAGTAG 256 
Gusb NM_017015.2 GAGCGAGTATGGAGCAGACG GGCACTGAACCGTAACCTCT 306 
Il-10 NM_012854.2 CCTGGTAGAAGTGATGCCCC GATGCCGGGTGGTTCAATTT 281 
Il-1rn NM_022194.2 GGGGACCTTACAGTCACCTA ACTTGACACAAGACAGGCACA 279 
Il-1β NM_031512.2 TGGCAACTGTCCCTGAACTC ACACTGCCTTCCTGAAGC TC 192 
Il-6 NM_012589.2 CACTTCACAAGTCGGAGGCT TCTGACAGTGCATCATCGCT 114 
Itgam, 
Cd11b, Cr3 
NM_012711.1 TGCTGAGACTGGAGGCAAC CTCCCCAGCATCCTTGTTT 101 
Mtco2 GenBank: S67722.1 TGGCTTACAAGACGCCACAT TGGGCGTCTATTGTGCTTGT 156 
Rpl22 NM_031104.1 CACTTCCGAGGAGCCTTTCT TCGTAGCTCTCCTTGCTGTTG 117 
Rpl32 NM_013226.2 GGTGAAGCCCAAGATCGTCA ATCTTCTCCGCACCCTGTTG 125 
St13 NM_031122.1 GAGCCATCGAGTGAGGAGAG AAACACTGGCTCTCTTGGCA 256 
Tgf-β NM_021578.2 CTGGAAAGGGCTCAACACCT AGAAGTTGGCATGGTAGCCC 172 
Tnf-α NM_012675.3 ACCATGAGCACGGAAAGCAT GTTTGCTACGACGTGGGCTA 297 
Usp14 NM_001008301.1 TCCAGCCAGCCAGACAAAAA GAGCATCTGCTGACCCCATC 117 
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2.4.4.1 Endpoint PCR 
Standard polymerase chain reaction was performed for each primer pair to produce 
a high copy number of each PCR product for assessing the primers efficiency using MyTaq 
Red Mix (Bioline, UK), according to the kit instructions. 200 ng of cDNA was combined 
with 1 µl primer and 25 µl MyTaq Red Mix, and after 1 min initial denaturation, went 
through 40 PCR cycles (15 s denaturation at 95 oC, 15 s at 55 oC, 10 s extension at 72 oC). 
The final product was either used for primer efficiency (the fraction of target molecules that 
are copied in one PCR cycle (Svec et al. 2015)) or run on agarose gel to detect the amplicon 
length.  
2.4.4.2 Gel electrophoresis  
Two microliter of each standard PCR product was mixed with 4 µl loading buffer 
(Bioline). The mixture was electrophoresed on 2 % agarose gel (prepared from dissolve 
agarose powder in trisborat-ethylene diamine acid (TBE) buffer and visualised using 
ethidium bromide) for one hour at 100 Volt then imaged using UV transillumination and 
digital photography. The size of each unknown primer pair was calculated with the standard 
curve equation derived from the ladder (hyper ladder 100 pb, Bioline). 
2.4.5 RT-qPCR  
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was 
performed for each sample using SYBR Green Supermix (Bio-Rad) for 40 cycles with a 2-
step program (5 s at 96 °C (denaturation) and 10 s at 60 °C (annealing temperature)). 
Amplification specificity was assessed by melt curve and electrophoresis analyses. Two 
qPCR controls were run with each qPCR plate RT- and NTC (no template control; general 
61 
 
control for extraneous nucleic acid contamination), which helps in detecting any 
contamination. 
2.5 Time-lapse microscopy 
Dynamic time-lapse transmitted light allowed real-time assessment of microglial 
numbers, behaviours and morphologies. Images captured at a frequency of 1 frame/120 s 
over a period of 24 h. 
2.6 Immunocytochemistry  
For immunocytochemistry 300 µl (6 x 105 cell/ml) microglia were plated onto glass 
PDL-coated coverslips, incubated in 37 °C, 5 % CO2, 95 % humidified air overnight and 
then treated according to the experiment condition. Microglia cultures were gently washed 
three times with PBS (5 min; room temperature) then fixed [4 % w/v paraformaldehyde 
(PFA) in PBS; 20 minutes; room temperature; in fume hood]. Fixed cells were washed three 
times with PBS (5 min; room temperature), non-specific staining was blocked (blocking 
solution: 5 % normal donkey serum (NDS) and 0.3 % Triton in PBS) for 20 min at room 
temperature, then primary antibodies in blocker (overnight; 4 °C; Table 2-3). Cells were then 
washed three times with PBS (5 min; room temperature), blocked with blocking solution (30 
min, room temperature), incubated with secondary antibodies (2 h; room temperature; Table 
2-4), washed three times with PBS (5min; room temperature) and then mounted with DAPI 
(4',6-diamidino-2-phenylindole; nuclear stain) (Vector laboratories, UK). 
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Table 2-3: List of primary antibodies used in the immunostaining. Type of antigen, primary antibody with their 
source species and concentration used on microglia imaging.  
Antigen/marker Antibody (label, product code) Specificity for 
secondary antibody 
Concentration 
Poly–N–acetyl lactosamine 
sugar residues 
Lectin (Sigma-Aldrich, L0651) Biotin-labelled 1:200 
CD200 OX-102 (Abdserotec, MCA 1959GA) Mouse IgG Anti-Rat 1:200 
Fractalkine receptor Cx3cr1 (Amsbio, TP501) Rabbit IgG Anti-Rat 1:200 
 
Iba1 Anti-Iba1 (Abcam, ab 5076) Goat IgG Anti-Rat 1:500 
Iba1 Anti-Iba1 (Wako, 019-19741) Rabbit IgG Anti-Rat 1:2000 
iNos iNos (N-20) (Santa Cruz, sc-651) Rabbit IgG Anti-Rat 1:100 
 
Table 2-4: Secondary antibody dyes/fluorophores, with excitation and emission wavelengths. 
Secondary antibody label 
Excitation 
wavelength (nm) 
Emission 
wavelength (nm) 
Concentration 
Cyanine 3 (Cy3) 550 570 1:200 
Fluorescein isothiocyanate 
(FITC) 
495 525 1:200 
 
2.7 Microscopy and image analysis 
2.7.1 Fluorescence microscopy 
Immunostaining and phase contrast images for each sample were obtained using an 
Axio Scope A1 fluorescence microscope (Carl Zeiss MicroImaging, Germany), the images 
have been taken using 200 or 400 x magnification, similar exposure time was used to cross 
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the different condition / culture/ experiment. Photoshop CS3 (Adobe, USA) was used to 
merge counterpart images; three channels were merged to form ‘triple merge’ images. At 
least 100 cells from at least four microscopic fields were captured per condition for 
subsequent analysis using ImageJ software. Individual cells were delineated using phase 
contrast micrographs, and this outline transferred to the corresponding red or green channel 
micrographs for integrated density measurement, which is the sum of the pixel values in the 
selected area (with background intensity subtracted for each image; fluorescence intensity 
measured in multiple cell-free regions).  
2.7.2 Morphology (shape parameters) 
Several morphological parameters were also measured while the integrated density 
analysis was being performed. The morphology analysis has been done to test the hypothesis 
that microglia change their shapes in the activation state. These parameters are shown in 
Figure 2-2. 
2.7.2.1 Area  
Area was calculated automatically by ImageJ once individual objects were 
delineated and is expressed in square micrometres. 
2.7.2.2 Perimeter 
This parameter was calculated based on the outline length of a given object and is 
expressed in microns.  
2.7.2.3 Feret’s maximum and minimum diameters 
Feret’s maximum diameter is the distance between the two furthest points of an 
object. Feret’s minimum diameter represents the perpendicular distance between the closest-
possible two parallel lines, that touch the object edge while the entire object is between them. 
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Therefore, it can be stated as the shortest distance at which callipers could be set, while 
capturing the entire object. Feret’s minimum is not necessarily perpendicular to Feret’s 
maximum. 
2.7.2.4 Aspect ratio 
Aspect ratio is calculated as the ratio between the major and the minor axis of the 
best fitted ellipse to a given object.  
 
Figure 2-2: Morphological analysis involved multiple features. Outline of cell (red line) was drawn using ImageJ 
software, and computer analysis provided area, perimeter, longest axis (yellow) = Feret’s diameter, shortest axis 
(yellow) = Feret’s minimum diameter, and aspect ratio = Feret’s diameter / Feret’s minimum diameter. 
2.8 Nitrite Quantification: Griess assay 
Pro-inflammatory microglia produce ROS and RNS, including NO (Zielasek et al. 
1992). To assess the production of NO in microglia, the extracellular release of nitrite 
(NO2−), a stable metabolite of NO, was measured by Griess reagent (Promega) according to 
the instructions provided by the manufacturer. Supernatant samples (50 μl) were mixed with 
50 μl of Griess reagent (sulfanilamide solution) in a 96-well plate and incubated at room 
temperature for 10 min in the dark then 50 μl of NED (N-(1-Naphthyl) ethylenediamine) 
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solution was added and incubated at room temperature for a further 10 min in the dark. The 
absorbance was measured with a 550 nm filter by a Promega microplate spectrophotometer 
(Promega Biosystems Sunnyvale, USA). A sodium nitrite standard curve was constructed 
with nitrite concentrations ranging from 0 to 100 μM. The concentration of nitrite was 
calculated with the linear equation derived from the standard curve. 
2.9 Statistical analysis 
 Regarding the statistical analysis of qPCR results, advice was sought from a statistician. 
The advice was to perform the statistical analysis on the summary of the dose- response 
curve (half-maximal effective concentration (EC50) and maximum dose response) which is 
representative for the curve behaviour. Separate best-fit curves were produced for each 
dataset (GraphPad Prism software). EC50 and maximum dose response values were then 
derived from these curves and subjected to heteroscedasticity testing. The curves are 
generated from semilogarithmic plots, and the parameters derived from these curves were 
log normally distributed (Kenakin 2014). It was decided that Tukey’s or Dunnett’s post-hoc 
tests would be appropriate for datasets subjected to ANOVA. 
The 2–∆∆Cq method of qPCR analysis was used here (Livak & Schmittgen 2001). It has been 
suggested that the raw quantitation cycle (Cq) values generated by RT-PCR were unsuitable 
for statistical analyses unless been transformed to 2–∆∆Cq (Schmittgen & Livak 2008). 
Changes in the gene of interest (GOI) expression are calculated relative to the average 
expression of three references genes, as recommended by MIQE guidelines (Bustin et al. 
2009). The fold change was calculated by the following equation: 
∆Cq = Cq (target gene) – Cq (average of three reference genes) 
∆∆Cq = ∆Cq (treated) – ∆Cq (untreated) 
Fold change = 2–∆∆Cq 
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Individual dose-response curves have been fitted for each time point and medium in 
chapter 4 and 5 respectively, using GraphPad Prism software version 7 (GraphPad, USA), 
which allows the determination of dose-response curve summary statistics (EC50 and 
maximum dose response). A statistical comparison of dose response curves has not been 
carried out, only a comparison between summary statistics. 
EC50 is concentration of an agonist that provokes a response halfway between the 
baseline (bottom) and maximum response (top). The EC50 values were derived using 
GraphPad Prism software, which can automatically generate these values by using the 
following equation: 
Y=Bottom + (Top - Bottom) / (1+10 ((LogEC50-X) *Hillslope)) 
The EC50 values have been expressed as p-values (−log of the value, pEC50) since 
EC50 values are log normally distributed, meaning that pEC50 will give a normal 
distribution. This approach is strongly recommended by Kenakin (2014). The baseline 
expression was calculated by comparing the controls (untreated) of serum free media to D10 
media (in chapter 4). 
Levene’s test was used to determine the homogeneity of variance across the data. 
Non-homogenous data have been transformed (to become homogenous) by using log10. All 
statistical parametric tests were performed using normally distributed data (logarithmically 
expressed data) (Kenakin 2014), except the data discussed below which has been compared 
by the non-parametric Kruskal –Wallis test. 
Statistical analyses including unpaired t-test, one-way ANOVA with Tukey’s, one-
way ANOVA with Dunnett’s and Kruskal-Wallis with Dunn’s were used throughout this 
thesis. Unpaired t-test was used to compare between two groups of data. One-way ANOVA 
with Tukey’s was used for all-pairwise comparisons (Savillee, 1990), while, one-way 
ANOVA with Dunnett’s was used for multiple-to-one comparisons (Shun et al., 2003). 
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Kruskal-Wallis with Dunn’s was used for non-homogenous data (that could not be 
transformed with conventional transforming methods). This test has been used to compare 
nitrite concentration and immunostaining intensity, MNP-associated fluorescence intensity, 
and morphometrics with their controls. The chosen statistical test and level of significance 
were indicated in each figure legend. All data are presented as mean ± standard error of the 
mean (S.E.M.). 
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Chapter 3 : Validating the culture system and 
methods for microglial studies 
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3.1 Introduction 
3.1.1 Microglial culture systems  
Microglia cell culture systems were first described in the early twentieth century 
(Cammermeyer 1966). However, studying microglial behaviour has been delayed until 
methods to obtain and culture large number of microglial cells were developed and 
optimised. Although they are likely to behave differently from microglia in vivo, in vitro 
cultures provide large numbers of pure microglial cells which allows the detailed study of 
microglia phenotype, motility and other crucial mechanisms that characterise microglia, 
which cannot be sufficiently examined in vivo. 
Nowadays there are many models to study the role of microglia n 
neurodegenerative diseases. These include primary microglia cultures, and microglia cell 
line cultures. These culture models share similarities but on the other hand they have critical 
differences that must be considered when choosing an appropriate model for 
neurodegenerative research. 
3.1.1.1 Primary microglia cultures 
The first description of a technique to isolate high-purity primary microglia was by 
Giulian and Baker (1986). Giulian and Baker used a neonatal rodent brain to produce 
sufficient numbers of microglia to perform microglia functional assessments. Warm-shake 
method was Giulian and Baker’s principle which is still widely use today, although several 
modifications have been made to it, this technique could be performed on different species 
(mouse or rat). Most of early protocols to produce high purity microglial cultures were based 
on the use of neonatal rodent CNS tissue and few protocols have been designed to isolate 
adult microglia (Stansley et al. 2012). Although, adult microglia more mimic the in vivo 
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microglia in the mature brain (Ponomarev et al. 2005), however, cultured adult microglia do 
not survive for a long time, and are generated with low output and low purity (Nikodemova 
& Watters 2012). Therefore, it is difficult to use primary adult microglia to understand the 
biology of these cells (Frank et al. 2006) (as discussed in section 1.12).  
Primary microglial cell culture has been used in many neuroinflammatory studies 
(Hunot et al. 1999; Parvathenani et al. 2003; Sondag et al. 2009; Gillardon et al. 2012), since 
they mimic in vivo microglia more closely than cell lines do. For example, in terms of 
secretory products and cell surface markers, it has been found that primary microglial cells’ 
stimulation with LPS, that leads to activation of microglia in vitro in similar to in vivo 
activation (Colton 2009; Ransohoff & Perry 2009). The activated primary microglia has the 
ability to produce several pro-inflammatory cytokines such as: Il-1β, Il-6 and Tnf-α, also 
production of NO via upregulation of iNos and superoxide anions via activation of 
nicotinamide adenine dinucleotide phosphate (NADP) oxidase (Boje & Arora 1992). 
The ability to measure microglia cellular function and morphology using this model 
makes it a useful first line research tool to screen the immunomodulatory potential of novel 
therapeutics.  
3.1.1.2 Microglial cell lines  
Microglial cell lines are typically easy to maintain in culture, which overcomes low 
yield and cost problems. However, apart from the genomic alterations that make them 
immortal, other differences in comparison to primary microglia include lack of production 
of some cytokines, nitrite free radical’s production and different response to some stimuli 
(Table 3-1) (Stansley et al. 2012). 
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Table 3-1: Microglial cell lines often differ from primary and in vivo microglia. All of the cell lines listed here, fail 
to replicate a normal microglial response to these stimuli, whereas primary-derived microglia do mimic in vivo 
responses. Adapted from Stansley et al. (2012) 
Stimulus 
Normal in vivo 
response 
Primary microglia 
Cell lines 
BV-2 HMO6 HAPI 
LPS-treatment 
IL-1β release + - + + 
NO production  + + - + 
Aβ-treatment IL-1β release + + - - 
LPS = lipopolysaccharide; Aβ= amyloid-beta, IL-1β= Interleukin-1 beta, NO= nitric oxide. 
 
3.1.1.2.1 Animal-derived microglial cell lines  
Immortalised cell lines can be generated by infecting the cells with a retrovirus. 
Two commonly used mouse-derived cell lines are BV-2 and N9, and rat-derived lines 
include HAPI. 
BV-2 cells were derived from murine neonatal microglia and are the most 
frequently used substitute for primary microglia. They have been used to study many 
neurodegenerative disease such as AD (Soccio et al. 2002; Simard et al. 2006; Lewis et al. 
2010), PD (GAO et al. 2003) and stroke (Jin et al. 2014). Regarding neurodegeneration 
studies, it is important that BV-2, similar to primary microglia, express functional NADPH 
oxidase (key producers of ROS), an enzyme frequently implicated in microglia induction of 
neuronal damage (Wu et al. 2006). However, doubts have been raised that this cell line does 
not always model the reaction of primary or in vivo microglia. Horvath et al. (2008) 
compared BV-2 to primary rat microglia, demonstrating that primary microglia release the 
three pro-inflammatory cytokines Tnf-α, Il-1β and Il-6 in response to LPS stimulation. 
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However, BV-2 cells increased release of Tnf-α and Il-6 but not Il-1β, following LPS 
treatment. This lack of Il-1β production is a significant change from normal microglial 
behaviour. Another study also compared primary microglial and BV-2 cultures, this study 
found that LPS enhanced the release of Il-12 and keratinocyte derived chemokine in primary 
mouse microglia culture, however BV-2 displayed impaired capacity for the release of Il-12 
and keratinocyte derived chemokine (Häusler et al. 2002). 
N9 cells were also derived from murine neonatal microglia, but are less-frequently 
used in comparison to BV-2 cell line (Stansley et al. 2012). It has been suggested that this 
cell line shares many phenotypical characteristics with primary microglia (Hickman et al. 
2008), for example unlike BV-2, N9 cells readily produce cytokines Il-6, Tnf-α and Il-1β 
upon stimulation with Aβ (Delgado et al. 1998). But in another study when both primary 
microglia and N9 cells were treated with a protein derived from the parasite Angiostrongylus 
cantonensis, a worm that causes a CNS infection, N9 expressed high mRNA level of Il-6, Il-
1β, Tnf-α, iNos, Il-5 and Il-13 but primary microglia only expressed Il-5 and Il-13 mRNA 
(Wei et al. 2013). Such differences mean that data derived from cell lines should be validated 
using primary and in vivo testing. 
HAPI were derived from rat neonatal microglia and are less frequently used in 
comparison to BV-2 and N9 (Stansley et al. 2012). There are two main studies that compare 
HAPI to the BV-2 cell line. The first one includes direct comparison of chemokine 
expression between BV-2 and HAPI cells following LPS treatment (Kremlev et al. 2004). 
This study found that LPS treatment of BV-2 enhanced the release of Ccl3, Ccl5, and Cxcl10, 
which are all upregulated in primary microglia; however, in HAPI, LPS induced release of 
Ccl3 and Ccl5, but not Cxcl10 (Kremlev et al. 2004). A second study directly compared the 
reactive and inflammatory profiles of the BV-2 and HAPI immortalised cell lines to primary 
rat microglia cell cultures across a broad range of assays including cell migration and 
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cytokine/chemokine production and release (Horvath et al. 2008). This study found that LPS 
enhanced the release of pro-inflammatory cytokines Tnf-α, Il-1β and Il-6 in primary 
microglia but different expression profiles were observed in both BV-2 and N9 which led 
the authors to suggest that BV-2 and HAPI cell cultures only partially model primary 
microglia and that their use should therefore be carefully considered (Horvath et al. 2008).  
3.1.1.2.2 Human cell line: HMO6 
Earlier studies on human microglia have been mostly in histological (i.e. dead) 
sections and less in primary cultures, as it is rare that human microglia become available in 
sufficient numbers to study their detailed cellular and molecular properties. One way to 
circumvent this problem was to produce a permanent (immortalised) human microglia cell 
line. Thus, Nagai and his group (2001) generated several stable clones of human microglia, 
including HMO6, by transduction of embryonic human microglia with a retroviral vector 
containing cDNA encoding for v-Myc oncogene. The HMO6 cells exhibited cell type-
specific antigens for microglia-macrophages lineage cells including CD11b, CD68, CD86, 
HLA-ABC and actively phagocytosed latex beads. In addition, HMO6 cells showed ATP-
induced responses like human primary microglia in Ca2+ influx spectroscopy. Both human 
primary microglia and HMO6 cells showed the similar cytokine gene expression in IL-1β, 
IL-6, IL-8, IL-10, IL-12, IL-15 and TNF-α. Using HMO6 cells, Nagai and his group 
investigated whether both Aβ fragments and LPS could activate these cells. This study found 
that treatment of both human primary microglia and HMO6 immortalised human microglia 
cell line with Aβ and LPS upregulated gene expression and protein production of pro-
inflammatory cytokines and chemokines in these cells in the same way (Nagai et al. 2001). 
HMO6 are commercially-available, but relatively expensive since the cells were 
patented, which likely partly explains their limited usage. This may also be due to the fact 
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that these cells require biosafety level 2 procedures, due to risk to human health (American 
Type Culture Collection, ATCC). There are also few reports from non-affiliated groups 
about how representative these cells are of in vivo microglial behaviours. 
3.1.2 LPS is a stereotypical pro-inflammatory stimulator 
LPS is an important structural component of the outer membrane of gram-negative 
bacteria, it binds to Toll-like receptor (TLR)4 leading to the activation of microglia through 
a series of interactions with several proteins (Ulevitch & Tobias 1999). LPS enhances 
microglial activation and produces pro-inflammatory mediators such as Tnf-α, Il-1β and Il-
6 both in vitro and in vivo (Nakamura et al. 1999; Possel et al. 2000). 
LPS is one of the most widely studied immune-stimulatory components of bacteria 
and can induce systemic inflammation (Beutler & Rietschel 2003). Upon LPS recognition, 
TLR4 downstream leads to activation of NF-κB pathways in microglia (Kawai et al. 1999), 
Mitogen-activated protein kinases (MAPKs) pathways (Qin et al. 2005) and interferon 
regulatory factor 3 (IRF3) through the activation of several mediators (Figure 3-1). 
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Figure 3-1: Illustration of the molecular events following LPS-TL4 interaction. Adapted from Murshid et al. (2015). 
NF-κB, a major transcription factor, modulates inflammatory system through 
expressing pro-inflammatory genes (Ghosh et al. 1998). Under normal conditions, inhibitors 
of κB (IκB) form a complex with NF-κB, maintaining it in an inactivate form in the 
cytoplasm. Once stimulated by inflammatory signals such as LPS, IκB is phosphorylated 
and degraded releasing free NF-κB (Lappas et al. 2002). Afterward, NF-κB translocates into 
the nucleus and binds to the DNA binding site related to regulating the transcription of its 
target genes, triggering expression of pro-inflammatory enzymes and cytokines such as iNos, 
Tnf-α and Il-β. 
MAPKs are one of the major kinase families associated with cellular processes such 
as differentiation, stress responses, apoptosis and immune defence (Bennett et al. 1997). 
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IRF3 translocation into the nucleus leads to regulation of the transcription and expression of 
type I interferons such Inf-β, Ccl5 and chemokine (C-X-C motif) ligand 10 (Cxcl10) 
(McCarthy et al. 2017). These three pathways are involved in regulating the inflammatory 
process. 
LPS induction of Tnf-α leads to autocrine activation of TNFR, activation of 
JAK2/STAT1, and subsequent increase in Il-6 production; thus LPS-activation of Il-6 is a 
direct secondary effect, and this likely explains the delay in production of Il-6 reported in 
several studies (Minogue et al. 2012) (Figure 3-2). 
 
Figure 3-2: LPS-induced signalling and cytokine release. TLR4 is stimulated by LPS, (1) TLR4 leads to activation 
of NF-κB/MAPK pathways, (2) which leads to release of Tnf-α and Il-1β. (3) Released Tnf-α interacts with its 
receptor, (4) activating Janus kinase-2 (JAK2) and activators of transcription (STAT) (5) which up-regulate 
transcription and release of Il-6. (6) Il-6 feeds back to inhibit further release of Tnf-α and Il-1β. Adapted from 
Minogue et al. (2012). 
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3.1.3 Most microglial qPCR studies used insufficient and unvalidated 
reference genes 
Reliable reference genes are vital for reliable qPCR data, and MIQE guidelines 
recommend multiple reference genes be employed (Bustin et al. 2009; Hellemans et al. 
2007). It is increasingly recognised that some widely used reference genes (e.g., Gapdh) 
(Jimenez et al. 2008; Lisak et al. 2009; Fenn et al. 2012) may be unsuitable, with reports of 
experimental condition-induced changes in Gapdh expression (Everaert et al. 2011; Al-
Sabah et al. 2015). For example Al-Sabah et al. (2015) reported that in vivo model of 
inflammatory joint pathology Gapdh transcript levels were significantly reduced compared 
to the control of this experiment. Another study suggested that the highly used Gapdh and 
ACTB have variable expression levels when they compared the mRNA levels directly in a 
cross sectional series of biopsy tissue from normal controls and subjects with asthma (Glare 
et al. 2002). This could be a problem since expression levels of reference genes should 
remain constant between the cells of different tissues and under different experimental 
conditions (Thellin et al. 1999). If these requirements are not fulfilled, then normalisation to 
varying references could cause misleading results (Bustin 2000). From this, a single 
reference gene cannot be used to accurately normalise RT-qPCR data and that the 
combination of multiple reference genes is preferred. Although increasing the number of 
reference genes for normalisation will improve the accuracy of the analysis, this is expensive 
and time consuming. Therefore, it has been suggested that the number of reference genes 
needed to be employed is dependent on the considerations of a researcher’s purpose (Hu et 
al. 2009). Use of two to three stable reference genes is a valid normalisation strategy in most 
experimental conditions. 
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3.2 Aims and objectives 
3.2.1 Aims 
The aim of the study described in this Chapter is validation of primary microglial 
culture and qPCR methods.  
3.2.2 Objectives 
The objectives are:  
• To determine the purity of microglial cultures derived from primary mixed glial 
culture. 
• To confirm that primary microglia respond to LPS (e.g., concentrations and time 
points). 
• To design and validate qPCR primers for multiple reference genes and genes of 
interest. 
• To study sex-dependent differences in microglial gene expression. 
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3.3 Results 
3.3.1 Microglial cultures were of high purity 
Microglial markers were identified from the literature, and tested with microglial 
cultures. As described in section 2.6, cultures were maintained on coverslips, and 
immunostained to assess culture purity. All cultures were of high purity as judged by lectin-
reactivity (>98 %). Cells also expressed Iba1 and lectin, confirming their microglial identity 
(Figure 3-3) (Shrivastava et al. 2012). 
 
Figure 3-3: Iba1 and lectin labelling of microglia. Cells expressed Iba1 and lectin, confirming their microglial 
identity. Figure shows DAPI-stained nuclei as blue, Iba1 as green, and Lectin as red. 
3.3.2 Confirmation of microglial response to LPS  
A range of experimental LPS concentrations was chosen based on the literature 
search, but to confirm the biological efficacy of these doses in this experimental system, and 
to estimate response times, microglia were exposed to selected concentrations of LPS. As 
described in section 2.6, cultures were maintained on coverslips and immunostained to 
assess culture purity with and without LPS. All cultures were of high purity as judged by 
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lectin-reactivity (>98 %) treatment with LPS led to a significant increase in lectin integrated 
density (Figure 3-4). Time-lapse microscopy revealed clear cellular responses (e.g., 
morphological changes and cell death) (Jenkins et al. 2014) within 2 h at all concentrations 
(10, 50 and 1000 ng/ml; Figure 3-5; video 2 (video file submitted with thesis, Video 2; 
internet link: youtube.com/watch?v=JrN_OrGyQ2Q)), with no comparable changes evident 
in control cultures (same microscope/incubator setup, 6 h; without LPS; video 3 (video file 
submitted with thesis, Video 3; internet link: youtube.com/watch?v=LjcdbLhpm2s)). 
 
Figure 3-4: Microglial cultures were of high purity and intensity of lectin reactivity increased with LPS treatment. 
(A) Bar graph indicating cell count (microglia per image). (B) Bar graph indicating percentage of all nuclei showing 
lectin reactivity, confirming microglial identity. (C) Bar graph indicating intensity of lectin reactivity, which 
increased with the highest LPS concentration tested. These cultures were assessed after 2 h LPS treatment. 
***p<0.001; One-way ANOVA with Dunnett’s post-hoc test versus 0 LPS. All data are presented as mean ± S. E. 
M. of three independent experiments. . 
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Figure 3-5: Microglia primary culture cells response to LPS in vitro. Transmitted light micrographs showing typical 
microglial morphologies immediately post-LPS (50 ng/ml). Many microglia exhibited short, thick processes after 5 
h exposure at 50 ng/ml. Images are stills from time-lapse microscopy, 30 frames/hour. See supplementary video2; 
(video file submitted with thesis, Video2; internet link: youtube.com/watch?v=JrN_OrGyQ2Q). 
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3.3.3 qPCR  
3.3.3.1 Multiple candidate reference genes were identified 
It is a recommended practice to select multiple reference genes, rather than relying 
on a single reference gene (Bustin et al. 2009). But most researchers rely on a single 
reference gene, typically Gapdh. To the best of my knowledge, there are no reports 
attempting to validate Gapdh as a reference gene for microglia. 
Microarray analyses of M1 activated microglia were identified in the literature and 
datasets obtained from repositories (Rock et al. 2005; Moran et al. 2007; Zawadzka et al. 
2012). Only one study using LPS was identified (Zawadzka et al. 2012), but two further 
studies using the pro-M1 stimulus IFN-γ were found (Rock et al. 2005; Moran et al. 2007). 
Moran et al. (2007) study used primary new-born rat microglia. Rock et al. (2005) used 
primary human foetal microglia. Concentrations and timings of treatment varied between 
these studies (1 – 24 h), but all used pro-M1 stimuli. Datasets included fold-change in gene 
expression, following IFN-γ or LPS treatment (versus untreated controls), as well as copy 
numbers for each mRNA transcript. Genes present in high copy numbers were shortlisted, 
and fold-change averaged across all datasets. Then these transcripts with average fold-
change less than 0.9 or greater than 1.1 were excluded, and candidate reference genes were 
selected from this list, and compared with Gapdh (Table 3-2) (Tarca et al. 2006). Notably, 
the widely-used reference gene ACTB showed a 16.5-fold increase with IFN-γ treatment 
(Moran et al.2007), raising questions about its validity. Gapdh data were not available for 
LPS treatment. IFN-γ showed varied Gapdh responses, with a 3.9-fold increase at 16 h 
(Moran et al. 2007), and 1.67-fold increase on average. However, Rock et al. (2005) showed 
0.98-fold at 24 h. This variation meant that it was unclear whether Gapdh would likely serve 
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well as a reference gene. But due to its widespread use, it was included here for validation 
work. 
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Table 3-2: Candidate reference genes identified from microarray analyses. Number of fold change between 
treatment and control for the reference gene candidates. Note that most candidate reference genes were minimally 
affected, or unaffected by treatment with pro-M1 stimuli (average fold change 0.94 – 1.08), whereas Gapdh showed 
an average 1.67-fold increase in expression. However, no LPS-treated data were available for Gapdh, and most of 
this increase is represented by the 16 h data for IFN-γ (3.94-fold increase). 
  Fold change in microglial mRNA expression 
Gene name 
IFN-γ, human 
primary foetal cells 
(Rock et al. 2005) 
IFN-γ, 
primary 
newborn rat 
cells 
(Moran et al. 
2007) 
IFN-γ, 
human 
primary 
foetal cells  
(Rock et al. 
2005) 
LPS, primary 
newborn rat cells 
(Zawadzka et al. 
2012) 
Average 
1 h, 200 
U/ml 
6 h, 200 
U/ml 
16 h, 100 
U/ml 
24 h, 200 
U/ml 
24 h, 100 ng/ml 
Atp6ap2 1.09 0.92   1.04 1.10 1.04 
Gapdh 0.93 0.84 3.94 0.98   1.67 
Gusb     0.90   1.11 1.01 
Mtco2 (Cox-2)         0.97 0.97 
Rpl22 1.14 0.87 0.99 0.76 0.97 0.95 
Rpl32 1.27 0.87 0.84 0.70 1.01 0.94 
St13 1.04 0.86 1.06 0.85 0.92 0.95 
Usp14         1.08 1.08 
INF-γ, interferon; LPS, Lipopolysaccharide; Atp6ap2, ATPase H (+)-transporting lysosomal accessory protein 2; 
Gapdh, Glyceraldehyde 3-phosphate dehydrogenase; Gusb, Beta-glucuronidases; Mtco2, Mitochondrially Encoded 
Cytochrome C Oxidase II; Rpl22, ribosomal protein L22; Rpl32, ribosomal protein L32; St13, suppression of 
tumorigenicity 13; Usp14, Ubiquitin Specific Peptidase 14. 
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3.3.3.2 Comparison of primers for candidate reference genes 
 qPCR primers were designed for Gapdh and the seven other candidate reference 
genes listed above. They generated clear amplicon bands, with several also producing faint 
bands, of sizes <100 bp, likely to indicate primer-dimers (Figure 3-6). The greatest size 
discrepancies were St13 and Gusb (>26% difference versus calculated amplicon size), which 
were then excluded as candidates. By assessing the predicted (software) and measured sizes 
(Table 3-3), microarray data and clarity/reproducibility of gel bands, Rpl32 and Usp14 were 
selected for further validation. 
 
Figure 3-6: Gel image for reference gene candidate. Note that there is a single strong band present for each gene. 
Atp6ap2, ATPase H (+)-transporting lysosomal accessory protein 2; Gapdh, Glyceraldehyde 3-phosphate 
dehydrogenase; Gusb, Beta-glucuronidases; Mtco2, Mitochondrially Encoded Cytochrome C Oxidase II; Rpl22, 
ribosomal protein L22; Rpl32, ribosomal protein L32; St13, suppression of tumorigenicity 13; Usp14, Ubiquitin 
Specific Peptidase 14. 
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Table 3-3: List of primers amplicons size and melt curve (Tm) values. 
  Amplicon size (bp; gels) Amplicon melting 
temperature Tm (melt 
curves) 
Gene Predicted Measured Difference Primer-
dimers? 
Lower Upper 
Atp6ap2 138 120 -13 % N   83.8 
Gapdh 256 234 -9 % Y 84.4 84.7 
Gusb 306 226 -26 % N 89.5 90 
Mtco2 156 130 -17 % N 
 
80 
Rpl22 117 105 -10 % N 
 
84 
Rpl32 125 104 -17 % Y 83.2 84 
St13 138 192 39 % Y 
 
89 
Usp14 117 107 -9 % N 
 
80.2 
Atp6ap2, ATPase H (+)-transporting lysosomal accessory protein 2; Gapdh, Glyceraldehyde 3-phosphate 
dehydrogenase; Gusb, Beta-glucuronidases; Mtco2, Mitochondrially Encoded Cytochrome C Oxidase II; N, No; 
Rpl22, ribosomal protein L22; Rpl32, ribosomal protein L32; St13, suppression of tumorigenicity 13; Usp14, 
Ubiquitin Specific Peptidase 14; Y, Yes. 
 
qPCR was performed using the three reference genes. The results show there was 
no LPS or Il-4 (M2 stimuli)-induced change in expression for the reference genes tested 
(Gapdh, Usp14, Rpl32), across a wide range of LPS and Il-4 (Figure 3-7, Figure 3-8), and 
there was no evidence of a dose-response effect. Therefore, the average of their Cq values 
should allow reliable evaluation of LPS-induced changes in GOI. 
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Figure 3-7: Candidate reference genes (Usp14, Rpl32 and Gapdh) were unresponsive to LPS treatment. LPS was 
tested at a range of concentrations from 0.001- 100 ng/ml, and in the absence of LPS (signified on these graphs as 
the lowest LPS concentration 10-12), for three different cultures at three-time points. For the 2, 6 and 24 h data, three 
technical replicates were performed for each culture (128, 129 and 130: biological replicates). Note that the error 
bars show that standard error of mean between technical replicates was limited. Also, note that the three biological 
replicates produced similar values, demonstrating high reproducibility. 
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Figure 3-8: Candidate reference genes (Usp14, Rpl32 and Gapdh) were unresponsive to 24 h of Il-4. Note that the 
four biological replicates produced similar values, demonstrating high reproducibility, for four different cultures. 
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3.3.3.3 qPCR primers validation for GOIs 
Samples were taken from pilot qPCR experiments and subjected to gel 
electrophoresis to determine whether each reaction/well generated a single amplicon of the 
expected size (Figure 3-9). Any amplified gDNA should appear as a larger than expected 
band, since primers were selected to bridge exon boundaries wherever possible. DNA 
ladders were used to generate a standard curve of migration distance versus nucleic acid size, 
which was in turn used to estimate amplicon size. (Figure 3-9 A) shows that single clear 
bands were generated for all genes, with migration distances close to expected size, with the 
exception of Tgf-β, which was investigated in more details, and new primers designed. These 
tests confirmed which qPCR signals were genuine, giving confidence in generated data. 
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Figure 3-9: Example analysis to confirm amplicon identity and specificity. (A) gel images show that there is a single 
intense band present for each primer pair. (B) Standard curve of migration distance versus nucleic acid size for 
markers. (C, D) gel image and melt curve for Tnf-α (sample, RT- and NTC). Note that NTC and RT- do not show 
bands at the expected migration point for the Tnf-α amplicon (~297 bp), but sample does show bands near the 300 
bp ladder marker. These samples generated melt curves at ~87 C, demonstrating that this Tm value is indicative of 
appropriate amplicon generation. In all lanes, bands have migrated beyond the 100 bp markers, indicative of non-
specific signal, perhaps primer-dimers. These are possibly associated with the peak at 66.4 °C in the melt curve 
analysis. (E, F) gel and melt curve for Il-1β. Note that there is a single band present in Il-1β-Sample, with a migration 
distance suggesting a product size of 194 bp, compared to the expected size of 192 bp. Comparing this gel with the 
melt curve analysis demonstrates that the Il-1β amplicon has a Tm of ~83 °C. Both the NTC and RT- lanes show no 
clear signal, consistent with the lack of strong peaks in melt curve analysis. All samples generated faint bands 
smaller than 100 bp, suggesting some primer-dimer formation. NTC= no template control; RT= no reverse 
transcriptase control; Tm= primer melting temperature (the temperature at which one-half of the DNA duplex will 
dissociate to become single stranded). 
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3.3.3.4 Determining primer efficiency 
The ∆∆Cq method of qPCR analysis depends upon primer’s efficiency being close 
to 100% (Kenneth J. Livak & Schmittgen 2001). In order to determine efficiency, qPCR was 
carried with a range of starting material concentrations. These were prepared as follow for 
each qPCR reaction: 
• Microglial cDNA was used as the template for an endpoint PCR reaction, to provide 
cDNA enriched with the amplicon of interest. 
• A second round of endpoint PCR was carried out using this amplicon-enriched 
source as the template, to generate DNA samples containing essentially only the 
amplicon of interest. 
• The absorption at 260 nm was used to calculate the DNA concentration, and the Mw 
of the amplicon to calculate the amplicon concentration. 
• Ranges of dilution were made with amplicon concentration from 1x107 to 1x100 
amplicons/ 2 µl, and 2 µl aliquots of these were used as template for qPCR reactions. 
• The Cq from qPCR reactions were plotted against amplicon concentration Figure 
3-10 and the slope of the linear fit to these points used to calculate the efficiency of 
the qPCR since:  
PCR efficiency = 10 -1/slope -1 
Table 3-4 summarises the slope for these standard curves and their related primer 
efficiency, which was close to 100 % efficiency for all primer pairs.  
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Figure 3-10: Calibration curves indicating qPCR amplification efficiency for primer pairs. X-axis represents 
increasing quantities of template (copy number, amplicons per well), which is associated with decreasing Cq values 
(y axis; threshold signal being reached at an earlier amplification cycle). As copy number (amount of template) 
increases, rate of amplification should increase proportionally (reducing Cq), if the reaction is 100 % efficient. The 
slope of each best-fit line is compared to the value predicted for 100 % efficiency. Note that the relationship between 
copy number and Cq is consistent except at the lowest copy number values for some primer pairs. 
 
Table 3-4: List of primer standard curves slope, with their calculated primer efficiency. 
Gene n Slope R2 
10-1/slope Efficiency 
Atp6ap2 3 -3.4 0.93 1.97 97 % 
Cnx 3 -3.4 0.99 1.97 96 % 
Gapdh 6 -3.4 0.99 1.98 98 % 
Il-1β 6 -3.4 0.99 1.97 97 % 
Il-1rn 3 -3.3 0.99 2.01 101 % 
Il-6 3 -3.4 0.99 1.99 99 % 
Il-10 6 -3.3 0.99 2.02 102 % 
MtCo2 3 -3.3 0.99 2.03 103 % 
Rpl22 3 -3.1 0.99 2.09 109 % 
Rpl32 3 -3.5 0.99 1.94 94 % 
Tgf-β 4 -3.2 0.99 2.05 105 % 
Tnf-α 3 -3.2 0.99 2.06 106 % 
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3.3.3.5 Total RNA yield varied between cell types and affected mRNA 
purity 
The amount of RNA extracted from microglia in the first few experiments was low. 
Therefore, a pilot study was performed to compare RNA yield of microglia with two other 
glia cell types (oligodendrocyte precursor cells [OPCs] and astrocytes) and a macrophages 
cell line (THP-1; human monocytic leukaemia) to determine whether the low yield was 
inherent to the microglial cells or to the RNA extraction techniques. Different cell numbers 
were used (36, 72, 144 and 720 x 104 cells per vessel) and two different flasks/plates (T25 
flasks and 12 well plates) for the glia cells, but only one density for THP-1 (12 x 104 cell) 
since this cell line has markedly higher levels of proliferation. In each case, the cell number 
stated here was collected into a single RNeasy kit tube (i.e. increasing numbers of cells in 
the particular sample being processed for RNA extraction; so, volumes of all reagents are 
constant, while cell number varies). The data showed an increase in RNA yield with 
increasing concentration of cells in the extraction process, as expected, with microglia 
exhibiting a significant increase in RNA yields when extracted from a T25 flask (i.e. highest 
number of cells: 720 x 104; Figure 3-11; Figure 3-12). Therefore, by the time the experiments 
in chapter seven were performed, microglia were being routinely cultured in T25 flasks. 
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Figure 3-11: RNA extraction from microglia versus astrocyte versus OPCs versus macrophages from THP-1 cell 
line using RNeasy columns. Different plating density and wells effect on the RNA concentration. *p < 0. 05; One-
way ANOVA with Tukey’s post-hoc test for each cell type. All data are presented as mean ± S. E. M. of three 
independent experiments.  
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Figure 3-12: mRNA purity from RNA extraction from microglia versus astrocyte versus OPCs versus macrophages 
from THP-1 cell line using RNeasy columns. Different plating density and wells effect on the RNA purity. No 
significant difference; One-way ANOVA with Tukey’s post-hoc test for each cell type. All data are presented as 
mean ± S. E. M. of three independent experiments.  
 
 
 
  
96 
 
3.3.4 No differences were detected between male and female microglia 
A pilot study was performed to compare male and female microglial gene 
expression. All data are n = 1 or 2, which precludes any statistical evaluation, furthermore 
only one reference gene was used to normalise this data (Gapdh) since it was one of the first 
experiments and it was performed before the full validation of the three reference genes. 
Similar responses were observed for all genes (Figure 3-13). Although our data suggest 
limited (if any) gender differences, the literature indicated the presence of differences, at 
least later in development (Mouton et al. 2002; Schwarz & Bilbo 2012; Lenz et al. 2013; 
Hanamsagar et al. 2014; Sidor et al. 2014; Lenz & McCarthy 2015). Therefore, this thesis 
has limited the initial investigations to cultures derived exclusively from males, so that if 
any relevant gender differences were later discovered experimentally or in the literature, this 
would not be confounding for the data gathered here. 
 
Figure 3-13: Male versus female microglial gene expression, following 2 and 6 h LPS treatment. LPS effect on 
different genes (Il-1β, Il-6, Tnf-α and Il-10) on 1-2 cultures at two times points (2 and 6 h). Note that for most genes 
and most concentrations/time points, changes in expression were similar for male and female samples. Males and 
females were compared from the same litters; Gapdh as reference gene; n =1 – 2 for all data presented here.  
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3.4 Discussion  
Microglia are routinely cultured using the system described here, so data can be 
compared to the literature. The culture system described is robust and allowed consistent 
derivation of high purity microglial cultures, with large numbers of cells. 
3.4.1 Microglial in cell culture 
Lectin and Iba1 are widely used for the identification of microglia in brain tissue 
and in cell culture (Taylor et al. 2004). Lectin is a carbohydrate binding protein obtained 
from Lycopersicon esculentum (tomato), with affinity for poly-N-acetyl lactosamine sugar 
residues (Zhu & Laine 1989). It has been reported to label microglia through the recognition 
of glycoproteins containing terminal alpha-D-galactose residues in the rat nervous system 
(Ambalavanar and Morris, 1991). In another study, the authors reported that tomato lectin 
binding was found in relation to microglia cells (Acarin et al. 1994). Furthermore, Iba1 has 
been found to be highly and specifically expressed in microglia among the cultured brain 
cells (Ito et al. 1998). And that is why they have been used to detect the purity of microglia 
culture (Figure 3-3; Figure 3-4). 
This study results suggested that LPS treatment leads to an increase in lectin 
staining intensity and microglial activation which go in parallel with what Acarin et al. 
(1994) have reported when they studied rat postnatal brain, that is amoeboid microglial cells 
always showed stronger binding of tomato lectin compared with ramified microglial. 
The LPS concentration used in this study did not led to cell death (Figure 3-4), this 
result is in line with what Chao et al. (1994) have reported that treated microglia with 10 
ng/ml LPS for 20 h had not induced a reduction in microglia cells number. Studies also 
reported that activated microglia display morphological changes from a highly branched 
resting state to a more amoeboid or rounded reactive state (Davis et al. 1994; Petersen & 
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Dailey 2004) which are in line with the results from time-lapse observations of this study. 
Furthermore, this time-lapse showed a range of microglial motility behaviours during and 
after activation, individual microglia cell extended a process to phagocytose another dead 
cell or migrate to the infection site. This indicates that a single microglial cell may take on 
different morphologies, and the morphological appearances in static images are not 
necessarily accurate predictors of cell motility behaviours. This supports the finding of 
Stence et al. (2001) that time-lapse analysis suggest not all microglia responded with the 
same time course, but there was a stereotypical sequence of dynamic morphological changes. 
3.4.2 LPS as robust M1 stimulus; biological activity 
LPS is one of the major outer surface membrane components present in almost all 
Gram-negative bacteria and acts as an extremely strong stimulator of innate or natural 
immunity in species ranging from insects to humans. For this reason, it has been used in 
many studies for investigation of cytokine induction in the brain (Ransohoff & Benveniste 
1996). Many studies used only a single concentration of LPS (Mayer et al. 2001; Fan et al. 
2005; Wang et al. 2005), and often few time points, or even a single time point. Therefore, 
I determined to carry out a more detailed characterisation of the dose- and time-
responsiveness of the LPS response. 
Data from this chapter are consistent with microglia being LPS-responsive and 
confirmed the biological activity of the LPS stocks used here. Early data also showed 
increased gene expression for pro-inflammatory genes (Il-1β, Il-6 and Tnf-α). Therefore, the 
cell system, LPS and qPCR primers used here seem suitable for characterising M1 microglial 
activation. 
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3.4.3 Multiple reference genes identified and validated 
The MIQE guidelines suggested that more than one reference gene should be used 
to insure reliable qPCR result that could promote consistency between laboratories, and 
increase experimental transparency (Bustin et al. 2009). Using more than one reference gene 
increases the chances of detecting genuine changes in gene expression. Therefore, this study 
aimed to validate microglia reference gene that is lacking in microglia field. 
This study results showed that three genes (Rpl32, Usp14 and Gapdh) from the 7 
candidates showed no dose-response changes across a wide range of concentration (0.00 – 
100 ng/ml) of two different stimuli (LPS and Il-4). Over three different time points (2, 6 and 
24 h) for LPS and one time point 24 h for Il-4. Therefore, this validatory data suggests that 
these genes can be recommended as standard reference genes, something currently lacking 
in rat microglial research. 
3.4.4 Primers for genes of interest have been validated 
The MIQE guidelines suggested that robust qPCR assays are correlated with high 
PCR efficiency (Bustin et al. 2009). If the PCR efficiencies vary that would be problematic 
during the interpretation of the results. Previous studies have reported that PCR efficiencies 
may vary from 80 % to 100 % (Kamphuis et al. 2001), or from 65 % to 90 % (Tichopad et 
al. 2003). However, this is not always included in calculations, with some researchers simply 
assuming 100% in their calculations. 
When PCR efficiency is assumed to be 100%, but it is not 100%, then this leads to 
inaccurate 2-∆∆Cq results. For example, when efficiencies vary over a range as small as 0.04, 
from 1.78 to 1.82, it results in a 4-fold error in relative expression (Ramakers et al. 2003). 
Therefore, it is necessary to evaluate specific PCR efficiencies before doing relative 
quantification (Rao et al. 2013).  
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PCR amplification efficiency has been established by means of calibration curves, 
because such calibration provides a simple, rapid and reproducible indication of the mean 
PCR efficiency. The results obtained here showed that the primer pairs selected for 
continuing study have efficiency close to 100%, with range from 94 % (Rpl32) to 106 % 
(Tnf-α), making these primer pairs suitable for quantification using 2-∆∆Cq method. 
3.4.5 Total RNA yield per cell/culture: microglia versus astrocyte versus 
OPCs versus THP1 
The low total RNA yield and purity was a concern in the first few experiments on 
microglia. Several changes in the extraction protocol were made without improvement either 
in terms of yield or the purity. Therefore, a hypothesis that microglia has low quantities of 
total RNA per cell was generated. 
To test this hypothesis, a comparison between different types of cells has been 
made. Also, different densities of cells per total RNA extraction procedure (e.g., standard 
volumes of reagent; 1 tube per sample) were compared. The results showed that microglia 
have low total RNA yield in comparison to other cell types. This is consistent with 
Dumbacher’s report that RNA yields vary widely from different tissues and samples 
(Dumbacher 2013). Results generated here suggest that total RNA yield and purity increase 
with the number of cells being processed. Therefore, larger quantities of cells were used for 
qPCR studies, to improve yield and purity of total RNA.  
3.4.6 Male versus female microglia 
Various reports in the literature indicated differences between male and female 
microglia, especially in adult brain, although in neonatal brain reports are inconsistent ( 
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Mouton et al. 2002; Schwarz & Bilbo 2012; Lenz et al. 2013; Hanamsagar et al. 2014; Sidor 
et al. 2014; Lenz & McCarthy 2015;).  
In adult rodent CNS, there are differences in microglial morphology between male 
and female rodents (Schwarz et al. 2012). Significantly higher number of microglia are 
present in female rodents (rats and mice) hippocampus in comparison to male rodents 
hippocampus (Mouton et al. 2002; Schwarz et al. 2012). Female microglia have 
morphologies more closely resembling M1 microglia (Schwarz et al. 2012). Furthermore, 
female brains show higher immune activation as shown by higher level of Ccl20 and Ccl4, 
despite the presence of the great concentration of neuroprotective steroids estrogen and 
progesterone in compare to male microglia (Schwarz & Bilbo 2012).  
In the neonatal rodent CNS, studies showed contradictory results. For example 
Crain et al. (2013) reported that in P3 mouse, female microglia has higher mRNA level of 
Tnf-α, Il-1β, Il-10 and Il-6 but no difference in iNos and Arg1 expressions. On the other hand, 
Loram et al. (2012) reported no different between neonatal male and female microglia 
isolated from P (0-1) pups. However, the same study suggested an increased Il-1β gene 
expression of male microglia when treated with a high concentration of LPS (100 ng/ml). 
The data presented in this chapter showed no difference between male and female 
rat microglia, in terms of pro-inflammatory gene expression, after treating them with low 
and medium doses of LPS (two time points). But it was decided to avoid possible sex 
differences by limiting initial investigations to cultures derived exclusively from males. 
Therefore, if any relevant gender differences were later discovered, experimentally or in the 
literature, this would not be confounding for the data gathered here. 
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3.5 Summary  
This chapter has described validatory work on an in vitro microglial culture system, 
showing that this protocol generated a high purity microglia culture. Furthermore, this study 
showed (for the first time) validation of three reference genes: the widely used Gapdh and 
two other reference genes (Rpl32 and Usp14) remained unaffected across a wide range of 
concentrations of different treatments, at different time points. Wide adoption of these 
reference genes could improve comparisons of qPCR results for microglial gene expression 
between different laboratories.  
The preliminary results of this study suggested that there are no differences between 
male and female microglial pro-inflammatory gene expression, in response to LPS, at two 
time points. However, more biological replicate are required to be able to prove that 
statistically and further investigation of the possible effects of gender on microglial gene 
expression, which might become more obvious in juvenile or adult animals.  
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Chapter 4 : Characterising primary microglial 
culture in serum-free media 
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4.1 Introduction 
4.1.1 In vivo data are important, but it is difficult to study microglia in vivo 
In vivo experimentation is low throughput and difficult to both control and monitor. 
However, typical in vitro systems fail to mimic in vivo features that could be critical to 
microglial activation status. Differences between in vitro and in vivo include oxygen levels 
(Lennon et al. 2001), unrealistic 2D environment (Sun et al. 2006) and cellular environment 
(i.e. tissue-specific construction), mechanical and biochemical signals, with cell–cell 
communication also being altered under such simplified and highly biased conditions 
(Pampaloni et al. 2007).  
The effects of the differences between the brain and the culture environment may 
confound the study of microglial activation for example, some studies showed that astrocytes 
(which are also cells of the CNS) were less activated in a 3D environment compared to a 2D 
environment (East et al. 2009; LaPlaca et al. 2010; Tickle 2017). Furthermore, the 
monocellular composition of the culture differs from the in vivo multicellular composition 
which may limit the ability to model diseases (Duell et al. 2011; Miki et al. 2012). In the 
case of this study, the inclusion of serum in culture media could be a confounding factor, as 
the presence of cytokines and other signalling molecules in serum might lead to low-level 
M1 activation or priming of microglia (priming microglia theory will be further discussed in 
Chapter Five). That is, although a strong (greater than physiologically-relevant) stimuli can 
increase pro-inflammatory responses in vitro, it is possible that the non-treated/ ‘control’ 
microglial cultures might be in a partially-M1 state, rather than the ideal M0 state (Figure 
4-1). 
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Figure 4-1: Hypotheses relating to microglial activation in serum versus non-serum media. LPS may produce a 
consistent increase in magnitude of activation, whether serum is present or not. But, if serum-exposed microglia are 
already activated to some extent, then I hypothesise that in serum-free media: 1. microglia will be in low level of 
activation (lower baseline in compare to serum contain media), 2. Higher EC50 and 3. Lower maximum dose 
response. 
The BBB limits the access of most blood-borne molecules to the brain parenchyma, 
with the interstitial fluid here being of a more restricted composition than blood. Molecules 
are present at much lower levels in the brain than the blood, such as glucose (Mcnay et al. 
2001), hormones (Amado et al. 1995) and immunoglobulins (Parsons & Webb 1982) (Table 
4-1). 
It would be of benefit to identify a serum-free media which can support microglia 
growth, as serum is an undefined mixture of growth factors and cytokines, many of which 
microglia would only encounter if the BBB becomes compromised. Microglia in vivo are 
surrounded by interstitial fluid, similar to the CSF, which is devoid of most serum-associated 
molecules. Here we propose that the use of serum is confounding, and culturing microglia 
without serum would more accurately mimic in vivo conditions, and possibly produce more 
clinically-predictive microglial behaviour. 
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Additionally, using serum-free medium would provide a defined culture 
environment, without confounding molecules which can induce immune-relevant responses, 
such as LPS, complement proteins and immunoglobulins, data relating to microglial 
activation could be more reliably generated. Finally, the investigations of the metabolic 
changes, namely; glucose, insulin and vitamins. can be more reliably performed, as serum 
would not introduce unknown quantities of these molecules, in addition to these introduced 
by the experimenter. 
4.1.2 The differences between fetal bovine serum and cerebrospinal fluid 
Fetal bovine serum (FBS) is a common supplement of cell culture media. It has 
been used for almost all human and animal cell culture (Brunner et al. 2010). FBS contains 
a mixture of factors that stimulate cell survival and regulate pH (van der Valk et al. 2004). 
There are concerted efforts to reduce and eliminate its use, since it its composition is an 
undefined mixture of nutrients, salts, hormones, growth factors and hundreds of different 
proteins and metabolites: proteomic studies showed over 1000 proteins (Anderson & 
Anderson 2002; Anderson et al. 2004), and another study found four thousand metabolites 
(Psychogios et al. 2011) present in serum. There are several further disadvantages of using 
FBS in cell culture media, including the increasing concerns about the global supply versus 
demand of FBS (Gstraunthaler et al. 2013), batch-to-batch variations and the different 
molecules present in serum that could cause different reactions, especially in immune cells. 
All those factors might affect culture health and confound immune studies, which could be 
classified as endogenous and exogenous substances. 
4.1.2.1 Endogenous proteins  
The major elements of serum, albumin and transferrin, are known, but serum also 
contains a wide range of minor components that may have a significant effect on microglia. 
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These components include nutrients (i.e. sugars), growth factors (i.e. cytokines), hormones, 
minerals and lipids. The different concentrations of these substances between microglia in 
vivo and in vitro, and their actions have not been fully studied (Freshney 2005).  
Microglia in their natural brain environment get supplementary (nutritional) 
materials from the brain fluid, namely CSF. CSF composition and concentration are different 
from these of the serum present in the cell culture media (De Graaf et al. 2011). Despite the 
absence of serum in the CNS, current studies of CNS disease are performed in cultures 
containing serum. However, serum is thought to be a confounding factor, due to the presence 
of chemicals that may elicit an immune response, that might have a role in immune-mediated 
diseases within the CNS (Aizenman & de Vellis 1987). For example, in normal serum there 
is always an amount of cytokines (interleukins) (Kleiner et al. 2013), which is important for 
many functions such as regulating development and differentiation of the cells but normally 
their concentration is lower in the CNS than the blood circulation due to the selectivity of 
the BBB. Therefore, we hypothesise that culturing microglia in a serum-supplemented media 
may lead to activation of microglia or at least prime them.  
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Table 4-1: Variation of components contained within serum compared to the typical composition of CSF, which is 
like the interstitial fluid surrounding microglia in vivo.  
 Typical composition of fetal bovine 
serum (contribution to media when 
supplemented at 10 %) 
Composition of 
cerebrospinal fluid 
(CSF) 
Fold difference between 10 
% FBS and CSF 
Components  Range Average 
concentrations 
Average 
concentrations 
10 % FBS / CSF 
Total protein  
(g/100 ml) 
3.2 – 7.0 3.8 0.04  
(Hong et al. 2010) 
95 
Albumin (g/100ml) 2.0 – 3.6 2.3  0.02  
(Seyfert et al. 2004) 
115 
Endotoxin (ng/ml) 0.01 – 10.0 0.3 0.06  
(Pentreath et al. 
1996)  
5 
Haemoglobin 
(mg/100ml) 
2.4 – 18.1 11.3  0.02 
 (Hong et al. 2010) 
565 
Cholesterol 
(mg/100ml) 
12 – 63 31  0.2  
(Mulder et al. 1998) 
155 
Glucose (mg/100ml) 85 – 247 125  60  
(Tiraboschi et al. 
2016) 
2 
Insulin (IU/ml) 6 – 14 10  0.92  
(Molina et al. 2002)  
11 
The serum components value adapted from Price and Gregory (Price & Gregory, 1982). 
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4.1.2.2 Exogenous substances  
Serum can be a potential source of microbial contamination, such as fungi, bacteria 
or viruses (Dormont 1999; Wessman & Levings 1999). Furthermore, quality manufacturing 
testing allowances of endotoxin may reach 2.58 ng/ml which mean that 10 % FBS-
supplemented media could have a total of 0.25 ng/ml of endotoxin. This is a concern for 
microglial studies as the endotoxin in the CSF does not typically exceed 0.012 ng/ml. 
Schaafsma et al. (2015) reported that 1 ng/ml LPS is the threshold concentration required to 
trigger mild and low-grade expression of pro-inflammatory mediators in primary microglia 
culture. The same study used a very low concentration of 0.005 ng/ml LPS which may be 
unrealistic since D10 media may contain 0.26 ng/ml endotoxin (LPS) (Table 4-2).  
Table 4-2: Endotoxin in 10 % serum media versus CSF. 
  FBS 10 % serum Contact with CSF 
EU 12.9 1.29 0.06 
 ng/ml 2.58 0.258 0.012 
 EU value is from Certificate of Analysis, Life Technologies, Lot number 41Q8641K, Brazilian FBS, 
catalogue number 10270. 
EU = endotoxin units are used to describe lipopolysaccharide detection by Limulus amebocyte lysate (LAL) 
assay. One EU equals approximately 0.1 to 0.2 ng endotoxin/ml of solution. CSF = cerebrospinal fluid.  
FBS = foetal bovine serum. 
Consequently, many trials have been done to culture CNS cells in serum-free 
media. For example Saneto and de Vellis (1985) have cultured oligodendrocytes isolated 
from primary neonatal rat in chemically defined serum-free media. Brewer et al. (1993) 
optimised the survival of rat embryonic hippocampal neurons in serum-free media. 
However, there has been no systematic examination of the use of serum-free media for 
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microglial culture, with most researchers either withdrawing serum for several hours during 
an experimental treatment or continuing with serum throughout (Zielasek & Hartung 1996; 
Franciosi et al. 2005; Kobayashi et al. 2013). 
4.1.3 Alternatives to fetal bovine serum in cell and tissue culture 
Considering the mentioned disadvantages, many approaches for reducing the 
requirements for FBS in culture media and alternative animal serum replacements were 
defined (Jayme & Smith 2000). These authors have defined five classes of media: serum-
containing media, reduced serum media, serum-free media, protein-free media and 
chemically defined media. While Brunner et al. (2010) have classified media into serum-
free, animal-derived component-free or chemically defined media for cell culture 
applications.  
• Chemically defined (CD): Chemically defined media do not contain proteins, 
hydrolysates or any other components of unknown composition. Highly purified 
hormones or growth factors added can be of either animal, plant or recombinant, but 
are added in known concentrations. 
• Animal-derived component free (ADCF): These media contain no components of 
animal origin and are not necessarily chemically defined (e.g., may contain bacterial 
or yeast hydrolysates or plant extracts). 
• Serum-free (SF): Serum-free media do not require supplementation with serum but 
may contain some protein fractions (e.g., animal tissue or plant extracts) and are thus 
regarded as chemically undefined (Yao et al. 2006; Chen et al. 2008). Thus, there is 
an urgent necessity to understand the effect of these media on the immune response 
of the immune cells and if serum has a real effect on stimulating the immune 
response.  
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4.1.4 Rationale for choices and design 
A defined serum-free medium which supports microglial survival and phenotype-switching 
would be beneficial to researchers. This study described two commercially available serum-
free media, developed for immune cell culture, were compared to a serum-supplemented 
medium typically used with primary microglia. 
Macrophages-SFM (from here onwards, referred to as SFM) is a serum-free 
medium designed for the culture of human peripheral blood monocytes and macrophages. 
This medium has been used to study macrophages responses to LPS. For example in a study 
by Buechler et al., (2000) 1 ng/ml of LPS has induced monocyte activation in a serum-
supplemented medium while in macrophages-SFM media much higher doses of LPS (1000 
ng/ml) are required to achieve identical responses. These media-dependent differences in 
cellular responses to LPS may be due to the activity of LPS-binding protein (LBP), which is 
known to be present in serum (Buechler et al. 2000). Similarly, Shapira et al. (1994) 
suggested that Tnf-α production in the presence of serum was higher than that in the absence 
of serum (1 ng/ml LPS in both cases). As microglia closely resemble macrophages, it has 
been suggested that this medium may support microglia too. Two studies have used this 
medium with microglia, in which Toescu et al. (1998) have studied the impact of depletion 
of intracellular Ca2+ stores in mouse brain microglia and its effect on plasma membrane Ca2+ 
pathway. Minelli et al. (2000) studied the effect of ammonium on cytoplasmic pH and Ca2+ 
concentration in cultured mouse microglial cells. However, none of these studies have 
measured the effect of serum on inflammatory profile.  
Xvivo media are serum-free and chemically defined cell culture media. These 
media do not contain any artificial stimulators of cellular proliferation or undefined 
supplements. Although these media were specifically developed for hematopoietic cells, 
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many researchers used them to culture macrophages (Henriksen et al. 2004; Carter et al. 
2011). Interestingly, Rey-Giraud et al. (2012) used Xvivo media to generate an in vitro 
model of monocyte-derived macrophages (MDM) under serum-free conditions. In which 
macrophages derived from monocytes were cultured in (I) serum-supplemented media with 
M-CSF for M2 macrophages, (II) GM-CSF for M1 macrophages, (III) Xvivo media 
supplemented with M-CSF and Il-4, Il-10 to induce activated M2 and (IV) GM-CSF and 
LPS together with IFN-γ to generate activated M1 phenotype. MDM differentiated under 
serum-free conditions displayed enhanced activity for M1 and tumour promoting property 
for M2 macrophages in contrast to MDM differentiated in the presence of serum (Rey-
Giraud et al. 2012). Also, Lalive et al. (2005) have used these media to culture primary 
microglia, since the media support microglia survivor for a day before the experiment ended. 
In the subsequent chapters in this thesis, I examined the concentration-response 
relationship between LPS and Il-4, and microglial activation towards M1 and M2 
phenotypes, and the effect of repeat stimulation. For both of these types of investigation it is 
important that: 
1. Basal activation of cells is minimal, as any underlying activation would alter the dose 
response relationship. 
2. That cells can survive for the prolonged period (4 days) between bouts of stimulation. 
In this Chapter, the hypothesis is that the presence of serum may alter basal 
activation; by using two serum free media to test this hypothesis; and to investigate whether 
these media support long-term culture. 
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4.2 Aims and objectives 
4.2.1 Aims 
The primary aim of this study is to assess whether microglia can be successfully 
cultured without serum supplementation. The secondary aim is to assess whether their 
behaviour is altered. To the best of my knowledge, there is no published work has directly 
compared of microglia behaviour, including LPS dose response using the normal serum 
containing media head to head with serum-free media, a question of significant importance 
for researchers, the reduction of animal protection usage, and potential clinical engineering 
of human microglia. 
This Chapter aims to answer the following questions:  
1. Do microglia survive in the absence of serum, in short and medium incubation 
times? 
2. Does microglial activation differs when incubated in serum free media for acute 
(a day) and chronic (6 days) period of time?  
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4.2.2 Objectives 
For a period of time that is sufficient for microglia to ‘recover’ from the first 
treatment, and then be challenged a second time, i.e. facilitating future experiments relating 
to priming: 
• To confirm that qPCR reference genes are suitable for serum-free testing.  
• To compare microglial viability and morphology between serum-free and serum-
supplemented media. 
• To compare dose-response curve summary statistics (EC50, baseline and maximum 
dose response) of pro-inflammatory genes, with or without serum-supplemented 
media. 
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4.3 Experimental procedures  
4.3.1 Reagents and equipment  
All reagents and equipment used are as described previously in Chapter Two. Two 
types of media (macrophages-SFM) were from Thermofisher Fisher Scientific 
(Loughborough, UK) and Xvivo were from Lonza (Cambridge, UK).  
4.3.2 Preparation and treatment of microglia culture 
Mixed glia culture preparation and high purity microglia culture isolation were 
described previously in Chapter Two. Microglia cultures were incubated in D10 media for 
6 h, then media have been changed to serum-free media (Xvivo and SFM) and further 
incubated at 37 °C in 5 % CO2/95 % humidified air for 24 h (Figure 4-2), then cells have 
been treated with serial doses of LPS (0, 0.001, 0.01, 0.1, 1, 10 and 100 ng/ml). Later, cells 
were fixed and stained for morphological analysis, and RNA has been extracted for gene 
expression as described in Chapter Two. 
 
Figure 4-2: Schematic diagram illustrating the main procedure for serum-free media experiment. Microglia were 
isolated from rat mixed glia culture by mechanical shaking, and cultured at high purity culture. After microglia 
rested for 6 h, 10% FBS containing medium was removed, and replaced with serum-free medium . Then the cultures 
have been left in serum-free media for a day or 6 days. Then experimental treatment (e.g., LPS to induce M1 
phenotype) has been added for 2 h; then cells were fixed and stained. In parallel, RNA can be extracted from cultures 
for qPCR analysis. 
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4.4 Results 
4.4.1 The acute effects of serum-free conditions on microglia (24 h) 
4.4.1.1 Microglial viability and morphology at 24 h serum-free media culture 
All cultures were of high purity as judged by lectin-reactivity (>98 %; Figure 4-3A). 
No reduction in microglial numbers were observed in either serum-free media at 24 h (Figure 
4-3B). 
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Figure 4-3: Intensity of microglial marker expression and cell number. (A) Intensity of lectin reactivity, in a pilot 
experiment (n = 2). Lectin-reactivity confirmed microglial identity. (B) Cell number. These cultures were assessed 
after 2 h LPS treatment (n = 3). No significant difference between D10 and the two serum free media was found; 
One-way ANOVA with Dunnett’s post-hoc test versus D10, Also, unpaired t-tests for LPS versus control. All data 
are presented as the mean ± S. E. M. of two independent experiments in (A) and three independent experiments in 
(B). D10 = DMEM supplemented with 10 % FBS; SFM = serum-free media; Xvivo = hematopoietic media.  
Cells were viable in D10 and the two serum free media, and expressed Cx3cr1 and CD200R, 
with the latter confirming their microglial identity, being exclusively expressed by microglia 
(Figure 4-4), there was no effect of serum or LPS on Cx3cr1 and CD200R expression (Figure 
4-5). Furthermore, microglia were morphologically similar across all media (Figure 4-6).  
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Figure 4-4: Fluorescence micrographs of immunostained microglia cultured in typical serum-supplementary media 
(D10) and two serum free media (SFM and Xvivo) . Cells expressed Cx3cr1 and CD200R, the latter confirming their 
microglial identity. The figure shows DAPI-stained nuclei as blue, Cx3cr1 as green and CD200R as red.  
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Figure 4-5: Intensity of microglial CD200R and Cx3cr1 markers expression in different media for one day. (A) 
Intensity of CD200R. (B) Intensity of Cx3cr1. These cultures were assessed after 2 h LPS treatment. All data are 
presented as mean ± S. E. M. of a pilot experiment (n = 2). D10 = DMEM supplemented with 10 % FBS; Xvivo = 
hematopoietic media. 
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Figure 4-6: Morphological analyses of lectin-reactive microglia cells after treatment with 10 ng/ml LPS in different 
media for one day. (A) Area, (B) cell perimeter, (C) Feret’s diameter, (D) minimum Feret’s diameter, (E) aspect 
ratio. These cultures were assessed after 2 h LPS treatment. No significant differences were detected; one-way 
ANOVA with Dunnett’s post-hoc test versus D10 without LPS. Also, unpaired t-tests for LPS versus control, within 
each medium. All data are presented as the mean ± S. E. M. of four independent experiments. D10 = DMEM 
supplemented with 10 % FBS; SFM = serum-free media; Xvivo = hematopoietic media. .   
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4.4.1.2 Validation of three reference genes: Gapdh, Usp14 and Rpl32 on 
three different media 
qPCR was performed using the three reference genes identified in Chapter Three. 
The results show there was no LPS-induced change in expression for the reference genes 
tested (Gapdh, Usp14 and Rpl32), across a wide range of LPS concentrations and across 
different media (D10, SFM and Xvivo). No variations in relative expression (fold change) 
(Figure 4-7), and no evidence of a dose-response effect was observed. Therefore, the average 
of their Cq values should allow reliable evaluation of LPS-induced changes in GOI. 
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Figure 4-7: Reference genes (Usp14, Rpl32 and Gapdh) were unresponsive to LPS treatment for 2 h, in three different 
media for one day. Y-axis represents log fold change versus average of reference genes (1 = no change) y= 1 showing 
average values for control within each media (i.e. D10 is compared to D10 control) and X-axis represents LPS 
concentration. The biological replicates produced similar values, demonstrating high reproducibility. All data are 
presented as the mean ± S. E. M. of three independent experiments. D10 = DMEM supplemented with 10 % FBS; 
SFM = serum-free media; Xvivo = hematopoietic media. 
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4.4.1.3 The acute effect of serum on Il-1β gene expression after 2 h of LPS 
treatment 
There is a dose-responsive increase in Il-1β with LPS treatment in D10 and both 
serum-free media (SFM and Xvivo) (Figure 4-8). 
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Figure 4-8: Il-1β dose response in different media for one day. Y-axis represents log fold change for each medium 
(1 = no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; SFM = serum-free media; Xvivo = hematopoietic 
media.  
No significant difference in EC50, baseline expression and maximum gene 
response were detected between media (Figure 4-9).  
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Figure 4-9: Il-1β dose response curves summary in different media for one day. (A) EC50 (B) Maximum dose 
response and (C) Baseline expression. In figure (A), Y-axis represents pEC50 in (g/ml), while in figures (B) and (C) 
the Y-axis represents log fold change and X-axis represents the different media. No significant difference between 
D10 and the two serum free media was found; One-way ANOVA with Dunnett’s post-hoc test versus D10. All data 
are presented as mean ± S. E. M. of three independent experiments. D10 = DMEM supply with 10 % FBS; SFM = 
serum-free media; Xvivo = hematopoietic media. 
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4.4.1.4 The acute effect of serum on Il-6 gene expression after 2 h of LPS 
treatment  
There is a dose-responsive increase in Il-6 with LPS treatment in D10 and both 
serum-free media (SFM and Xvivo) (Figure 4-10). 
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Figure 4-10 : Il-6 dose response in different media for one day. Y-axis represents log fold change for each media (1 
= no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; SFM = serum-free media; Xvivo = hematopoietic 
media. 
No significant difference in EC50, baseline expression and maximum gene 
response were detected between media (Figure 4-11). 
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Figure 4-11: Il-6 dose response curves summary in different media for one day. (A) EC50 (B) Maximum dose 
response and (C) Baseline expression. In figure (A), Y-axis represents pEC50 in (g/ml), while in figures (B) and (C) 
Y-axis represents log fold change and X-axis represents the different media. No significant difference between D10 
and the two serum free media was found; One-way ANOVA with Dunnett’s post-hoc test versus D10. All data are 
presented as the mean ± S. E. M. of three independent experiments. D10 = DMEM supply with 10 % FBS; SFM = 
serum-free media; Xvivo = hematopoietic media.  
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4.4.1.5 The acute effect of serum on Tnf-α gene expression after 2 h of LPS 
treatment  
There is a dose-responsive increase in Tnf-α with LPS in D10 and both serum-free 
media (SFM and Xvivo) (Figure 4-12). 
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Figure 4-12: Tnf-α dose response in different media for one day. Y-axis represents log fold change for each medium 
(1 = no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; SFM = serum-free media; Xvivo = hematopoietic 
media. 
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No significant difference in EC50, baseline expression and maximum gene 
response were detected between media (Figure 4-13). 
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Figure 4-13: Tnf-α dose response curves summary in different media for one day. (A) EC50 (B) Maximum dose 
response and (C) Baseline expression. In figure (A), Y-axis represents pEC50 in (g/ml), while in figures (B) and (C) 
Y-axis represents log fold change and X-axis represents the different media. No significant difference between D10 
and the two serum free media was found; One-way ANOVA with Dunnett’s post-hoc test versus D10. All data are 
presented as mean ± S. E. M. of three independent experiments. D10 = DMEM supply with 10 % FBS; SFM = 
serum-free media; Xvivo = hematopoietic media.  
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4.4.2 The chronic effects of serum-free conditions on microglia (6 DIV)  
4.4.2.1 Microglial viability at 6 DIV serum-free media culture 
Cells expressed Iba1, confirming their viability in D10 and Xvivo. However, SFM 
did not support microglia survival. Although some fields show nuclei, no Iba1 is associated 
with these nuclei also there is a reduction in microglial numbers in serum-free media (SFM) 
when compared to both D10 and Xvivo, at 6 DIV (Figure 4-14).  
 
Figure 4-14: Iba1 labelling of microglia in different media for six days. Cells expressed Iba1, confirming their 
microglial identity. Figure show DAPI-stained nuclei as blue and Iba1 as red. 
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4.4.2.2 Validation of three reference genes: Gapdh, Usp14 and Rpl32. 
qPCR was performed using three reference genes (identified in Chapter Three) for 
microglia cultured in D10 and Xvivo, the data for microglia cultured in SFM for 6 days has 
been excluded due to unhealthy culture. The results show there was no LPS-induced change 
in expression for the reference genes tested (Gapdh, Usp14 and Rpl32), across a wide range 
of LPS concentrations and across two different media (D10 and Xvivo). With no evidence 
of a dose-response effect (Figure 4-15). Therefore, the average of their Cq values should 
allow reliable evaluation of LPS-induced changes in GOI. 
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Figure 4-15: Reference genes (Usp14, Rpl32 and Gapdh) were unresponsive to LPS treatment in different media for 
six days. Y-axis represents log fold change for each medium (1 = no change) and X-axis represents log LPS 
concentration. Best fit line produced by GraphPad Prism software, Line of best-fit calculated using (Y=Y intercept 
+ slop * X) equation. All data are presented as mean ± S. E. M. of three independent experiments. D10 = DMEM 
supplemented with 10 % FBS; Xvivo = hematopoietic media.  
128 
 
4.4.2.3 The chronic effect of serum on Il-1β gene expression after 2 h of 
LPS treatment  
There is a dose-responsive increase in Il-1β with LPS treatment both in D10 and 
Xvivo (Figure 4-16). 
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 Figure 4-16: Il-1β dose response in different media for six days. Y-axis represents log fold change for each medium 
(1 = no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; Xvivo = hematopoietic media.  
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A significant difference was detected between D10 and Xvivo in EC50 (Figure 4-17 
A), while no significant difference in baseline expression and maximum gene response was 
detected between media (Figure 4-17). 
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Figure 4-17: Il-1β dose response curves summary in different media for six days. (A) EC50, a significant difference 
between D10 and Xvivo was found. (B) Maximum dose response. (C) Baseline expression. In figure (A), Y-axis 
represents pEC50 in (g/ml), while in (B) and (C) Y-axis represents log fold change and X-axis represents the different 
media. *p < 0.05; unpaired t-test Xvivo versus D10. All data are presented as mean ± S. E. M. of three independent 
experiments. D10 = DMEM supply with 10 % FBS; Xvivo = hematopoietic media.  
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4.4.2.4 The chronic effect of serum on Il-6 gene expression after 2 h of LPS 
treatment  
There is a dose-responsive increase in Il-6 with LPS treatment both in D10 and Xvivo 
(Figure 4-18). 
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 Figure 4-18: Il-6 dose response in different media for six days. Y-axis represents log fold change for each medium 
(1 = no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; Xvivo = hematopoietic media. 
No significant difference in EC50, baseline expression and maximum gene 
response was detected between D10 and Xvivo (Figure 4-19). 
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Figure 4-19: Il-6 dose response curves summary in different media for six days. (A) EC50 (B) Maximum dose 
response and (C) Baseline expression. In figure (A), Y-axis represents pEC50 in (g/ml), while in figures (B) and (C) 
Y-axis represents log fold change and X-axis represents the different media. No significant difference was found; 
unpaired t-test Xvivo versus D10. All data are presented as mean ± S. E. M. of three independent experiments. D10 
= DMEM supply with 10 % FBS; Xvivo = hematopoietic media.  
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4.4.2.5 The chronic effect of serum on Tnf-α gene expression after 2 h of 
LPS treatment  
There is a dose-responsive increase in Tnf-α with LPS treatment both in in D10 and 
Xvivo (Figure 4-20). 
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Figure 4-20: Tnf-α dose response in different media for six days. Y-axis represents log fold change for each medium 
(1 = no change) and X-axis represents log LPS concentration. All data are presented as mean ± S. E. M. of three 
independent experiments. D10 = DMEM supply with 10 % FBS; Xvivo = hematopoietic media.  
No significant difference in EC50, baseline expression and maximum gene 
response detected between media (Figure 4-21). 
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Figure 4-21: Tnf-α dose response curves summary in different media for six days. (A) EC50, (B) Maximum dose 
response and (C) Baseline expression. In figure (A), Y-axis represents pEC50 in (g/ml), while in figures (B) and (C) 
Y-axis represents log fold change and X-axis represents the different media. No significant difference was found; 
unpaired t-test Xvivo versus D10. All data are presented as mean ± S. E. M. of three independent experiments. D10 
= DMEM supply with 10 % FBS; Xvivo = hematopoietic media.  
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4.5 Discussion 
Understanding microglia-specific behaviours is critical to understanding 
neurological disease and developing therapeutic interventions. 
Culture systems, which typically use serum-supplemented media, failed to replicate 
the serum-free environment of the brain. Although some studies temporarily omitted serum, 
basal media without supplemented serum are typically insufficient for microglial survival 
and possibly impair responsiveness (Zielasek & Hartung 1996; Franciosi et al. 2005; 
Kobayashi et al. 2013). Due to these problems, serum-supplementation remained a routine 
for microglial culture (Lian et al. 2016; Chi et al. 2018; Yousif et al. 2018). A defined serum-
free media which supports microglial survival and phenotype-switching would be of 
scientific benefit for researchers. Here, two commercially available serum-free media, 
developed for immune cell culture, were compared to a serum-supplemented media typically 
used with primary microglia. 
4.5.1 Microglial viability and morphology in serum-free media 
No reduction in microglial cells numbers was observed in either serum-free media, 
at 24 h (Figure 4-3), suggesting that either of these media could be suitable for studying 
acute effects in microglia in short experiment length (one day in culture). Although, 
microglia survived when cultured in Xvivo media for 6 days, SFM did not support microglia 
survival (Figure 4-14). This suggests that SFM is not a good alternative media for long-term 
culturing of microglia. 
Several in vivo studies have suggested that resting microglia adopt ramified shape 
characterised by small soma size and highly branched dynamic processes to scan their brain 
environment (Lawson et al. 1990; Thanos et al. 1993; Morrison & Filosa 2013). Changes in 
microglial morphology may be associated with alterations in their activation state; microglial 
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function may also change without a noticeable change in their morphology (Perry et al. 
2010). Studies have described this morphological changes in vivo as a de-ramification in 
which the number of processes and process length are gradually reduced until the cell 
displays an amoeboid morphology characterised by increased cell bodies and irregular 
process shape (Orr et al. 2009; Qin et al. 2013; Hellwig et al. 2016). However, it has been 
reported that microglia in high purity culture adopt an amoeboid morphology with short and 
thick processes which become bipolar or tripolar when treated with activation stimuli such 
as LPS (Abd-El-Basset & Fedoroff 1995). It has been reported that culturing microglia in 
coculture with astrocytes leads to a morphology more like the ramified in vivo morphology 
(Kloss et al. 2001).  
The hypothesis that 10 % serum leads to low level M1 activation could allow 
predictions that D10 microglia may be more rounded, with fewer processes. This study 
results showed that microglia were morphologically similar across all media which disagrees 
with Tanaka et al. (1998) study that reported that microglia adopt non- ramified morphology 
when cultured in serum-free media. My data do not support the hypothesis that serum free 
culture leads to less M1 activation. However, it is possible that, as my microglia were all 
derived from mixed glial cultures with 10 % serum, any alterations to activation status may 
have already occurred. 
4.5.2 Pro-inflammatory response in D10 
In serum-supplemented media, exposure of the microglial cells to LPS led to 
increased pro-inflammatory cytokine (Il-6, Il-1β and Tnf-α), indicative of M1 activation 
(Zhang et al. 2001; Liu et al. 2012; Pan et al. 2015; Orihuela et al. 2015). All three genes 
showed positive dose-response curves. The plateau suggests the highest dose of LPS chosen 
here (100 ng/ml) produces the maximal response for key M1-associated cytokines.  
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 Results from D10 media are consistent with other researchers work. For example 
Puffenbarger et al. (2000) reported a similar expression for Il-1β and Il-6 after incubating 
primary rat microglia with 10 ng/ml LPS for 24 h, and analogous expression was reported 
when using primary mouse microglia and a cell line (Puffenbarger et al. 2000; Liu et al. 
2012; Kobayashi et al. 2013; Orihuela et al. 2015). 
Few studies have fully investigated LPS dose responses, and most of them studied 
the effect of a small range of different LPS concentrations in terms of protein production, 
such as IL-1 (Lee et al. 1993) and Il-10 (Sheng et al. 1995). Although Loram et al., (2012) 
described Il-1β gene dose response, they have used only three LPS concentrations. 
Therefore, determining a dose response curve allows EC50 to be calculated, which predicts 
the amount of LPS required to induce the half of maximum gene expression. Such 
information would be important when studying different drug effects on microglia. 
4.5.3 Pro-inflammatory response in serum-free media 
The hypothesis was that if the presence of serum led to primed microglia, then the 
amount of pro-inflammatory cytokine expression in serum-supplemented media will be 
higher than that of microglia plated in non-serum media when treating both of them with 
LPS. 
If serum-free data were identical to the serum-supplemented response, this would 
imply that the presence of serum in microglia culture media does not cause microglial 
priming nor inhibition. But if serum-supplemented data showed a stronger pro-inflammatory 
response, this would imply that the presence of the serum in microglia culture media plays 
a role in priming microglia, which produces more pro-inflammatory cytokines in response 
to the next activation agent (LPS). A more limited pro-inflammatory response with serum, 
would imply that the serum had inhibitory agents which reduce microglial activation. For 
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example, anti-inflammatory stimuli such as Il-4, Il-10 or Tgf-β can be present in serum 
(Kleiner et al. 2013). 
To test this hypothesis the effect of the presence of serum on microglial activation 
state was studied in the short term (only one-day on D10 in compare to other serum free 
media) and in longer term (6 days). Microglia in each medium were treated with LPS (0.01-
100 ng/ml), and baseline response, maximum response and EC50 were compared between 
media. 
In the short term, for both serum-free media tested, LPS-induced up-regulation of 
pro-inflammatory M1 genes (Il-1β, Tnf-α and Il-6) and was comparable with serum-
supplemented media. EC50 values in D10 were similar to that of SFM and Xvivo. If 
microglial priming is caused by exposure to serum, it would be expected that D10 would 
have a high pEC50 value (more potent), as any given concentration of LPS would produce 
a greater response than seen in serum-free media. Furthermore, the baseline response and 
the maximum dose response of D10 was comparable to that of both serum-free media which 
indicate that serum containing media are not more harmful than the serum-free media in the 
short term. 
Upon longer term exposure to serum (six days in vitro), this study data showed clear 
dose responses in the three pro-inflammatory genes (Il-1β, Il-6 and Tnf-α) in D10 and Xvivo 
media only, as microglia did not survive in SFM and this prevented statistical comparison 
of SFM with D10 (and Xvivo). pEC50 in D10 was significantly higher in Il-1β in compared 
to Xvivo. Il-6 pEC50 showed reduction in Xvivo, although it wasn’t statistically different. 
The high potency in gene expression is consistent with the theory of serum might prime 
microglia.  
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This study results will be of value to the research community since they provide 
two alternative media that could be used to study microglia in short term culture, further 
validation to the three reference genes as being stable with and without serum, which will 
be a good tool to study microglia gene expression. Serum-supplementation media supports 
cell survival in even in longer incubation time (6 DIV), with no reduction in the number of 
cells, viability and morphology with increases in the incubation time. Therefore, D10 media 
have been chosen to perform the remaining experiments in this thesis. 
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4.6 Summary 
In summary, this study has shown that primary microglial cells can be maintained 
in serum-free media. Importantly for neuropathological research and drug testing, microglia 
displayed typical pro-inflammatory responses in both these serum-free media. These 
findings showed that more realistic and tightly controlled experimental conditions (i.e. 
serum-free) could be used to assess microglial activation/phenotype-switching for short-
term culture. In long-term culture this study showed that there is shift in the EC50 between 
D10 (serum supply media) and Xvivo (serum free media), however further study needed to 
confirm that.  
Further experimental work should identify other media, including possibly 
developing chemically-defined media without proprietary (undeclared) concentrations of 
individual components, validate other assays in serum-free conditions, perform more 
detailed morphological assessments, test longer culture periods or gather in vivo data for 
comparison. 
These advances offer substantial benefits to the microglial research community, 
including greater confidence in the clinical applicability of in vitro findings. 
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Chapter 5 : Characterising microglial responses to 
pro-inflammatory activation 
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5.1 Introduction 
5.1.1 Neuroinflammation: activated microglia can exhibit various phenotypes 
and behaviours  
Microglia exhibit a wide variety of behaviours largely intended to destroy foreign 
substance and remove debris, with additional roles in the development, brain remodelling, 
infections and trauma (see Chapter One). To achieve these effects, microglia can reversibly 
alter their phenotypes between the ‘inactivated’ state and various ‘activated’ states including 
a pro-inflammatory phenotype that induces neuroinflammation. Microglia are activated in 
response to different pathological states within the CNS including injury, ischemia and 
infection. The subsequent neuroinflammation produces pro-inflammatory cytokines such as 
Il-1, Il-6, Tnf-α and enzymes, such as iNos, which might be toxic to other neural cells 
(Smith et al. 2012). Pro-inflammatory cytokines play important roles in neuroprotection but 
could also contribute to damage of neurons and other glia cells. 
Each microglial cell responds to its immediate microenvironment, which can 
include signals from distant cells, either within or outside the CNS. In particular stages of 
disease/injury, most microglia at the lesion site adopt a specific phenotype, but this dominant 
phenotype often changes over time, until resolution of the disease state. For example, M1 
microglia may dominate to combat infection, then M2 microglia become more numerous to 
stimulate tissue ‘recovery’, and finally, M0 microglia re-occupy the healthy tissue.  
5.1.2 LPS induced responses 
Microglia activated by LPS and/or IFN-γ are characterised as M1 classically 
activated microglia phenotype (Boche et al. 2013). LPS acts through the TLR4 receptor and 
induces a signal transduction cascade that modulates NF-κB-mediated gene expression and 
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leads to the production of pro-inflammatory cytokines, such as Il-1β, Il-6 and Tnf-α and free 
radicals such as RNS and ROS (Alexander & Rietschel 2001).  
Tnf-α, a pro-inflammatory cytokine, interacts with one of two main receptors: 
TNFR1 or TNFR2. Their biological effects include cell proliferation, cell migration and 
apoptosis mediated through the activation of several downstream signal transduction 
cascades involving NF-κB, c-Jun N-terminal kinase (JNK) and p38 (Montgomery et al. 
2013). Tnf-α has important neuroprotective effects, for example, Tarkowski et al. (1999) 
showed that Tnf-α expression is significantly and inversely correlated with intracerebral 
apoptosis and neuronal degradation. Furthermore, incubation of human neuronal cells with 
TNF-α led to production of B-cell lymphoma, a molecule known to down-regulate neuronal 
apoptosis. 
Il-1β is a major pro-inflammatory cytokine in the brain, a member of the Il-1 
cytokine family. The immune cells in the brain, microglia and astrocytes, both have the 
ability to synthesise and release the pro-Il-1β forms. Pro-Il-1β is cleaved by the protease 
caspase-1 to generate mature and bioactive Il-1β (Liu et al. 2013). The production of Il-1β 
depends on the activation of MAP kinases and NF-κB signalling pathways. 
Il-6 is a pro-inflammatory cytokine mainly produced by activated microglia and 
astrocytes in different brain regions. Il-6 functions include regulation of neuronal processes, 
such as learning and memory (Donegan et al. 2014). The production of Il-6 relies on the 
activation of Toll-like receptor 2 (TLR2)-MyD88 signalling pathways in microglia (Jana et 
al. 2008; Vukic et al. 2009). Il-6 could stimulates microglia and astrocytes to release a 
cascade of pro-inflammatory cytokines and acute-phase proteins, such as C-reactive protein 
(CRP) (Querfurth & LaFerla 2010).  
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Other stimuli can induce a M1 phenotype in microglia. In an in vitro model to mimic 
myelin debris produced after injury, the exposure of microglia to myelin leads to the 
production of NO and Tnf-α with subsequent neuronal death (Pinteaux-Jones et al. 2008). 
Exposure of microglia to abnormal protein aggregates associated with neurodegenerative 
diseases, such as Aβ in AD and α-synuclein in PD, which drive microglia toward the M1 
phenotype characterised by expression of pro-inflammatory markers such as NO and Tnf-α 
( Qin et al. 2002; Zhang et al. 2005). In an in vitro model, the exposure of microglia to dying 
neurons leads to microglial activation with cytokines production such as Tnf-α, Il-6 and 
RNS, as well as an increase in the expression of iNos enzyme (Pais et al. 2008). Notably, 
media from microglia exposed to dying neurons induced subsequent neuronal death. 
5.1.3 The role of microglia in neurodegenerative processes 
M1 microglia produce pro-inflammatory cytokines such as Il-1β, Tnf-α and Il-6, 
which are usually effective responses to infection or trauma. However, prolonged or 
excessive neuroinflammation can be toxic to neurons and other neural cells (Smith et al. 
2012). This is proposed to contribute to the progression of some neurodegenerative diseases, 
although the precise role of microglia is still being investigated (McGeer et al. 1988; Rogers 
et al. 1988). Microglia can be neuroprotective by phagocytosing Aβ plaques as a reaction 
against Aβ accumulation (Takata et al. 2010). M2 microglia surround the plaques for Aβ 
phagocytosis as labelled by Ym1 (Jimenez et al. 2008). However, an age-dependent increase 
in both of the number and the size of Aβ plaques in AD might reflect a shift in microglia 
phenotype (Hardy & Selkoe 2002; Jimenez et al. 2008). The phagocytic activity of microglia 
is reduced by pro-inflammatory cytokines such as Ifn-γ, Il-1β and Tnf-α, which most likely 
shifts microglia into the pro-inflammatory M1 state (Jantzen et al. 2002) (Figure 5-1). The 
mechanism behind this inappropriate phenotype switching is unclear.  
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Figure 5-1: Schematic illustration of microglial phenotype proposed role in Alzheimer disease. The inappropriate 
microglia phenotype (M1) leads to AD progression and neuronal death.  
5.1.4 Microglial ‘priming’ theory 
Primed microglia may be defined as exhibiting an exaggerated inflammatory 
response to a second stimulus after an initial stimulus (hypersensitive pro-inflammatory 
phenotype), the initial stimulus could be a systemic illness or infection, and it leads to 
subsequent responses to disease, injury and affects disease outcome (Haley et al. 2017). 
Primed microglia may also be described as hyper-reactive cells, secreting large amounts of 
cytokines, chemokines and other reactive molecules associated with neurotoxicity (Holtman 
et al. 2015). However, the concept that microglia are primed remains poorly defined: no 
clear or unique descriptors (biomarkers) of primed microglia have been established to date. 
Lull and Block (2010) anticipated that primed microglia profile is defined by a lower 
threshold to be activated and ‘switch’ to a pro-inflammatory state, higher baseline expression 
of markers of inflammation and inflammatory mediators (Combrinck et al. 2002) and an 
exaggerated inflammatory response following immune activation (Norden et al. 2014). 
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Evidences suggested that microglial priming might be resulted from various causes, 
such as ageing (Niraula et al. 2017), systemic inflammation and/or neuroinflammation, for 
example TBI (Ziebell et al. 2016) or neurodegenerative disease (Hoeijmakers et al. 2016). 
As a result, primed microglia exhibit an exaggerated inflammatory response to secondary 
and sub-threshold challenges (Ouchi et al. 2005; Gao & Hong 2008; Wolf et al. 2017). 
The microglial priming theory was first proposed in prion disease model, where 
Combrinck et al. (2002) hypothesised that microglia could be primed by chronic 
neurodegeneration. ME7-induced mouse has been used as a prion disease model associated 
with pro-inflammatory (M1) microglial activation, followed by further activation through 
LPS to mimic a peripheral infection. In prion disease model, application of LPS leads to 
increased microglial Il-1β and iNos expressions (Cunningham et al. 2005). Peripheral 
infection usually causes changes in behaviour (e.g., reduced appetite, depression, reduced 
motivation…, etc). These behavioural changes are mediated via the brain, suggesting that 
systemic inflammation can influence the CNS, often previously thought of as an ‘immune-
privileged’ system, unaffected by systemic immune activity (Larson & Dunn 2001). 
Combrinck et al. (2002) showed that the sickness behaviour (temperature and activity 
responses) induced by LPS in animals with pre-clinical prion disease were exaggerated 
compared with controls and that this was associated with a significant increase in brain levels 
of Il-1β. This study found an interaction between peripheral and neuro-inflammation and 
suggested that further stimulation of an already primed microglial population by a peripheral 
infection may drive disease progression (Combrinck et al. 2002). After this study, other in 
vivo studies showed that the priming phenomena is not exclusive to prion disease 
(Cunningham et al. 2009; Fielda et al. 2010). Püntener et al. (2012) reported similar findings 
of microglial priming after systemic infection. In Püntener et al. (2012) study, a single LPS 
injection increased serum levels of Il-1β with no changes in brain Il-1β levels. However, a 
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second injection (24 h later) significantly increased brain Il-1β levels with a much smaller 
increase in serum Il-1β. Therefore, in several animal models of chronic neurodegenerative 
conditions, it seems that microglia become primed by the ongoing pathology. This result 
may indicates that sickness behaviour alters with repeated infection, suggesting priming 
phenotype. 
Holtman et al. (2015) compared the gene expression networks in cell populations 
of primed microglia (isolated from mouse models for neurodegenerative disease and ageing) 
to M1 microglia (isolated from mouse models injected with LPS (10 mg/kg)), to study the 
difference in gene expression between M1 and M0’ genes network. The acute LPS-activated 
microglia were most significantly enriched for the ribosome, TLR signalling and NOD-like 
receptor signalling pathways while the priming was significantly enriched: AD signalling, 
antigen presentation, lysosome and phagosome. Which according to Holtman et al. (2015) 
suggested a fundamental differences between the acute classical M1-profile and the priming 
profiles. Furthermore, Holtman et al. (2015) predicted that primed microglia are 
characterised by expression of cell surface markers like MHC II and Cxcr4. In addition, 
primed microglia enhanced response includes not only pro-inflammatory cytokines, such as 
Tnf-α, Il-1β and Il-6 but also Il-10 and Tgf-β.  
To investigate whether microglia could be primed by systemic inflammation, Perry 
& Teeling (2013) microinjected a very small amount of LPS into the brain parenchyma, 
which, in normal animals, induced little or no inflammatory response. However, in animals 
previously challenged with S. typhimurium, there was a more robust inflammatory response 
at the site of the LPS injection.  
Evidence from preclinical studies showed that microglia priming and the 
subsequent inflammatory response leads to tissue damage in animal models of prion disease 
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(Perry 2010), AD (Kitazawa et al. 2005), PD and MS (Pott Godoy et al. 2010; Moreno et al. 
2011). 
In summary, experimental and clinical evidences indicated that microglia do not 
return to homeostasis after injury but instead develop a primed and potentially hyper-reactive 
phenotype (Witcher et al. 2015). First infection may or may not trigger microglia to release 
cytokines; a secondary insult could induce primed microglia to release additional pro-
inflammatory cytokines. Primed microglia are characterised by exaggerated responses to 
secondary insults such as repeated TBI (Witcher et al. 2015), immune challenge or stress 
(Niraula et al. 2017). This result in an amplified and prolonged neuroinflammation that 
negatively influences cognitive function (Figure 5-2). Studying microglial priming theory is 
important to provide a good understanding of how chronic systemic and/or 
neuroinflammation experienced throughout life may alter the responses of microglia 
potentially contributing to neurodegenerative disease progression.  
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Figure 5-2: Schematic illustration explaining the output of testing the priming theory. The blue lines indicate the 
predicted microglial responses if microglia do not alter with ‘priming’ effects and return to standard M0 states after 
activation. Treating M0 microglia with LPS induces M1 activation, which dissipates over time. Repeating the LPS 
dose produces the same intensity of M1 response and the same dissipation to M0. However, if priming is simulated 
in our system, we can predict that the LPS will leave microglia ‘primed’ (neither M0 nor M1), and these primed 
microglia may show a greater M1 response on later LPS challenge (red line). 
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5.2 Aims and objectives 
Although modulating microglial behaviour could provide a powerful technique to 
deliver therapy for previously untreatable diseases, it will require a thorough understanding 
of microglial phenotype switching in disease states, and the identification of 
drugs/interventions, which can bring about these changes. Therefore, an experimental 
system must be developed to study microglial behaviour, with a validation through exposure 
of microglia to well-established phenotype-inducing molecules, followed by assessment of 
markers’ expression. Once validated, strategies to control phenotype switching can be 
evaluated using such model. 
5.2.1 Aims 
The first aim of the research described in this Chapter is to characterise phenotypic 
responses to the well-known microglial pro-inflammatory activator LPS, at a wide range of 
concentrations and multiple time points. To the best of my knowledge, no report covering 
such a wide range of concentrations, allowing the calculation of the EC50 for LPS with 
microglia has been found in the literature. Such comprehensive data would be of significant 
importance for the scientists and engineering of human microglia fields.  
The second aim is to identify whether primary microglia are susceptible to 
‘priming’. If in vitro priming of microglia could be demonstrated, this would represent a 
useful model to study the mechanisms of priming, and to explore the interactions between 
different priming mechanisms. 
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5.2.2 Objectives 
The objectives are:  
• To generate qPCR dose-response data for LPS-treated microglia. 
• To compare dose-response curve summary statistics (EC50 and maximum dose 
response) for each gene, and across different time points. 
• To characterise NO expression across different LPS concentrations and time points. 
• To determine whether microglial M1 responses are heightened after priming.  
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5.3 Experimental procedures  
5.3.1 Reagents and equipment 
All reagents and equipment used were described previously in Chapter Two.  
5.3.2 Preparation and treatment of microglial culture 
Mixed glia culture preparation and high purity microglia culture isolation were 
described previously in Chapter Two. Microglia cultures were incubated in D10 media for 
24 h at 37 °C in 5 % CO2, 95 % humidified air. Cells have been treated with LPS (0, 0.001, 
0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 100 ng/ml) for 24 h, later RNA has been extracted for gene 
expression and media collected to run Griess assay as described in Chapter Two. 
5.3.3 Repeated LPS treatment 
To investigate priming (double dose) effect on microglia, an experiment was 
designed to determine the effect of second dose of LPS on pre-exposed microglia and if the 
second dose will lead to priming or tolerance status. 
A pilot experiment was performed to determine how long the ‘recovery’ period 
should be, post-LPS treatment, for microglia to lose their M1 activation state. In this 
experiment, Il-1β was highly elevated after LPS treatment (6 h, 10 ng/ml). But when parallel 
cultures were allowed to recover (100 % media change without LPS, maintained for further 
24, 48 or 96 h), Il-1β expression was indistinguishable from untreated microglia. This 
suggested that a 24 h ‘recovery’ period would be sufficient for M1 activation to expire. 
However, from the literature, ‘recovery’ periods for microglia were often chosen to be longer 
than 24 h. It was therefore decided to allow a 96 h ‘recovery’ period after removing LPS. 
There are 10 different conditions (Figure 5-3). 
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Figure 5-3: Illustration of repeated LPS experiment. There are 10 different conditions through 10 days where the 
blue boxes represent microglia in D10 media, striped boxes represent microglia facing 6 h of LPS then microglia 
have been washed and a fresh media added, then cells been left to recover or, media been collected for Griess assay 
and RNA been extracted for qPCR analysis. C: control; L: 6 h LPS; L-R: 6 h LPS followed by 96 h ‘recovery’ 
without LPS; C-R-C: microglia in D10 for 5 days; L-R-L: 6 h LPS followed by 96 h ‘recovery’ without LPS then 
2nd dose LPS (6 h); C-R-L: microglia in D10 for 5 days then received LPS (‘2nd’ dose only); C-R-C-R: microglia in 
D10 for 10 days; L-R-L-R: 6 h LPS followed by 96 h ‘recovery’ without LPS then 2nd dose LPS (6 h) then another 
96 h ‘recovery’; C-R-L-R: microglia in D10 for 5 days then received LPS (‘2nd’ dose only) then 96 h ‘recovery’ 
without LPS; L-R-C-R: 6 h LPS followed by 96 h ‘recovery’ without LPS then D10 for 5 days.  
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5.4 Results 
5.4.1 LPS dose-response effects  
Gene expression analyses were performed, for a range of LPS concentrations and 
multiple time points. For each gene, dose-response curves were plotted, maximal responses 
determined and EC50 values calculated. Also, Griess assays were used to assess dose-
response and time course in terms of nitrite production. 
5.4.1.1 The effect of LPS on Il-1β  
There is a dose-responsive increase in Il-1β with LPS treatment, at 2, 6 and 24 h 
(Figure 5-4).  
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Figure 5-4: LPS effect on Il-1β gene expression at 2, 6 and 24 h. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents log LPS concentration in (g/ml). All data are presented as the 
mean ± S. E. M of three independent experiments.  
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There is a significant decrease in LPS potency in 24h in comparison to both 2 and 
6 h (Figure 5-5 A). There is a significant difference in maximum fold changes between 6 
and 24 h (Figure 5-5 B).  
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Figure 5-5: Il-1β dose response curves summary at different time points. (A) EC50, Y-axis represents pEC50 in 
(g/ml) and X-axis represents the different time points. EC50 concentration at 24 h is significantly less potency than 
2 and 6 h. (B) Maximum fold change, Y-axis represents log fold change and X-axis represents the different time 
points, maximum dose response at 24 h is significantly lower than 6 h. *p < 0.05, **p < 0.01; One-way ANOVA with 
Tukey’s post-hoc test for each time point versus the other two time points. All data are presented as mean ± S. E. 
M. of three independent experiments. 
  
156 
 
5.4.1.2 The effect of LPS on Il-6 
There is a dose-responsive increase in Il-6 with LPS treatment at 2, 6 and 24 h 
(Figure 5-6). 
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Figure 5-6: LPS effect on Il-6 gene expression at 2, 6 and 24 h. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents log LPS concentration in (g/ml). All data are presented as the 
mean ± S. E. M of three independent experiments.   
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There is no significant difference in EC50 and maximum fold changes between 
the different time points (Figure 5-7). 
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Figure 5-7: Il-6 dose response curves summary at different time points. (A) EC50, Y-axis represents pEC50 in (g/ml) 
and X-axis represents the different time points. (B) Maximum fold change, Y-axis represents log fold change and 
X-axis represents the different time points. No significant difference; Kruskal-wallis with Dunn’s post-hoc test for 
each time point versus the other two time points for pEC50;One-way ANOVA with Tukey’s post-hoc test for each 
time point versus the other two time points for Maximum fold change. All data are presented as mean ± S. E. M. of 
three independent experiments. 
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5.4.1.3 The effect of LPS on Tnf-α 
There is a dose-responsive increase in Tnf-α with LPS treatment at 2, 6 and 24 h 
(Figure 5-8). 
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Figure 5-8: LPS effect on Tnf-α gene expression at 2, 6 and 24 h. Y-axis represents log fold change versus average 
of reference genes (1 = no change) and X-axis represents log LPS concentration in (g/ml). All data are presented as 
the mean ± S. E. M of three independent experiments.  
There is no significant difference in EC50 between different time points (Figure 
5-9A). There is a significant decrease in maximum dose response at 24 h in comparison to 2 
and 6 h (Figure 5-9 B).  
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Figure 5-9: Tnf-α dose response curves summary at different time points. (A) EC50, Y-axis represents pEC50 in 
(g/ml) and X-axis represents the different time points. (B) Maximum fold change, Y-axis represents log fold change 
and X-axis represents the different time points. #p = 0.05; One-way ANOVA with Tukey’s post-hoc test for each 
time point versus the other two time points. All data are presented as the mean ± S. E. M. of three independent 
experiments. 
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5.4.1.4 The effect of LPS on Il-10 
There is a dose-responsive increase in Il-10 with LPS treatment at 6 and 24 h only 
but not in 2 h (Figure 5-10). 
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Figure 5-10: 2, 6 and 24 h LPS effect on Il-10 gene expression. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents log LPS concentration in (g/ml). All data are presented as the 
mean ± S. E. M of three independent experiments.  
There is no meaningful curve fit was achieved for 2 h, and therefore no maximum 
fold changes and EC50 values that could be calculated for Il-10 at 2 h. There is no significant 
difference in EC50 and maximum fold changes between 2 and 6 h (Figure 5-11). 
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Figure 5-11: Il-10 dose response curves summary at different time points. (A) EC50, Y-axis represents pEC50 in 
(g/ml) and X-axis represents the different time points. (B) Maximum fold change. Y-axis represents log fold change 
and X-axis represents the different time points. No significant difference was found; unpaired t-test between 2 and 
6 h. All data are presented as the mean ± S. E. M. of three independent experiments.  
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5.4.1.5 The effect of LPS on Tgf-β 
There is no LPS-induced change in expression of the M2 marker Tgf-β, since no 
consistent increase or decrease was detected in any time point (Figure 5-12). There is no 
meaningful curve fit for Tgf-β, and therefore no maximum fold changes and EC50 values 
could be calculated.  
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Figure 5-12: 2, 6 and 24 h LPS effect on Tgf-β gene expression. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents log LPS concentration (g/ml). All data are presented as the 
mean ± S. E. M of three independent experiments.  
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5.4.1.6 Nitrite production  
To investigate the effects of LPS-stimulated on nitrite production in primary 
microglia cells, cells were treated with a different LPS concentrations for 2, 6 and 24 h. The 
levels of nitrite in the culture media were determined with the Griess assay. LPS significantly 
increased nitrite production in primary microglia cells in a dose-dependent manner (Figure 
5-13).  
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Figure 5-13: LPS-induced nitrite production. Nitrite production in microglia cells (6 × 105 cell/ml) after treatment 
with different LPS concentration (0-100 ng/ml) for 2, 6 or 24 h. LPS effect was assayed by measuring the levels of 
nitrite in the supernatant fluid using Griess reagent. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; One-way 
ANOVA with Dunnett’s post-tests for each time point in compare to its control (LPS=0). All data are presented as 
the mean ± S. E. M. of three independent experiments.  
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5.4.2 Repeated LPS treatment 
After characterising the microglial response to single doses of LPS, it was important 
to investigate the priming effect of LPS on microglia. Therefore, an experiment was designed 
to investigate the effect of second dose of LPS on pre-exposed microglia.  
As a routine through this work, qPCR was performed using the three reference 
genes identified in Chapter Three. The results show that there was no LPS-induced change 
in expression for the reference genes tested (Gapdh, Usp14 and Rpl32), across the 10 
different conditions. Variations in relative expression (fold change) was not statistically 
significant (Figure 5-14). Therefore, the average of their Cq values should allow a reliable 
evaluation of LPS-induced changes in GOI. 
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Figure 5-14: Reference genes were unresponsive to LPS treatment. (A) Gapdh, (B) Rpl32, (C) Usp14. The three 
biological replicates produced similar values, demonstrating high reproducibility. No significant difference, One-
way ANOVA with Dunnett’s post-hoc test versus C. All data are presented as mean ± S. E. M. of three independent 
experiments. C: control; L: 6 h LPS; L-R: 6 h LPS followed by 96 h ‘recovery’ without LPS; C-R-C: microglia in 
D10 for 5 days; L-R-L: 6 h LPS followed by 96 h ‘recovery’ without LPS then 2nd dose LPS (6 h); C-R-L: microglia 
in D10 for 5 days then received LPS (‘2nd’ dose only); C-R-C-R: microglia in D10 for 10 days; L-R-L-R: 6 h LPS 
followed by 96 h ‘recovery’ without LPS then 2nd dose LPS (6 h) then another 96 h ‘recovery’; C-R-L-R: microglia 
in D10 for 5 days then received LPS (‘2nd’ dose only) then 96 h ‘recovery’ without LPS; L-R-C-R: 6 h LPS followed 
by 96 h ‘recovery’ without LPS then D10 for 5 days. 
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5.4.2.1 ‘Recovery’ after first LPS 
After 6 h LPS-treatment, microglia displayed a classical pro-inflammatory profile, 
with high levels of Il-1β, Il-6, Tnf-α and iNos expressions The expression of Il-10, a non 
classical M1-associated gene, was lower, at 7.2-fold. For cultures allowed to recover for 96 
h, post-LPS exposure, M1-associated genes were all expressed at significantly lower levels 
(7.3-fold or lower), close to these in untreated microglia. In contrast, Il-10 expression levels 
did not differ following the ‘recovery’ period (Figure 5-15). 
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Figure 5-15: Microglia ‘recovery’ after first LPS treatment effect on gene expression. (A) Il-1β, (B) Il-6, (C) Tnf-α, 
(D) iNos and (E) Il-10. Y-axis represents log fold change versus average of reference genes (1 = no change) and X-
axis represents difference conditions. **p<0.01, ***p<0.001; unpaired t-test L versus L-R. All data are presented as 
the mean ± S. E. M. of three independent experiments. (L) 6 h LPS. (L-R) 6 h LPS followed by 96 h ‘recovery’ 
without LPS.   
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5.4.2.2 Second dose of LPS after ‘recovery’ from the first dose. 
After 6 h LPS-treatment, microglia displayed a classical pro-inflammatory profile, 
with high levels of Il-1β, Il-6, Tnf-α and iNos expressions. For cultures that received either 
one dose or two doses of LPS, there is no significant difference in any of M1-associated 
genes. In contrast, there is a significant increase in Il-10 expression in these cultures that 
received only the second dose of LPS (Figure 5-16). 
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Figure 5-16: Microglia receiving 2nd dose of LPS after recovery from the first LPS treatment effects on gene 
expression. (A) Il-1β, (B) Il-6, (C) Tnf-α, (D) iNos and (E) Il-10. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents difference conditions. Il-10 gene expression in C-R-L is 
significantly higher than in L. *p < 0.05, One-way ANOVA with Dunnett’s post-hoc test versus L. All data are 
presented as the mean ± S. E. M. of three independent experiments. (L) 6 h LPS; (L-R-L) 6 h LPS followed by 96 h 
‘recovery’ without LPS then second 6 h LPS; (C-R-L) microglia in D10 for 5 days then received LPS (‘2nd’ dose 
only). 
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5.4.2.3 ‘Recovery’ after second LPS treatment 
Cultures allowed a 2nd recovery for 96 h, post-LPS exposure, M1-associated genes 
were all expressed, close to these in untreated microglia. In contrast, Il-10 expression levels 
have shown a significant increase in these cultures that receive only the second dose of LPS 
and left to recover from it (Figure 5-17).  
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Figure 5-17: Microglia ‘recovery’ after 2nd dose of LPS treatment effect on gene expression. (A) Il-1β, (B) Il-6, (C) 
Tnf-α, (D) iNos and (E) Il-10. Y-axis represents log fold change versus average of reference genes (1 = no change) 
and X-axis represents difference conditions. Il-10 gene expression in C-R-L-R is significantly higher than in C-R-C-
R. *p < 0.05, One-way ANOVA with Dunnett’s post-hoc test versus C-R-C-R. All data are presented as the mean ± S. 
E. M. of three independent experiments. (C-R-C-R) microglia in D10 for 10 days; (L-R-C-R) 6 h LPS followed by 9 
days in D10 (without LPS); (L-R-L-R) 6 h LPS followed by 96 h ‘recovery’ without LPS then second 6 h LPS 
followed by another 96 h ‘recovery’ without LPS; (C-R-L-R) microglia in D10 for 5 days then received LPS (‘2nd’ 
dose only) then 96 h ‘recovery’ without LPS.  
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5.4.2.4 Repeated LPS treatment effect on nitrite production 
To investigate the effects of repeated LPS treatment on nitrite production in primary 
microglia cells, the levels of nitrite in the culture media were determined using Griess assay. 
Figure 5-18 shows that the nitrite concentration is significantly increased in these cultures 
that were treated two times with LPS and microglia recovered from two dose of LPS. 
However, there is no significant increase in any of other conditions. 
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Figure 5-18: Nitrite concentration for the repeated LPS treatment. (A) nitrite production after 6h of LPS, two dose 
of LPS with 96 h recovery time between them (L-R-L) is significantly higher than only one first dose of LPS (L). (B) 
nitrite production after 96h recovery from LPS, microglia culture that recover from two dose of LPS (L-R-L-R) is 
significantly higher than control (C-R-C-R). *p < 0.05, **p < 0.01; One-way ANOVA with Dunnett’s post-hoc test. 
All data are presented as the mean ± S. E. M of three independent experiments. L: 6 h LPS; L-R-L: 6 h LPS followed 
by 96 h ‘recovery’ without LPS then second 6 h LPS; C-R-L: microglia in D10 for 5 days then received LPS (‘2nd’ 
dose only). C-R-C-R: microglia in D10 for 10 days; L-R-C-R: 6 h LPS followed by 9 days in D10 (without LPS); L-
R-L-R: 6 h LPS followed by 96 h ‘recovery’ without LPS then second 6 h LPS followed by another 96 h ‘recovery’ 
without LPS; C-R-L-R: microglia in D10 for 5 days then received LPS (‘2nd’ dose only) then 96 h ‘recovery’ without 
LPS.  
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5.5 Discussion 
5.5.1 Microglial stimulation by LPS induces M1 phenotype 
Exposure of the microglial cells to LPS led to an increased pro-inflammatory 
cytokine expression (Il-6, Il-1β and Tnf-α), suggestive of M1 activation (Zhang et al. 2001; 
Liu et al. 2012; Pan et al. 2015; Orihuela et al. 2016). All three genes showed positive dose-
response curves as expected.  
Il-1β showed a dose response curve at 2, 6 and 24 h. There is significance less 
potency at 24 h on compare to 2 and 6 h, it might be due the LPS-TLR4 pathways nature, as 
the production of Il-6 feeds back to inhibit further release of Tnf-α and Il-1β (Minogue et al. 
2012). The data also showed a significant reduction in maximal dose response at 24 h, it 
might be due to the potential impact of reduced potency (EC50 shifts to the right). Therefore, 
it is possible that, if a higher LPS concentrations has been tested, the maximum dose 
response would be more closely matches these seen at 2 and 6 h.  
Il-6 showed a dose response curve at 2, 6 and 24 h. There are no significantly 
different in both EC50 and the maximum dose response at the different time points. 
However, the pEC50 was around 6 in Figure 5-7, while it was around 9 for the same gene 
and same condition media in Figure 4-11, which might be due to experimental artefact.  
Tnf-α also showed a dose response curve at 2, 6 and 24 h. The high concentration 
at 24 h showed a significant reduction in Tnf-α expression. In agree with this results, Chao 
et al. (1992) reported that Tnf-α protein release decrease with increased LPS incubation 
time. Although there is no direct evidence of this, the cells might have gone over the 
maximum tolerated exposure to LPS. In line with this theory, Sawada et al. (1989) had 
showed increase in LPS cytotoxicity with increase the concentration. Furthermore, there is 
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evidences of bell-shaped dose response curve with two of the biological replicate showing 
fold change less than two fold change in 100 ng/ml. 
As Table 5-1 indicates, many studies use a single (usually high) dose of LPS, or a 
small range of LPS concentrations. For example, Loram et al. (2012) used three LPS 
concentrations and measured the gene expressions of Il-1β, Cd14 and TLR4. In agreement 
with the data presented here, they showed a dose response in Il-1β gene expression, when 
primary rat microglia cultures have been treated with 1, 10 and 100 ng/ml for 4 h. However, 
Loram et al. (2012) qPCR data analysis relied on using only one reference gene (Gapdh) 
and did not calculate EC50 values. Lee et al. (1993) study showed a dose dependent response 
of IL-1β with LPS up to a concentration of 10 µg/ml. The same study revealed that protein 
production of TNF-α in LPS stimulated microglia reached a peak at 4 h, the difference 
between their time point and ours might be related to the fact that they measured protein 
expression while this study measured gene expression (Lee et al. 1993). It should be noted 
that this study was carried out using human microglia, which adds translational value to their 
findings. Puffenbarger et al., (2000) use the semi quantitative RNAse protection assay to 
investigate the effects of LPS on rat microglia. This report is one of the few microglial 
studies with a wide range of LPS concentrations: 1 – 1000 ng/ml. The authors did perform a 
time-course study (2 – 24 h) for Il-1β, Il-6 and Tnf-α. Il-1β expression has been strong 
throughout, from 2 to 24 h. However, the LPS dose used (10 ng/ml) produced maximal gene 
expression in their dose-response study, and so it is possible that they may not have 
recognised a reduction in the potency of LPS at the 24hr time point. They also utilised two 
reference genes, Gapdh and L32. 
The range of LPS doses used here provides EC50 values for each gene and reveals 
maximum fold-change for the major pro-inflammatory cytokines: Il-1β, Il-6 and Tnf-α. 
Plateau suggests the highest dose of LPS chosen here (100 ng/ml) produces maximal 
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response for most genes and time points, and the potential bell-shaped dose response seen 
with Tnf-a suggests that higher concentrations may not be well tolerated (Gibbons & 
Dragunow 2006). These data validate the use of the model for studying the magnitude of M1 
activation, enabling the comparisons between LPS and other stimuli. 
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Table 5-1: Comparison of the M1 microglia gene expretion in various time points and concentrations from various references.  
Cells
Primary 
mice 
microglia 
culture
Primary rat 
microglia 
culture
BV-2 Cell
Murine 
microglia 
cell line 
N9
Ref. 
(Chhor et 
al. 2013)
(Chhor et 
al. 2013)
(Pan et al. 
2015)
(Puffenbarg
er et al. 
2000)
(Orihuela 
et al. 
2015)
(Liu et 
al. 2012)
(Kobayashi 
et al. 2013)
Dose/ time 
point 
Not 
stated
2 h 6 h 8 h 15 h 36 h 72 h
1 ng/ml
↑ Il-1β, 
Tnf-α
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Il-6 Il-6 Il-6 Il-6 Il-6 Il-6
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
Il-6 Il-6
↑ Il-1β, 
Tnf-α, 
↑  Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑  Tnf-α, 
↑ Il-1β, 
Tnf-α, 
↑ Il-1β, 
Tnf-α, 
Il-6 Il-6 Il-6 Il-6
Il-6, 
Il10
Il-6, Il10
3 µg/ ml
↑Il-6, 
Tnf- α
1000 ng/ml
100 ng/ ml
4 h 12 h 24 h
10 ng/ml ↑ Il-1β
Primary rat microglia 
culture
Primary rat microglia culture
Primary mice microglia 
culture
Primary mice microglia culture
(Puffenbarger et al. 2000) (Puffenbarger et al. 2000) (Chhor et al. 2013)
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5.5.2 Other genes of interest 
Tgf-β (an M2-associated gene) was unresponsive to LPS at any time point, 
consistent with in vivo data (Sierra et al. 2007), however Chhor et al. (2013) reported an 
increased expression at 36 h. Therefore, it may be useful to extend future experiments to 
include later time points. Il-10 showed a dose response effect at 6 and 24 h . The literature 
contains some reports of Il-10 upregulation following LPS treatment, including in vivo 
treatment (Sierra et al. 2007) but also reported of no effect (Silva et al. 2016). This possibly 
delayed response (compared to Il-1β, Il-6 and Tnf-α) may indicate a secondary response to 
M1 activation (and so cytokine secretion) as LPS induces the production the pro-
inflammatory cytokine Il-6, which induces the production of Il-10. The activation of Il-10 
plays an important role in maintaining homeostasis. In CNS, microglia and astrocytes 
produce Il-10, which has been shown to inhibit LPS induced Il-6 secretion through negative 
feedback (Il-10 activates STAT3 which blocks TRAF6 downstream of LPS-TLR4 pathway) 
and stops the production of Il-6 (Lynch et al. 2004). However, there is no evidence of this 
in our study, since Il-6 production remains high even at 24 h. This could be followed up by 
even longer experiments. 
5.5.3 Nitrite production  
Griess reaction is an indirect method for NO determination, by detecting its stable 
breakdown products NO3
− and NO2
−. This method involve NO3
− reduction to NO2
− and 
then NO2
− determination by spectrophotometric measurement (Bryan & Grisham 2007). The 
production of nitrite is dependent on the dose of LPS; activated microglial cells can secrete 
nitrite. Stimulation of the NO pathway in microglial cells may be relevant to the pathogenesis 
of inflammatory and autoimmune demyelinating diseases of the brain (Zielasek et al. 1992). 
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NF-κB has been shown to be one of the most important upstream modulators for 
pro-inflammatory cytokines and iNos expression in microglia (Liu et al. 2011). iNos is the 
key enzyme for NO production and is quantitatively induced in activated glial cells after 
exposure to stimulus such as LPS and viral infections (McGeer et al., 1993; Chew et al., 
2006). Therefore, it may be interesting to measure dose-responsive increase of iNos with 
LPS treatment at 2, 6 and 24 h similar to what have been done with the other M1 markers.  
5.5.4 Repeated LPS treatment  
In vivo evidence suggested that systemic infections lead to an increased 
inflammatory response in the CNS, and it has been proposed that this interaction might have 
an important influence on disease processes in the CNS (Perry et al. 2003). Infections and 
events such as trauma, injury or surgery trigger systemic inflammation. These signals will 
have an important impact on microglia state either by fully activating them or at least priming 
them (Norden et al. 2014). Therefore, if later a neurodegenerative disease occurs, it could 
be hypothesised that M0’ microglia would generate a larger cytokine response than would 
unprimed microglia in the normal brain. Cytokines are typically not neurotoxic but 
imbalances and overproduction may lead to neuronal loss, and this may contribute to 
neurodegenerative diseases processes (Stroemer & Rothwell 1998). Even though studies 
suggested that M0’ microglia have an important role in neurodegenerative disease, the 
mechanisms are not well understood. Therefore, to establish an in vitro model will be helpful 
to explore and generate hypotheses about M0 microglia.  
The hypothesis was that if a microglial activation response was related to its 
previous experience, then the amount of pro-inflammatory cytokine produced by microglia 
treated with LPS and recovered from the first inflammation state will be higher than that of 
naïve microglia when treating both of them with LPS. We tested this hypothesis by 
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stimulating naïve microglia with LPS then leaving them to recover before stimulating them 
with a second dose of LPS and studying the differences in gene expression between naïve 
microglia and microglia with previous LPS experience.  
The results showed that the recovery time that has been chosen here (4 days) is 
enough time for microglia to lose the M1 activation state, for example, when microglia were 
treated with 10 ng/ml for 6 h there was a significant increase in Il-1β (~ 300 fold increase) 
which was comparable to what was previously reported in section 5.4.1.1. The 4 days 
recovery time led to a significant decrease in M1 markers (Il-1β, Il-6, Tnf-α and iNos) while 
Il-10 showed a non-significant change since it is a M2 marker which was not affected by 
LPS treatment. After the results confirmed the time point, a second dose of LPS was added. 
Although all the M1 markers were increased , the levels of these markers were almost similar 
across the different conditions (L, L-R-L and C-R-L). Furthermore, the effect of another 
recovery period tested here, to check if microglia have any memory for repeated infections. 
The results showed similar expression level in (C-R-C-R, L-R-L-R, C-R-LR and L-R-C-R) 
through all the M1 markers tested here, this result suggested that microglia M1 expression 
go back to the baseline expression when allowed them to recovered whether they received 
one or repeated dose of LPS. 
In summary, the results generated in this chapter suggest that double dose (6h; 10 
ng/ml LPS, recovery time and another 6h; 10 ng/ml LPS) does not exaggerate microglia 
inflammatory response. In line with this study, another study showed that when macrophages 
receive a similar LPS dose to what has been used here (10 ng/ml) no differences were 
recorded in Il-6 and Tnf-α upon secondary challenge (Deng et al. 2013). On the other hand, 
results generated here showed that the anti-inflammatory Il-10 marker has a higher 
expression in these cells that only received the 2nd dose of LPS (C-R-L) and these who 
recovered from the 2nd dose (C-R-L-R). Schaafsma et al., (2015) have reported a similar 
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result, Il-10 protein expression was higher in (PBS-LPS) than in (LPS-PBS) and (LPS-LPS) 
in vivo. And this might be due to the neuroprotective nature of Il-10 and its important role 
in regulating CNS inflammation and infection. Furthermore, LPS induced Il-6 has been 
shown to activate Il-10 production by microglia (Ye & Johnson 2001). In contrast, 
Schaafsma et al. (2015) reported that in a similar neonatal mice microglia experiment, 
multiple dose of LPS led to a reduction in the pro-inflammatory gene expression as facing 
an infection might lead to acquisition of tolerance to the next infection.  
In terms of Griess assay, it seems that microglia exposed to a double dose of LPS 
have a significantly higher nitric oxide production. Although, it is generally thought that NO 
production and pro-inflammatory mediators always increase in activated 
microglia/macrophages. Zhang and Morrison (1993) study showed that when macrophages 
are primed by pre-treatment with LPS NO production in response to second stimulation was 
increased, Tnf-α production is co-ordinately suppressed. Furthermore, this study result 
suggests that there is an increase in NO production even without high iNos gene expression 
(Figure 5-17). One explanation for this might be the disconnect between iNOS gene 
expression and iNOS protein, with significant enzyme activity present in the cell for a 
substantial length of time after gene expression is switched off. Counter to this argument, 
the half-life of iNOS protein is reported to be short (~1-2 hr) (Kolodziejski et al. 2004; Wang 
et al. 2009). These results support the concept that different mechanisms might be involved 
in priming and stimulating microglia to produce different genes and NO. 
This study results also demonstrated that the first dose of LPS did not lead to either 
less or more response to second dose of LPS, as shown by cytokines gene expression. The 
results of the current study should be considered in the context of previously reported 
investigations. Endotoxin primed macrophages has been well described in various in vitro 
studies (Hirohashi & Morrison 1996; Bosisio et al. 2002; Sorgi et al. 2012). On the other 
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hand many other in vitro studies reported ‘tolerance’ (pre-activated cell reduces pro-
inflammatory production) upon induction of systemic inflammation (Takasuka et al. 1991; 
Shinji et al. 1994).  
In vitro studies showed that macrophages pre-treated with LPS have an increased 
superoxide anion production (León et al. 1992). Lehner et al. (2001) showed that despite a 
reduced cytokines response, acquired LPS tolerance was associated with enhanced resistance 
to infections by Gram-negative bacteria, mediated primarily through improved innate 
immune effector function. Pre-treatment with LPS enhanced survival of mice (Rayhane et 
al. 2000). In rats, endotoxin tolerance was associated with reduced cytokine expression 
within the lung and liver (Flohé et al. 1999). In prion disease model, Combrinck and his 
colleges (2002) demonstrated an exaggerated behavioural response and increased Il-1β 
synthesis in the CNS following a peripheral LPS challenge to animals with a pre-existing 
chronic inflammation. Using similar model, Cunningham and his co-worker (2002) showed 
an increase in Il-1β and Tnf-α in prion-diseased animals relative to control animals after 
injection of LPS (100 μg/kg). 
As the goal of this experiment was to study the difference between naïve microglia 
and microglia with previous experience in term of gene expression using real time PCR. C-
R and L-R-C conditions have not been included in this experiment. C-R-C and C-R were 
considered to be similar in term of gene expression. Furthermore L-R and L-R-C were also 
considered to be similar since changing the media and leaving the cells in D10 for extra 6 h 
will not affect gene expression. However, future work should include these condition as 
changing the media might have an effect on measured nitrite. 
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5.6 Summary 
This Chapter has characterised the effects of a wide range of LPS concentration at 
three-time points (2, 6 and 24 h).  
Establishing this model is important for future work, as knowing the EC50 and the 
maximum dose response for M1 microglia will help to provide a base line to study the effect 
of using different substance in the CNS, such as nanoparticles, which are considered as a 
new approach in the treatment of neurodegenerative diseases. Also, it helps in studying the 
effects of a second pro-inflammatory challenge, which will possibly allow the investigations 
of the effects of age and systemic inflammation on the onset and the progress of 
neurodegenerative diseases. 
As part of future work, it will be helpful to study the effect of different challenges 
(e.g., ‘insulin’ dysregulation in diabetes and ‘leptin’ expression in obesity) on the second 
challenge. Also, the response to other materials in the presence of inflammation, for example 
is the nanoparticle effect on microglia different within a spinal cord injury site? Furthermore, 
the next step will focus more on the mediators that control the priming effect of microglia 
which will be of great benefit in terms of developing drugs designed to reduce the extreme 
microglia reaction in the neurodegenerative disease that leads to neuronal damage and death. 
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Chapter 6 : Characterising microglial responses to 
anti-inflammatory activation 
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6.1 Introduction 
6.1.1 The role of M2 microglia in health and disease 
Microglia play significant roles in the CNS. In normal healthy brain, microglia scan 
their environment for threats to homeostasis, and if an infection has been detected, microglia 
are activated and start to attack this infection by producing pro-inflammatory cytokines as 
described in Chapter Five. The pro-inflammatory state that followed by anti-inflammatory 
state, plays a role in tissue repair, wound healing and extracellular matrix composition 
(Colton & Wilcock 2010). Furthermore, the main M2 function is inhibiting inflammation 
and restoring homeostasis. Many of the characteristics of this anti-inflammatory state are 
reported to be recapitulated by in vitro stimulation by the anti-inflammatory cytokine Il-4 
(Cherry et al. 2014). 
Microglia can be driven toward M2 phenotype in vitro by stimulating them with 
Th2 cytokines, such as Il-4, Il-13, Il-10 and Tgf-β. Th2 is T helper cell type 2 that control 
other cells by releasing Th2 cytokines (Mills et al. 2000). As described in section 1.4.3, some 
researchers refer to M2 subtypes (a, b, c and sometimes others). This Chapter will use the 
broader M2 label, widely-used in the literature. These M2 microglia are characterised by the 
expression of anti-inflammatory markers: Arg1, Ym1 and Fizz1. 
Several studies have demonstrated that microglia do not permanently adopt one 
phenotype but can alternate between different phenotypes as the environment changes 
(Cherry et al. 2014; Franco & Fernández-Suárez 2015). However, in many 
neurodegenerative diseases, the continued production of pro-inflammatory cytokines is 
reported, and it is hypothesised that this may form some part of the neurodegenerative 
process. The roles of M2 phenotype microglia in neurodegenerative diseases such as PD are 
not fully understood (Tang & Le 2015).  
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6.1.2 Il-4 induced responses 
Il-4 is a multifunctional cytokine secreted mainly by Th 2 cells, mast cells, 
eosinophils and basophils (Gadani et al. 2012). Microglia can secrete Il-4 themselves, 
following M2 activation (Liu et al. 2017). Il-4 is well-known to control different immune 
responses, such as T-cell differentiation, and it is considered as an effective stimulus for the 
M2 phenotype in both microglia and macrophages (Fumagalli et al. 2015). Studies suggested 
that Il-4 has essential roles in brain function in both physiological and pathological 
conditions. For instance, T-cell derived Il-4 is critical in learning and memory in the healthy 
brain (Derecki et al. 2010). The brain level of Il-4 decreases with age, and it has been 
speculated that this may be associated with impaired memory function in aged populations, 
and the increased risk for development of neurodegenerative diseases such as AD (Nolan et 
al. 2005). 
Il-4 interacts with Il-4R on microglia in the presence of JAK1/3 leading to 
phosphorylation of the transcription factor STAT6 (Gordon 2003). STAT6 phosphorylation 
promotes nuclear translocation and anti-inflammatory gene transcription such as Arg1, 
Fizz1, Ym1 and Il-10 (McCormick & Heller 2015a) (Figure 6-1).  
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Figure 6-1: Il-4 pathway in microglia. Il-4 induced phosphorylation of JAK1/3, which in turn phosphorylates Il-4R 
and STAT6. This allows STAT6 to enter the nucleus and binds to a specific DNA sequences in IL-4–responsive 
genes. Adapted from Jiang et al. (2000) 
Arg1 is an M2 macrophages/microglia marker that contributes to arginine 
metabolism (Morris 2004). On the one hand, arginine is catalysed by iNos to produce 
citrulline and NO. On the other, M2 microglia deprive iNos of its substrate through Arg1 
activity, which metabolises arginine into urea and ornithine. NO production is controlled by 
the balance between expression of iNos and Arg1. This activity is upregulated with M1 
activation. The enzymatic products in the Arg1 pathway such as hydroxyproline, proline and 
polyamine contribute to tissue repair (Busch & Silver 2007), collagen synthesis, cell 
proliferation and differentiation (Thomas & Thomas 2001), and help to protect neurons from 
injury caused by pro-inflammatory cytokines and NO (Williams 1997). In summary, the 
Arg1 pathway is important in maintaining a low level of NO, as well as promoting repair-
related activities, which contributes to neuroprotection (Tang et al. 2014).  
Fizz1 (also known as Relm-α) is an M2 marker that has an essential role in the 
control of collagen expression (Nair et al. 2009). Which suggest that Fizz1 plays a role in 
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the tissue repair since collagen remodelling or production are useful in repair following 
injury. Fizz1 is upregulated in infected and inflammatory locations (Holcomb et al. 2000) 
and contributes to insulin resistance (Munitz et al. 2009).  
Ym1 (also known as Chi3l3) is an M2 marker induced by Il-4 or Il-13 stimulation 
by a STAT6-dependent mechanism (Welch et al. 2002). It dampens the inflammatory 
response and promotes tissue repair and healing response (Recklies et al. 2002). 
Furthermore, Ym1 positive microglia are always associated with increases in the phagocytic 
ability of microglia as in AD disease (Tang & Le 2015). 
Il-10 is an anti-inflammatory cytokine produced by M2 microglia/ macrophages to 
inhibit pro-inflammatory cytokine synthesis (Tang & Le 2015). It has also been found to be 
released by M1 microglia, although only 24-36 h after the M1-stimulus (Chhor et al. 2013), 
an event also described here (Chapter Five). Furthermore, Il-10 has an essential role in the 
regulation of Il-6 in the brain through a negative feedback mechanism as discussed in section 
3.3.2 (Orihuela et al. 2016). These markers are reported always to rise in vitro in response 
to Il-4. It would be useful, given that, to discuss how they change in vivo under different 
circumstances – in a way this is validation of the in vitro M2 state, rather than validation of 
these markers. 
Beside Il-4, three major anti-inflammatory cytokines Il-13, Il-10 and Tgf-β 
stimulate microglia to adopt the M2 phenotype, and lead to a decreased pro-inflammatory 
responses (Zhou et al. 2012). Similar to Il-4, Il-13 can suppress the production of pro-
inflammatory cytokines such as Il-1β, Il-6 and Tnf-α, and reduce NO release, which leads to 
protection against LPS induction of neuronal injury both in vitro and in vivo (Ledeboer et al. 
2000; Zhao et al. 2006). Although these stimuli could drive microglia to M2 activation state, 
their pathways are different from that of Il-4 (Figure 6-2). 
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Figure 6-2: Different M2 stimuli induce M2 microglia phenotype through different pathways. IRS, insulin receptor 
substrate; JAK, Janus kinase; STAT, signal transducers and activators of transcription; TGF-β, transforming 
growth factor-β. Adapted from McCormick & Heller (2015b). 
Tgf-β in general has an essential role in angiogenesis and ECM deposition, and 
contributes to suppressing pro-inflammatory microglial responses, all of which can be 
neuroprotective (Boche et al. 2003; Boche et al. 2006). Tgf-β enhances Il-4 stimulation of 
M2 microglia by increasing the expression of Arg1 and Ym1, suggesting that Tgf-β and Il-
4 signals could be used together to increase the protective behaviours of this phenotype 
(Zhou et al. 2012). However, most published articles simply use Il-4 alone. 
6.1.3 The importance of studying M2 microglia 
After characterising M1 microglia in Chapter Five, the obvious next step was to 
validate in vitro culture model for the M2 phenotype. A thorough understanding of M1 and 
M2 activation will provide data (e.g., maximum gene expression responses) for comparison 
with microglia responses to different disease states or treatments. For example, these data 
could be compared with microglial responses to Aβ or a-synuclein aggregates, or to drugs. 
This would help researchers to understand how to control phenotype switching. 
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Several in vivo studies have been performed to understand the therapeutic value of 
driving microglia towards an M2 phenotype. An AD mouse model, which was injected with 
Il-4/Il-13, showed an upregulation of Arg1 and Ym1 positive (M2) microglia, with a 
reduction in Aβ plaque load and improved cognition (Kawahara et al. 2012). In an 
autoimmune encephalitis model, intraperitoneal injection of engineered adult neural stem 
cells expressing Il-10 resulted in reduced CNS inflammation and demyelination, with an 
increase in remyelination (Yang et al. 2009). In a third in vivo study, an adeno-associated 
virus (AAV) vector expressing the mouse Il-4 gene was injected into a 3-month-old AD 
mouse model. Five months later the result showed a reduction in Aβ plaques, improvement 
in the memory, and increase in neurogenesis (Kiyota et al. 2010). Despite the fact that 
inducing M2 polarisation to treat CNS injuries is a promising strategy, to the best of my 
knowledge, no studies have been carried out to fully investigate microglial responses across 
a range of doses and time points. In particular, Il-4 is widely-employed as an M2-promoter, 
but its influence on gene/protein expression in microglia has not been fully characterised. 
By developing a better characterised model of M2 activation, we hope to have a 
model which can be used to study subtle changes in the sensitivity of the microglia to anti-
inflammatory activation. So, for example, does prolonged treatment with high levels of 
insulin enhance the response to Il-4, or does the uptake of magnetic nanoparticles decrease 
the ability of these cells to respond to Il-4?   
  
188 
 
6.2 Aim and objectives 
6.2.1 Aim 
The aim of this Chapter is to characterise phenotypic responses to the well-known 
microglial anti-inflammatory activator Il-4, at a wide range of concentrations. Since 
microglial reactions across such a wide range of concentrations have not been reported. 
These data would allow the calculation of the EC50 for Il-4 – a finding of importance for 
scientists, and potentially of utility for therapeutic immunomodulation of human microglia.  
6.2.2 Objectives 
The objectives are:  
• To identify M2 gene markers that respond to Il-4. 
• To generate qPCR dose-response data for Il-4-treated microglia. 
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6.3 Experimental procedures 
6.3.1 Reagents and equipment 
All reagents and equipment used were described previously in Chapter Two. Il-4, 
Il-13 and Tgf-β were from PeproTech (USA). Two types of media were from ThermoFisher 
Scientific (Loughborough, UK; macrophages-SFM) and Lonza (Cambridge, UK; Xvivo). 
6.3.2 Preparation and treatment of microglial cultures 
Mixed glial culture preparation and pure microglia culture isolation were as 
described previously in Chapter Two. Microglia cultures were incubated in D10 media for 
24 h at 37 °C in 5 % CO2, 95 % humidified air, before being treated experimentally. 
6.3.2.1 Dose response effect of Il-4 
Cells were treated with Il-4 (0, 0.001, 0.01, 0.03, 0.1, 0.3, 1, 3, 10 and 100 ng/ml) 
for 24 h, and then mRNA was extracted for gene expression analysis as described in Chapter 
Two. 
6.3.2.2 Effect of combined M2 stimuli combinations  
Cells were treated with Il-4 (10 ng/ml), Il-13 (10 ng/ml), Tgf-β (1 ng/ml), Il-4/Il-13 
or Il-4/Tgf-β for 24 h, then mRNA was extracted for gene expression as described in Chapter 
Two. 
6.3.2.3 Effect of different serum concentrations and M2 stimuli 
combination  
Microglia cultures were incubated in D10 media for 6 h, then media has been 
changed to normal 10 % FBS DMEM or (0 % FBS DMEM or HI 10 % FBS DMEM) and 
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further incubation at 37 °C in 5 % CO2, 95 % humidified air for 24 h, then cells were treated 
with Il-4 (10 ng/ml), Il-13 (10 ng/ml), Tgf-β (1 ng/ml), Il-4/Il-13 or Il-4/Tgf-β for 24 h, later 
RNA was extracted for evaluation of gene expression as described in Chapter Two. 
6.3.2.4 Effect of serum-free media on Il-4 treated microglia 
Mixed glial culture preparation and pure microglia culture isolation were described 
previously in Chapter Two. Microglia cultures were incubated in D10 media for 6 h, then 
media was changed to serum-free media (Xvivo and SFM) and further incubated at 37 °C in 
5 % CO2, 95 % humidified air for 24 h, then cells were treated with Il-4 (10 ng/ml) for 24 h, 
then RNA was extracted for gene expression as described in Chapter Two. 
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6.4 Results 
6.4.1 The effect of different time point of Il-4 on microglia gene expression  
A pilot study has been performed with a serial concentration of Il-4 at three time 
points (2, 6, and 24 h) (Figure 6-3). Since none of these three-time points had shown a sign 
of M2 phenotype, the 24 h time point was chosen because it has been suggested by many 
researchers (Zhou et al. 2012; Chen et al. 2015). 
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Figure 6-3: Effects of different time points of Il-4 on GOI gene expression. Y-axis represents log fold change versus 
average of reference genes (1 = no change) and X-axis represents Log Il-4 concentration in (g/ml). All data are of 
one experiment.  
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6.4.2 The effect of Il-4 on pro- and anti-inflammatory gene expression 
qPCR was performed using the three reference genes, which were validated in 
section 3.3.3.2. No dose-dependent effects of Il-4 were detected either on the pro- or anti-
inflammatory gene expression (Figure 6-4 and 6-5). 
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Figure 6-4: Il-4 effects on pro-inflammatory (Il-1β, Tnf-α and iNos) gene expression at 24 h. Y-axis represents log 
fold change versus average of reference genes (1 = no change) and X-axis represents log Il-4 concentration (g/ml). 
Dose response curves could not be fitted for any of the genes. All data are presented as the mean ± S. E. M. of three 
independent experiments. 
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Figure 6-5: Il-4 effects on anti-inflammatory (Il-10, Arg1 and Fizz1) gene expression at 24 h. Y-axis represents log 
fold change versus average of reference genes (1 = no change) and X-axis represents log Il-4 concentration. Dose 
response curves could not be fitted for any of the genes. All data are presented as the mean ± S. E. M. of three 
independent experiments. 
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6.4.3 The effect of Il-4 on Il-4R gene expression 
No significant change in Il-4R gene expression with any of Il-4 concentration was 
detected (Figure 6-6). 
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Figure 6-6: Il-4 effects on Il-4R gene expression at 24 h. Y-axis represents log fold change versus average of reference 
genes (1 = no change) and X-axis represents Il-4 concentration in (ng/ml). No significant difference was found; One-
way ANOVA with Dunnett’s post-hoc test versus C (control). All data are presented as the mean ± S. E. M. of three 
independent experiments. 
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6.4.4 The effect of different combinations of M2 stimuli on pro- and anti-
inflammatory gene expression  
Given that the previous experiments did not produce the expected responses from 
microglial cells, alternative methods to induce M2 activation were explored, including 
combinations of cytokines. There was a significant Il-1β downregulation with Il-4/Tgf-β 
stimuli (1/50th of control) (Figure 6-7A). There was no significant change in Cd200R 
expression (Figure 6-7 B).  
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Figure 6-7: M2 stimuli effects on Il-1β and Cd200r gene expression at 24 h. (A) Il-1β, a significant difference between 
Il-4/Tgf-β treated microglia and control was found. (B) Cd200r, a significant decrease in Il-4/Tgf-β treated microglia 
versus control was found. Y-axis represents log fold change versus average of reference genes (1 = no change) and 
X-axis represents different M2 stimuli. **p < 0.01; One-way ANOVA with Dunnett’s post-hoc test versus C 
(Control) for Cd200r; Kruskal-wallis with Dunn’s post-hoc test versus control (C) for Il-1β. All data are presented 
as the mean ± S. E. M. of three independent experiments. 
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There is a significant increase in Ym1 gene expression when treat microglia with Il-
4/Il-13 (~ 7-fold from control) (Figure 6-8B). Although, all the other treatment shows gene 
expression over 1, none of the other treatments show a significant increase in any of the other 
M2 markers (Figure 6-8 A and C). 
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Figure 6-8: M2 stimuli effects on M2 markers gene expression at 24 h. (A) Arg1. (B) Ym1, a significant increase in 
Il-4/Il-13 treated microglia versus control was found. (C) Fizz1. Y-axis represents log fold change versus average of 
reference genes (1 = no change) and X-axis represents different M2 stimuli. *p < 0.05; One-way ANOVA with 
Dunnett’s post-hoc test versus control (C) for Fizz1; Kruskal-Wallis with Dunn’s post-hoc test versus C (control) 
for Arg1 and Ym1. All data are presented as the mean ± S. E. M. of three independent experiments. 
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6.4.5 The effect of different serum concentrations and M2 stimuli on gene 
expression  
Due to the lack of robust changes in M2 markers, several experimental features 
were identified which could be masking or confounding the effects of pro-M2 stimuli. For 
example, molecules in serum may be binding/altering Il-4 and other M2 stimuli, reducing 
their effect on the cells. A pilot study was performed, using media without serum or with 
heat-inactivated serum (a process which is reported to denature immune-related proteins 
(Jungkind et al. 1986)), in combination with different M2 stimuli. Difference in serum 
conditions show no effect on microglial phenotypic markers (Figure 6-9). 
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Figure 6-9: Serum conditions and M2 stimuli have no detected effect on gene expression. (A) 0 % FBS, (B) 10 % 
FBS and (C) 10 % HI FBS. Y-axis represents log fold change versus average of reference genes (1 = no change) and 
X-axis represents different M2 stimuli. All data presented are for pilot study (n = 1). 
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6.4.6 The effect of serum-free media on microglia stimulated by Il-4 
There is no significant difference between D10 and the two serum-free media 
(Figure 6-10). 
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Figure 6-10: Effect of different media on M2 markers (Arg1, Ym1 and Tgf-β) gene expression, after 24 h of Il-4 
treatment. (A) Arg1, (B) Ym1, (C) Tgf-β. Y-axis represents log fold change versus average of reference genes (1 = no 
change) and X-axis represents different media. No significant differences were detected; one-way ANOVA with 
Dunnett’s post-hoc test versus D10 without Il-4. Also, unpaired t-tests for Il-4 versus control, within each medium. 
All data are presented as the mean ± S. E. M. of three independent experiments.  
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6.5 Discussion 
The main aim of this study was to generate a parallel data to Chapter Five (LPS and 
M1), but for M2 activation. Therefore, Il-4 was chosen as the stimulus, due to it being 
widely-used to drive both microglia and macrophage toward M2 phenotype. However, the 
data generated were not consistent with the gene expression changes that would be expected 
for M2 activation. Few significant changes in gene expression were detected. This was 
surprising, and a problem with the experimental setup was suspected. Various alterations 
were explored, but without success in resolving the issues. 
6.5.1 Il-4 to drive microglia toward M2 
Il-4 is well-known to induce microglia M2 polarisation in vitro and in vivo (Fenn et 
al. 2012; Chhor et al. 2013). Previous reports suggested that the main markers for M2 
microglia are Arg1, Il-10 and Fizz1 (Chhor et al. 2013). Expression of these markers is 
consistent with a repair/reparatory phenotype, as Arg1 catalytic activity produces 
polyamines that support extracellular matrix repair and mitochondrial functions (Pesce et al. 
2009). Within this model system, it was unexpected that many of M2 markers were not Il-4 
responsive, at least at the concentrations and time points examined here. This suggests that 
we failed to drive microglia toward M2 phenotype. 
The hypothesis was that if Il-4 led to anti-inflammatory microglia phenotype, then 
the amount of anti-inflammatory markers produced by treated microglia will be higher than 
that of non-treated (control) microglia. To test this hypothesis, a pilot study was performed 
with a serial concentration of Il-4 at 3-time points (Figure 6-3). Since none of these three-
time points have shown a sign of an M2 phenotype, the 24 h time point was chosen because 
it has been suggested by many researchers ( Zhou et al. 2012; Chen et al. 2015). Zhou et al. 
(2012) reported 25 fold change in mRNA expression on both Ym1 and Arg1, when they 
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treated primary microglia culture with 10 ng/ml Il-4 for 24 h. While, Chen et al. (2015) 
reported even higher mRNA fold change with treated BV-2 cell line with 10 ng/ml Il-4 for 
24 h. Furthermore, other researcher have reported an early detection of M2 marker even at 
4, 6 and 12 h (Michelucci et al. 2009; Chhor et al. 2013). Which suggests that the lack of 
impact on M2 markers in this experiment is not due my choice of time point. It may be of 
interest to test other time points since Zhao et al. (2012) reported a late response at 48 h. 
Similarly, Chhor et al. (2013) reported M2 microglia at 36 h and 72 h (Table 6-1). In this 
study a range of concentrations were used from 0.001 to 100 ng/ml. All reported studies 
showed M2 activation by Il-4 concentrations within this range, and so it is unlikely that the 
lack of response in this study is due to the choice of Il-4 concentration.  
Sawada et al. (1993) study found that mouse microglia expressed a basal level of 
Il-4R. Another study also reported that rat microglia expressed Il-4R, however, Zhao et al. 
(2006b) study suggested that treating primary microglia culture with 10 ng/ml Il-4 for 2 h 
did not induce an increase Il-4R gene expression. Although the results generated here were 
in line with Zhao et al. (2006b) report, we cannot be confident that Il-4R is unaffected by Il-
4, especially with the lack of change detected in other M2 marker which make these data 
unreliable. 
6.5.2 Why did we try different combinations? 
As Il-4 did not produce the expected changes in expression for all M2 markers, 
other pro-M2 stimuli were tested, including Il-13 and Tgf-β. In this study, we tried to mimic 
Zhou et al. (2012) work in BV-2 cell line in order to drive microglia toward M2 phenotype. 
Zhou et al. (2012) suggested that Tgf-β treatment alone is not able to induce M2 microglia 
but treated together with Il-4, strongly enhances Il-4 induced M2 phenotype. Arg1 and Ym1 
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expressions are significantly increased after co-treatment with Il-4 and Tgf-β. Unexpectedly, 
this observation was not seen in the primary microglia culture in term of M2 marker. 
Furthermore, Il-1β showed a significant down regulation in the gene expression in 
the combination of Il-4/Tgf-β, which might be due to type II statistical error (failing to reject 
a false null hypothesis), and that could be investigated by increasing the sample size. 
Increasing the sample size usually leads to an increased probability of detection of a genuine 
difference, and rejection of false positives. 
6.5.3 Why did we study the effect of serum? 
Given the lack of obvious changes in M2 markers, it was hypothesised that the 
presence of serum might be confounding. Serum may contain pro-inflammatory stimuli, 
producing antagonistic pro-M1 microglial stimulation or Il-4 (or other pro-M2) stimuli may 
be present in serum. Therefore, we have tested medium without serum and with 10% heat 
inactivated serum, as well as the standard 10% FBS. This induced no significant changes, 
although there is a hint of increased M1 gene expression in the presence of serum. This 
suggests that the hypothesis that serum increases M1 gene expression, (which can be 
switched off by Il-4) and suppresses M2 gene expression. Therefore, further work has been 
done using the two serum-free media that have been tested in Chapter four, different serum-
free formula SFM and Xvivo have been tested in comparison to normal D10 media; again, 
Il-4 induces no change in M2 marker gene expression. 
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Table 6-1: Comparison of M2 microglia gene expressions in various time points and concentrations from differant references. 
Cells Primary mouse microglia culture BV-2  
Primary 
mouse 
microglia 
culture 
Primary 
rat 
microglia 
culture 
Primary mouse microglia culture 
References  (Chhor et al. 2013) 
(Michelucci 
et al. 2009) 
(Chhor et 
al. 2013) 
(Chen et al. 2015) 
(Zhou et 
al. 2012) 
(Zhao et 
al. 2006) 
(Chhor et al. 2013) 
Dose/ time 
point  
4 h 6 h 12 h 24 h 48 h 36 h 72 h 
1 ng/ml   
↓Il-1β, 
Ccr2, Tnf-α 
and ↑Arg1, 
Mmr, Ym 
(1/2), Fizz1 
            
10 ng/ml       ↑Arg1, Fizz1, Ym1 
↑Arg1, 
Ym1 
↑Igf-1     
20 ng/ml ↑Cd206, Arg1, Il-12, Ifnγ, Il-13,    
↑Cd32, 
Cd206, 
Arg1, 
Igf1, Gal-
3, Il-12, 
Il-2, Ifnγ, 
Il-13 and 
↓Cxcr1 
      
↑ Il-12, Il-2, Ifnγ, 
Ccl2, Il-13 and 
↓Cxcr1, Tgf-β, Cd32 
↑Gal-3, 
Ccr2, Il-
12, Il-2, 
Ifnγ, 
Ccl2, Il-
13 
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6.6 Summary 
Researchers assumed that microglia follow the same phenotypes M1 and M2 
characteristic of macrophages. Microglial polarisation has not been fully established by 
research findings. Instead, the peripheral macrophages schema has been adopted in an 
attempt to simplify data interpretation. 
In vitro microglial culture systems suitable for assessing M2 phenotype would be 
of value to understand the protective effect of microglia in neurodegenerative diseases and 
developing novel immunotherapies. In this Chapter, several suggested stimuli, namely; Il-4, 
Il-13 and Tgf-β failed to reliably alter gene expression for widely-used M2 markers, even 
after multiple changes were made to protocols, such as different time points, different 
concentrations, different combinations of stimuli and different media. Although it does not 
match the findings of many literatures, we have not got any clear understanding of the 
reasons behind that. 
However, there is a potential value to be derived from a dataset covering gene 
expression changes over time and for a wide range of M2-stimulus concentrations. Future 
research should attempt to derive these data from an established culture system that reliably 
generates M2 microglia. 
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Chapter 7 : Microglial responses to different 
nanoparticle formulations, including ‘stealth’ coat   
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7.1 Introduction 
Previous Chapters (five and six) have discussed characterising microglial 
phenotypes and understanding phenotypic switching. This was in the context of 
understanding microglial behaviour in disease states, and with the possibility of one day 
manipulating these phenotypes as a therapy. It should be recognised that drug delivery to the 
brain (and so to microglia) is often difficult to achieve, largely because of the BBB, which 
prevents many molecules from entering the CNS. Numerous methods are being explored to 
increase delivery to the brain, including physical disruption of the BBB (ideally temporarily 
and safely (Bellavance et al. 2008)), using viruses as vectors (Davidson & Breakefield 
2003), and attaching various molecules to drugs to enhance crossing of the BBB (Gabathuler 
2010).  
Another alternative approach involves using nanoparticles (NPs) as non-viral drug 
delivery vectors. There are numerous reports of NPs formulations that can cross the BBB 
and enhance drug delivery to the CNS (Grabrucker et al. 2016; Saraiva et al. 2016; Belletti 
et al. 2018). Such techniques offer a better safety profile than the use of viruses or physical 
disruption of the BBB and allow relatively non-invasive systemic delivery (to the 
bloodstream), rather than direct, potentially dangerous, injection directly into the CNS.  
Although there is an increasing body of evidence for NP formulations crossing the 
BBB, it cannot be assumed that this will result in efficacy of the treatment. Understanding 
the ultimate fate of the NPs and their cargo requires more detailed investigation of the 
interactions between neural cells and NPs. As the dominant immune cells in the CNS and 
given the evidence for greater NP uptake by microglia compared to other neural cell types, 
it is critical to assess how microglia respond to NPs. In particular, it will be valuable to 
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determine whether inflammatory responses to NPs are induced. Therefore, this Chapter 
addresses microglial interactions with NPs, in the context of possible future therapies. 
7.1.1 Nanomedicines can cross blood brain barrier   
Nanomedicine is defined as the application of nanobiotechnologies to medicine, 
which is making or using devices and materials with at least one dimension less than 1000 
nanometres (Jain 2008). Nanomedicine represents a highly promising opportunity for the 
development of targeted drug delivery systems, non-invasive imaging, tissue regeneration 
methods, and with faster diagnostic treatments for various neurodegenerative disorders 
(Chen et al. 2016; Lee et al. 2016; Posadas et al. 2016; Poovaiah et al. 2018). The importance 
of NPs in particular are attributed to their ability to diffuse through biological membranes 
and interact closely with biomolecules to be functionalised in a wide variety of ways, e.g., 
drugs inside or attached to the surface, non-invasive tracking capabilities and remote 
manipulation, for example using magnetic fields (Tartaj et al. 2003).  
NPs have arisen as a revolutionary solution for drug delivery to the CNS, due to the 
ability to tailor their physicochemical (such as size, shape and charge) properties to 
overcome the selective nature of the BBB, following minimally-invasive delivery into the 
peripheral bloodstream. Advances in this field could enable the diagnosis and treatment of 
many CNS diseases (Begley 2004). Therefore, NPs have become a highly suitable option 
for increasing drug delivery into the brain because their ability to cross the BBB (Nair et al. 
2018). In the CNS, NPs can also be used as diagnostic tools, mainly in terms of contrast 
enhanced magnetic resonance imaging (MRI) of CNS malignancies (Weinstein et al. 2010). 
This may be particularly useful in tumour detection, delineation and maybe even treatment, 
as microglia (and invading macrophages) surround tumours and are prone to taking up NPs. 
Therefore, these NPs accumulations have been shown to reveal location and size of tumours. 
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Furthermore, the use of magnetic NPs is being investigated for hyperthermic ablation, where 
external magnetic fields are used to manipulate MNPs, delivering heat, thus thermally 
damaging tumour cells, which are less resistant to this effect. NPs could be targeted directly 
to the tumour cells, or this effect could be achieved through the neighbouring immune cells, 
including microglia (Zhu et al. 2016). NPs can also be designed to release their cargo in 
specific conditions, and so in specific locations, when given external signals. This can 
include magnetic stimulation. Research into these ‘smart’ NPs could provide valuable tools 
for CNS therapies. 
Thus, NPs could play important roles in the diagnosis and treatment of 
neurodegenerative disorders. However, despite the wealth researches on crossing the BBB, 
little attention has been paid to the fate of these NPs once inside the brain. This is critical to 
design therapies, as drug delivery NPs may be intended to release their cargo extracellularly, 
for example to act on cell-surface receptors, or it may be intended for the NPs to be 
internalised by cells. In the latter case, it may be important to control which specific cell 
types take up the NPs. For example, in order to alter microglial phenotype, it is likely that 
the activation of cell surface receptors (e.g., Il-4R and Il-10R (Fenn et al. 2012; Orihuela et 
al. 2016)) will be required. This relies on requiring extracellular drug release, and so NPs 
will be more effective if there is limited cellular uptake. Whatever the intended outcome, it 
will be important to understand how microglia respond to NPs, as these cells are the most 
phagocytic in the brain parenchyma, and can be expected to clear foreign materials, 
including NPs (Ransohoff & Perry 2009; Lull & Block 2010).  
7.1.2 Handling of nanoparticles by neural cells 
The different neural cells types play different roles in the CNS (Table 7-1). 
Therefore, it is important to understand how all neural cell types handle different NPs, in 
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order to predict drug delivery. Microglia exhibit all forms of endocytosis: micropinocytosis, 
macropinocytosis and phagocytosis. Other neural cells types, including astroglia and 
oligodendroglia, have endocytotic activity (Noske et al. 1982; Triarhou et al. 1985; Tansey 
& Cammer 1998), although their endocytotic capacity is less than that of microglia. This has 
been observed when NPs uptake was studied in different neural cell types. In vitro studies 
found that microglial uptake of NPs were greater than in other CNS cells (Fleige et al. 2001; 
Pinkernelle et al. 2012; Jenkins et al. 2016). Fleige et al. (2001) experiment was one of the 
first studies that directly compared NP uptake by different neural cells, showing that NPs 
uptake by microglia is the highest compared to astrocytes and glioma cells. In Pinkernelle et 
al. (2012) study, an incubation of dissociated cerebellar cultures (multiple neural cell types) 
with NPs, showed that microglial uptake of NPs is 2, 4 and 8 times higher than astroglia, 
OPCs and neurons respectively. In Jenkins et al. (2013) study, an incubation of different glia 
cell types with NPs, showed that extent of uptake of NPs by microglia is far greater than in 
astroglia, OPCs and oligodendrocytes. Similarly, in an in vivo study of glioblastoma 
multiforme patients, NPs uptake by macrophages (either microglia or macrophages from the 
bloodstream) is higher than that of glioblastoma cells, although human glioblastoma cells 
have high ability to take up the particles in vitro, in the absence of macrophages (van 
Landeghem et al. 2009). 
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Table 7-1: Different CNS cell types and their function. 
Cell type Cell function 
Astrocytes 
Nutrient support, neurotransmitter reuptake, neurovascular 
coupling, gliotransmitter production 
Microglia  Immune cells in the brain 
Neurons 
Information processing, sensory input integration, behaviour 
modulation 
Oligodendrocytes Myelination, trophic support for neurons 
 
As discussed, microglia take up NPs more rapidly and to a greater extent than other 
neural cell types, outcompeting them. The study of this process has been referred to as 
‘competitive nanoparticle uptake dynamics’ (Jenkins 2013). NPs taken up by microglia may 
inhibit nanoparticle uptake by other neural cell types, since it reduces the amount of available 
NPs to be taken up by other cells (Jenkins et al. 2016). Additionally, it has been proposed 
that the uptake of NPs by inactivated microglia may trigger an immune response, possibly 
affecting other nearby cells (Pickard & Chari 2010). This unintended inflammatory response 
could counteract the goal to use NPs in CNS pathological conditions. Also, NPs taken up by 
microglia are more likely to be degraded, possibly with destruction of the drug payload, 
without the intended effect. Effective delivery of drugs is likely to require that NPs escape 
uptake by microglia, and instead remain in the interstitial fluid, releasing drugs 
extracellularly. 
So, employing NPs to manipulate microglia may be a valuable therapeutic strategy, 
but NPs design will be important, as this will influence the fate of the NPs, and whatever 
they may be delivering. 
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7.1.3 Designing nanoparticles for use in the brain 
Nanoparticles are colloidal particles with all dimensions less than 1000 nm. For 
drug delivery purposes, an active ingredient (a drug or biologically active material) is 
attached, dissolved within or encapsulated (Singh & Lillard 2009). There are different 
classes of NPs, with diverse properties/applications related to their shapes, size and 
composition (Medina et al. 2007). To target the brain, it has been suggested that NPs with 
size of around 20 nm are small enough to cross the BBB and at the same time large enough 
to escape renal excretion (Tsou et al. 2017). Furthermore, different NP compositions are 
available such as liposomes, emulsions, polymers, ceramic NPs, metallic NPs, gold shell 
NPs, carbon NPs and quantum dots (Medina et al. 2007). 
 With respect to their applications in the CNS, liposomes, polymeric NPs and 
metallic particles have received particular attention to overcome crossing the BBB (Zeiadeh 
et al. 2018). 
• Liposomes are NPs comprised of lipid bilayer membranes surrounding an aqueous 
interior. The amphiphilic molecules used for the preparation of these compounds 
have similarities with biological membranes (Hofheinz et al. 2005).  
• Polymers such as polysaccharide chitosan NPs have been used as drug delivery 
systems (Agnihotri et al. 2004). Water-soluble polymer hybrids are polymer-protein 
conjugates or polymer-drug conjugates (Lee 2006). 
• Metallic particles such as iron oxide NPs (e.g., maghemite Fe2O3 and magnetite 
Fe3O4) (López-Quintela et al. 2003).  
Of these various formats, MNPs have been studied in recent years for their 
multifunctional biomedical capabilities, such as remotely controlled drug delivery 
(Adamiano et al. 2018), hyperthermic ablation of tumour cells (Cherukuri et al. 2010) and 
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non-invasive tracking through MRI (Daldrup-Link et al. 2011). These NPs are not composed 
purely of Fe3O4, as this will aggregate easily because of their large surface energy (Wu et al. 
2016). Furthermore, it is not easy to transport such hydrophilic particles across a biological 
membrane system. Therefore, MNPs are routinely coated with different materials, mainly 
polymers, to prevent agglomeration and facilitate uptake by cells. Furthermore, these 
coatings can enhance biocompatibility, and provide functionality (i.e. via functional groups 
that can enable attachment of specific structures, such as fluorescent labels, antibodies, 
drugs, nucleic acids, …, etc.). MNPs can be coated with natural or synthetic polymers, with 
some of the most widely used coatings being albumin, dextran, PEG and polyethylene oxide 
(PEO) (Sattarahmady et al. 2016; Karimzadeh et al. 2017; Nosrati et al. 2017; Shaterabadi 
et al. 2017).  
The choice of coating can dramatically influence particle fate and can be chosen to 
achieve particular therapeutic goals. In the case of prolonged extracellular drug delivery to 
microglia, following minimally-invasive delivery into the bloodstream, particle design 
should aim to avoid/limit clearance by the mononuclear phagocytise system (MPS; formerly 
the reticuloendothelial system, RES), enhance crossing of the BBB, and then also avoid/limit 
clearance by the microglia. To achieve such goals, material chemists have exploited so-
called ‘stealth’ coatings. 
Some of the stealth coatings that have been proposed include poly carboxybetaine, 
poly sulfobetaine, poly acrylic acid and PEG, due to their ability to escape clearance by the 
MPS, in comparison to non-stealth NPs (Li & Huang 2010). Some PEGylated NPs have 
been shown to cross the BBB and been found in the brain (Calvo et al. 2001; Hyun R Kim 
et al. 2007; Ensign et al. 2012). In the Calvo et al. (2001) study, PEGylated NPs have been 
compared to alternatively-coated and non-coated NPs, showing that the concentration of the 
PEGylated NPs is higher in the brain than the other non-coated and coated NPs. Importantly, 
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this high penetration of PEGylated NPs into the brain was achieved without any effect on 
permeability of the BBB. This is encouraging for clinical applications, as a disrupted BBB 
would be a serious side-effect. 
Hutter et al. (2010) reported that Au NPs produced a low-level activation of 
microglia, using N9 cells (microglia cell line) incubated with PEGylated or non-coated Au 
NPs. Non-coated NPs led to activated microglia assessed by increase in IL-1α using enzyme-
linked immunosorbent assay (ELISA), but that PEGylation of Au NPs prevented this 
activation. Furthermore, this study showed that PEGylated surface Au NPs were not take up 
by microglia at a significant level (Hutter et al. 2010).  
7.1.4 Several nanoparticles have been tested with microglia 
There are only a few reports in the literature studying microglial interactions with 
MNPs, and these will be summarised here. 
Pickard et al. (2011) examined microglial uptake of Sphero Nile Red fluorescent 
magnetic particles (diameter 200 – 390 nm). These particles were comprised of a polystyrene 
core (stained with the fluorophore Nile Red) surrounded by a layer of polystyrene and 
magnetite, over which carboxyl groups were attached (Jenkins 2013). Although Sphero 
particles are relatively large, compared to many other nanoparticles, particles with diameter 
up to 1000 nm diameter have been used to track cells post-transplantation into the CNS, 
without adversely affecting biological functions, such as myelination (Dunning et al. 2004). 
Sphero particles have been used in MRI and cellular labelling, indicating their utility for 
biological applications (Pickard et al. 2011; Jenkins et al. 2013). These Sphero particles only 
exhibited toxicity at the highest concentration tested, and were reliably internalised by 
microglia, which accumulated huge numbers of particles per cell (Jenkins et al. 2013). 
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Electron microscopy suggested degradation of iron oxide particles within microglia, 
possibly releasing the iron into the cells (Pickard et al. 2011; Jenkins et al. 2013). 
MNPs accumulation in microglia may lead to microglial activation and toxicity, 
this subsequently impairs the neuroprotective properties including the defence against 
pathogens and the repair function of microglia in brain (Petters et al. 2016). Petters et al. 
(2016) study, demonstrated that high concentrations of MNPs can induce toxicity in 
microglia, but that lower concentrations do not. Lysosome tracking indicated that MNPs 
taken up by microglia were likely to be degraded, supporting the idea that drug delivery 
MNPs should be designed to evade microglial uptake, or, possibly designed to escape 
intracellular trafficking into lysosomes. If MNPs escape this fate, and end up in the 
cytoplasm, cargo could be delivered to act inside microglia. 
Furthermore, MNPs might affect microglia morphology (Neubert et al. 2015). 
Neubert et al. (2015) study, showed that the change in microglia morphology from the 
ramified (as in non-treated culture) to more amoeboid morphology and microglia uptake of 
MNPs highly depends on NP types, concentration and exposure time, as the microglia uptake 
of superparamagnetic iron oxide nanoparticle increases with increasing incubation time (24 
h versus 6 h) and increasing MNPs concentration (0.5 versus 1.5 versus 3 mM). Furthermore, 
this study suggested that microglia exposure to MNPs leads to a change of microglia 
morphology such as thickened and enlarged cell bodies. However, the change in microglia 
morphology depends on MNP type since microglia showed more ramification when 
exposure to iron oxide nanoparticle and ferucarbotran but not ferumoxytol NPs (Neubert et 
al. 2015). To support the idea that the immune-effect of the MNPs on microglia, should be 
fully studied. 
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A recent study directly compared microglial interactions with PEGylated stealth 
MNPs, and a ‘control’ MNP, without a stealth coating (termed CMX-MNP particles) 
(Jenkins et al. 2016). Carboxymethyl dextran (CMX) coated Fe3O4 MNPs (termed CMX-
MNPs) were prepared through a two-step method (Liu et al. 2011). Coating surface of Fe3O4 
MNPs with dextran can reduce the aggregation of MNPs and help to form a stable colloid 
suspension in water. Dextran, a bacterially derived homopolysaccharide of glucose, is 
known for its biocompatibility, biodegradability, wide availability and ease of modification 
(Hermanson 2016). Carboxymethyl was chosen to modify dextran due to their well 
understood and stable pH-dependent hydrolysis rates (Park et al. 2011). CMX has been used 
in a range of biomedical applications because of its excellent aqueous solubility, 
biocompatibility and nonfouling properties (Hiemstra et al. 2007; Bachelder et al. 2008). 
Therefore, CMX represents a suitable coating for medical grade NPs. 
PEG is a biocompatible, nontoxic and water-soluble polymer of much use in 
biomaterials, biotechnology and medicine (Harris 1997). Attaching PEG can increase 
solubility and limit immune clearance, so prolonging bioavailability times (Zhang et al. 
2008; Wahajuddin & Arora 2012; Lehner et al. 2013). Two PEG-protein drugs, Adagen® 
and Oncaspar®, have been approved by the FDA (Zalipsky & Harris 1997). In fact, several 
PEGylated MNPs have been studied as depot devices for drug delivery, and they have been 
prepared in several fundamentally different ways (Zhao & Harris 1994; Brian et al. 2003). 
Researches about coating MNPs with a hydrophilic polymer such as PEG decreased particle 
recognition by macrophages cells and increased intracellular uptake by specific cancer cells, 
suggesting utility for cancer therapy and diagnosis (Zhang et al. 2002; Gupta & Curtis 2004; 
Gupta & Wells 2004). It has been widely used in drug/gene delivery, because of their 
‘stealth’ coating, that could reduce immune clearance and increase circulatory times (Zhang 
et al. 2008; Wahajuddin & Arora 2012; Lehner et al. 2013). 
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From Jenkins et al. (2016) study, a reduction in the extent of stealth PEG-MNP 
uptake compared to CMX-MNPs has been reported, for multiple neural cell types. The idea 
that stealth MNPs are predicted to be ‘invisible’ to microglia, evading specific uptake, was 
investigated. PEG-MNPs were taken up by microglia, demonstrating that they are not 
‘invisible’ to these cells, but the extent of uptake per cell was less than for the control NPs, 
showing some effect of PEG in terms of reducing clearance. Although this reduced uptake 
may only represent a modest benefit, it is not clear whether they also ‘invisible’ to cell 
surface or intracellular immune mechanisms?  
In this Chapter, I will examine whether ‘stealth’ NPs cause alteration in microglial 
activation state. 
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7.2 Aims and objectives 
7.2.1 Aims 
This study primarly aims to assess whether ‘stealth’ NPs produce more limited pro-
inflammatory microglial responses than other nanoparticles. To the best of my knowledge, 
a detailed study of microglial gene expression changes with ‘stealth’ NPs has never been 
done. The second aim is to examine whether microglia response to NPs will change if they 
are in the activation (M1) state – a question of significant importance for the scientists in the 
regenerative medicine fields. 
7.2.2 Objectives 
The objectives are:  
• To identify the effect of NPs uptake on primary microglial activation status. 
• To identify the effect of ‘stealth’ NPs on production of pro-inflammatory microglial 
responses, and if they more limited than for other nanoparticles. 
• To identify the effect of prior M1 activation of microglia on how they respond to 
NPs. 
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7.3 Experimental procedures 
7.3.1 Reagents and equipment 
All reagents and equipment used were described previously in Chapter Two. CMX-
MNPs and PEG-MNPs were supplied by Chemicell as aqueous suspensions. They were 
synthesised by the same manufacturer, having magnetite cores with a lipophilic dye 
(BODIPY) layer, overcoated with either carboxymethyl dextran (CMX-MNP) or 2 kDa 
diphosphate PEG (PEG-MNP) while Sphero were supplied by Spherotech Inc. (IL, USA). 
7.3.2 Microglia culture 
Mixed glia culture preparation and pure microglia culture isolation were as 
described previously in Chapter Two. Microglia cultures were maintained in D10-CM (D10-
conditioned media), containing 10 % FBS and 20 % conditioned media from mixed glial 
culture flasks (a mixture of molecules released by astrocytes, OPCs and microglial 
cells) (Jenkins et al. 2015). All cultures were incubated at 37 °C in 5 % CO2, 95 % 
humidified air. Cells were plated (6 × 105 cells/ml) on PDL-coated coverslips in 24-well 
plates for nanoparticle uptake and immunostaining or (24 × 105 cells/ml) on PDL-coated 
T25 flasks for gene expression. 
7.3.3 nanoparticles uptake experiments 
Based on previous work by Jenkins et al. (2016) a concentration of 2 µg/ml was 
chosen for both CMX-MNPs and PEG-MNPs and 20 µg/ml for Sphero. These 
concentrations did not produce toxic effects on microglia over 24 h, while allowing obvious 
identification of labelled cells (Pickard et al. 2011; Jenkins et al. 2016). 
All the MNPs were heavily vortexed to dissociate them before being diluted in D10-
CM, to 10 times the final concentration (i.e. 20 and 200 µg/ml, respectively). 
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7.3.3.1 Effect of nanoparticles on naïve microglia 
At 24 h after microglia were plated, cultures received a 10 % medium change (to 
replace D10-CM with 10 times final concentration of the MNPs in D10-CM) and were 
incubated for a further 24 h. Control microglia cultures were treated with equal volumes of 
fresh D10-CM media, without MNPs. Samples were washed with PBS, then either fixed for 
immunostaining and NPs uptake, or processed for gene expression and Griess assay.  
7.3.3.2 Effect of nanoparticles on M1 microglia 
At 24 h after microglia were plated, cultures received a 10 % media change (replace 
D10-CM with 10x final concentration of the LPS in D10-CM) and incubated for 24 h. Then 
100% of the media changes (MNPs in D10-CM). Control for this experiment first receive 
(LPS; 24 h) then cultures’ media were replaced with fresh D10-CM media. Samples were 
washed with PBS, then either fixed for immunostaining and NPs uptake or processed for 
gene expression and Griess assay. 
7.3.4 Nanoparticles uptake analysis 
The extent of microglial uptake of MNPs was quantified using integrated density 
function (ImageJ, NIH, US). Individual MNP-labelled cells were outlined (using phase 
micrographs), then this outline was transferred to the corresponding red channel (MNP) 
micrograph and the integrated density measured (with background intensity subtracted for 
each image). 
7.3.5 Viability assay 
Cell viability was measured following MNP treatment using live/dead 
viability/cytotoxicity kit which contains calcein AM and ethidium homodimer-1. Cells were 
washed with PBS, incubated for 15 minutes with a PBS solution consisting of 4 μM calcein-
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AM (produces green fluorescence in live cells) and 6 μM ethidium homodimer-1 (produces 
red fluorescence in dead cells). Cells were rewashed with PBS, fixed and then mounted for 
fluorescence microscopy. Cellular viability was measured by counting green (LIVE) and red 
(DEAD) cells using ImageJ software (NIH, US) then expressing the number of LIVE cells 
as a percentage of total cells (green + red) from a total of four images taken at 400 x 
magnification. 
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7.4 Results 
7.4.1 The effect of nanoparticles on non-activated microglia 
7.4.1.1 Nanoparticles toxicity 
Live/dead staining and cell counts were used to assess the effects of MNPs on the 
viability of microglia. Microglia were treated with PEG-MNP, CMX-MNP, Sphero or LPS 
for 24 h, before viability assay. After live/dead staining, most cells with normal microglial 
morphologies appeared green (LIVE) with small numbers of rounded cells appearing red 
(DEAD) in all conditions. There were no significant differences between treatments in terms 
of percentage live, percentage dead or cell counts (Figure 7-1). Live/dead staining and cell 
counts reveal high cellular viability after MNPs or LPS treatment, comparable to control 
(untreated) cultures. 
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Figure 7-1: Microglial viability was unaffected by 24 h NPs exposure. (A) Bar chart showing the percentage of viable 
and dead cells. (B) Bar chart showing the total cells. 24 h PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, Sphero= 20 
µg/ml, LPS= 10 ng/ml. No significant differences; One-way ANOVA with Dunnett’s post-hoc test versus C (control). 
All data are presented as mean ± S. E. M. of three independent experiments. 
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7.4.1.2 Nanoparticles uptake 
Primary microglia were exposed to PEG-MNP and CMX-MNP (2 µg/ml) for 24 h. 
Fluorescence microscopy confirmed the internalisation of MNPs by microglia (Figure 7-2). 
Nearly every microglial cell showed some degree of uptake of MNPs. Using ImageJ 
software, the extent of MNPs uptake was assessed by measuring the integrated density value 
for each cell. The results showed that average cellular uptake of CMX-MNPs was 
significantly greater than uptake of PEGylated MNPs (Figure 7-3). 
 
Figure 7-2: PEGylated MNPs are taken up by microglia less avidly than CMX-coated nanoparticles. Fluorescence 
micrographs of high purity microglial cultures following incubation with CMX- or PEG-coated fluorescent 
magnetic NPs (24 h). Micrographs show DAPI-stained nuclei as blue, cell bodies and processes as green (Iba1), and 
particles as red. Uptake of CMX-MNPs was extensive for almost all microglia, whereas uptake of PEG-MNPs was 
more heterogeneous, and often markedly lower, in extent (arrows indicate examples of uptake).  
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Figure 7-3: Uptake of PEGylated MNPs is significantly reduced compared to CMX-MNP (control nanoparticles) 
for microglia. Bar graph indicating the average extent of MNP-loading per cell, assessed by integrated density 
measurements, 24 h post-particle addition to high purity culture. *p < 0.05; unpaired t-test PEG versus CMX. All 
data are presented as mean ± S. E. M. of three independent experiments. 
7.4.1.3 Nanoparticle effects on gene expression 
7.4.1.3.1 Effect of nanoparticles on reference genes 
qPCR was performed using the three reference genes identified in Chapter Three. 
The results show that there was no MNPs-induced change in expression for the reference 
genes tested (Gapdh, Usp14 and Rpl32) (Figure 7-4). Therefore, the average of their Cq 
values should allow reliable evaluation of MNPs and LPS-induced changes in GOI. 
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Figure 7-4: No changes in microglial reference gene expression following 24 h MNPs treatment. Bar graphs 
illustrating gene expression for (A) Gapdh, (B) Rpl32, (C) Usp14. Y-axis represents log fold change versus average 
of reference genes (1 = no change) and X-axis represents different treatment. There was no effect of any of the MNPs 
or LPS on the reference gene expression of microglia; One-way ANOVA with Dunnett’s post-hoc test versus the 
control (C). All data are presented as the mean ± S. E. M. of three independent experiments. 
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7.4.1.3.2 Effect of nanoparticles on GOI 
Microglia were treated with PEG-MNP, CMX-MNP, Sphero or LPS for 24 h, then 
qPCR was used to measure the relative changes in gene expression. No significant 
differences in gene expression were detected for any of MNPs. LPS was used as a positive 
control for M1 activation; results showed a significant increase in both Il-1β and iNos (M1 
markers), as expected (Figure 7-5). No elevation in Tnf-a expression was detected, consistent 
with the values derived at 24 h in Chapter Five. The Chapter Five value for Il-1β (~18.5-fold 
increase) was comparable to the value here (~19.8-fold). 
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Figure 7-5: Microglia gene expression response to 24 h of MNPs. (A) Il-1β, (B) iNos, (C) Tnf-α, (D) Arg1, (E) Il-10. 
Y-axis represents log fold change versus average of reference genes (1 = no change) and X-axis represents different 
treatment. A significant increase in M1 markers (Il-1β and iNos) gene expression was found in LPS treated 
microglia. ****p < 0.0001, One-way ANOVA with Dunnett’s post-hoc test versus the control (C). All data are 
presented as the mean ± S. E. M. of three independent experiments.  
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7.4.1.4 Nanoparticles effects on morphology 
The effects of MNPs on microglial morphology were assessed using ImageJ after 
treatment with PEG-MNP, CMX-MNP, Sphero or LPS for 24 h. There was no significant 
difference between treated microglia and control (untreated cells) in any morphological 
measurements (Figure 7-6).  
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Figure 7-6: Morphological analyses of microglia cells treated with MNPs. Scatter plot showing average cellular (A) 
area, (B) perimeter, (C) Feret’s diameter, (D) minimum Feret’s diameter, and (E) aspect ratio. 24 h treatment with: 
PEG-MNP = 2 µg/ml, CMX-MNP = 2 µg/ml, Sphero = 20 µg/ml, LPS = 10 ng/ml. No significant difference; One-
way ANOVA with Dunnett’s post-hoc test versus C (control). All data are presented as mean ± S. E. M. of three 
independent experiments.  
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7.4.1.5 Nanoparticles effects on iNos protein expression 
The effect of MNPs on iNos protein expression was assessed using 
immunocytochemistry and integrated density measurements after treating microglial cells 
with PEG-MNP, CMX-MNP, Sphero or LPS for 24 h. LPS induced significantly greater 
expression of iNos (Figure 7-7), consistent with pro-inflammatory activation. Neither CMX-
MNPs nor PEG-MNPs altered iNos protein expression. 
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Figure 7-7: Microglial iNos protein expression was unaffected by MNP treatment. Bar graph indicating the extent 
of iNos expression per cell, assessed by integrated density measurements. After treatment with only media= C 
(control), PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, , LPS= 10 ng/ml for 24 h. **p<0.01; One-way ANOVA with 
Dunnett’s post-hoc test versus C. All data are presented as mean ± S. E. M. of three independent experiments. 
 
  
  
230 
 
7.4.1.6 Nanoparticles effects on nitrite 
To investigate the effects of MNPs on iNos activity (production of RNS), cells were 
treated with PEG-MNP, CMX-MNP, Sphero, or LPS for 24 h. The levels of nitrite in the 
culture media were determined with the Griess assay, as a proxy for NO production. LPS 
significantly increased nitrite levels, while none of the MNPs had any effect on nitrite 
production (Figure 7-8). 
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Figure 7-8: The effects of MNPs and LPS (as positive control) on nitrite production. Nitrite production was assayed 
by measuring the levels of nitrite in the supernatant fluid using Griess reagent after treating microglia with only 
media= C (control), PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, Sphero= 20 µg/ml, LPS= 10 ng/ml for 24 h. There 
was no effect of any of the MNPs on nitrite production. There was a significant increase in nitrite production induced 
by LPS. **p < 0.01; One-way ANOVA with Dunnett’s post-hoc test versus C. All data are presented as mean ± S. E. 
M. of three independent experiments.  
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7.4.2 The effect of nanoparticles on pro-inflammatory microglia (LPS 
pre-treatment) 
7.4.2.1 Nanoparticles uptake by M1 microglia 
Primary microglia were first exposed to LPS (10 ng/ml) for 24 h, to induce 
inflammatory activation, then exposed to PEG-MNP or CMX-MNP for 24 h (without LPS). 
Using ImageJ, the extent of MNP uptake per cell was assessed by measuring the integrated 
density. The result shows there is no difference in levels of MNPs uptake per cell with and 
without LPS pre-treatment (Figure 7-9). 
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Figure 7-9: Microglial uptake of each MNP type is unaffected by prior pro-inflammatory activation. Bar graph 
indicating the average extent of MNP-loading per cell, assessed by integrated density measurements. 24 h after LPS 
treatment, microglia were exposed to MNPs. No significant difference; unpaired t-test; with LPS versus without 
LPS, for each MNP type. All data are presented as mean ± S. E. M. of three independent experiments.  
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7.4.2.2 Nanoparticles effects on M1 microglia morphology 
The effect of MNPs on M1 microglia morphology was assessed using ImageJ. 
Microglia were first treated with LPS (10 ng/ml) for 24 h, then PEG-MNP, CMX-MNP, 
Sphero or LPS for a further 24 h. There was no significant difference in any morphological 
measurement between treated microglia and control (LPS-C) (Figure 7-10). 
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Figure 7-10: M1 microglial morphology was unaffected by MNP treatment. Scatter plot represent: (A) Area, (B) 
cell perimeter, (C) Feret’s diameter, (D) minimum Feret’s diameter, (E) aspect ratio. First cells were treated with 
LPS (10 ng/ml) for 24 h then treated with only media= C (control), PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, 
Sphero= 20 µg/ml, LPS= 10 ng/ml for 24 h. No significant difference; One-way ANOVA with Dunnett’s post-hoc 
test versus LPS-C. All data are presented as mean ± S. E. M. of three independent experiments. LPS-C: 24 h LPS 
followed by 24 h in D10 without LPS; LPS-CMX: 24 h LPS followed by 24 h CMX; LPS-PEG: 24 h LPS followed 
by 24 h PEG; LPS-LPS: 24 h LPS followed by another 24 h LPS; C-PEG: 24 h in D10 followed by 24 h LPS.  
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7.4.2.3 Nanoparticles effects on iNos protein expression on M1 microglia 
The effect of MNPs on M1 microglia iNos protein expression was assessed using 
integrated density measurements. Microglia first treated with LPS (10 ng/ml) for 24 h then 
another 24 h exposure to PEG-MNP, CMX-MNP, Sphero, or LPS. No significant differences 
were detected between treatment groups (Figure 7-11).  
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Figure 7-11: Nanoparticle effects on iNos protein expression on M1 microglia. First cells were treated with LPS (10 
ng/ml) for 24 h then treated with only media= C (control), PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, Sphero= 20 
µg/ml, LPS= 10 ng/ml for 24 h. Bar graphs indicating the extent of iNos expression per cell, assessed by integrated 
density measurements. No significant difference; One-way ANOVA with Dunnett’s post-hoc test versus LPS-C. All 
data are presented as mean ± S. E. M. of three independent experiments. LPS-C: 24 h LPS followed by 24 h in D10 
without LPS; LPS-CMX: 24 h LPS followed by 24 h CMX; LPS-PEG: 24 h LPS followed by 24 h PEG; LPS-LPS: 
24 h LPS followed by another 24 h LPS; C-PEG: 24 h in D10 followed by 24 h LPS.  
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7.4.2.4 Nanoparticles effects on nitrite in M1 microglia  
To investigate the effects of MNPs on nitrite production in M1 microglia, cells were 
first treated with LPS (10 ng/ml) for 24 h then another 24 h exposure to PEG-MNP, CMX-
MNP, Sphero or LPS. The levels of nitrite in the culture media were determined with the 
Griess assay, as a proxy for NO production. Pre-treatment of the cells with LPS, followed 
by 24 h without LPS (LPS-C) resulted in nitrite levels of ~2 µM (returned almost to baseline, 
compared to ~17 µM detected at 24 h LPS, Figure 7-8). Cultures treated identically, except 
for NP treatment during the latter 24 h period, exhibited comparable nitrite levels (no 
significant differences). In contrast, the cells that received a repeated dose of LPS (LPS-
LPS), or only the second dose (C-LPS), showed nitrite levels significantly greater than cells 
received only the first dose of LPS (LPS-C) (Figure 7-12) again, comparable to (Figure 7-8).  
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Figure 7-12: MNPs effect on nitrite production of M1 microglia. Nitrite production was assayed by measuring the 
levels of nitrite in the supernatant fluid using Griess reagent after treatment of microglia first with LPS (10 ng/ml) 
for 24 h then another 24 h exposure to only media= C (control), PEG-MNP= 2 µg/ml, CMX-MNP= 2 µg/ml, Sphero= 
20 µg/ml, LPS= 10 ng/ml. There was no effect of any of the MNPs on nitrite production. There was a significant 
increase in nitrite production induced in C-LPS and LPS-LPS. *p<0.05; Kruskal-wallis with Dunn’s post-hoc test 
versus LPS-C. All data are presented as mean ± S. E. M. of three independent experiments. LPS-C: 24 h LPS 
followed by 24 h in D10 without LPS; LPS-CMX: 24 h LPS followed by 24 h CMX; LPS-PEG: 24 h LPS followed 
by 24 h PEG; LPS-LPS: 24 h LPS followed by another 24 h LPS; C-PEG: 24 h in D10 followed by 24 h LPS.   
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7.5 Discussion 
The main aim of this study was to understand whether microglia exhibit altered 
gene expression profiles in response to MNPs. Three different MNPs were chosen, which 
have previously been characterised in terms of size and chemistry; and shown to be broadly 
biocompatible with neural cells including microglia (Pickard et al. 2011; Jenkins et al. 
2016). Consistent with previous reports, these NPs were internalised by microglia, and did 
not exhibit toxic effects. Also, PEGylated (stealth) MNPs were taken up to a lesser extent 
than control MNPs, consistent with the modest effects of a stealth coating reported 
previously (Jenkins et al. 2016). 
The data generated here are consistent with the theory that PEGylated MNPs would 
not induce a strong pro-inflammatory microglial response. However, these data also showed 
that ‘control’ MNPs, without a stealth coating, did not cause inflammatory microglial 
responses. This conclusion is based on gene expression, protein expression and functional 
assays (Griess), as well as morphological analyses. Broadly, these results are promising for 
the future development of MNP-based therapies, as avoiding an inflammatory response 
would be desirable in most scenarios.  
7.5.1 Nanoparticles toxicity  
The hypothesis was that if the MNPs are non-toxic to microglia, then the total cells 
count, and percentage of live cells would be unaltered. To test whether there were any toxic 
effects of MNPs on microglia, cells were treated with three different types of MNPs (CMX-
MNP, PEG-MNP and Sphero) or LPS. The results showed that none of the MNPs or LPS 
have a toxic effect on microglia either in these that received the previous dose of LPS or not. 
This study results are in line with Gupta & Wells (2004) report, that PEG-MNP is nontoxic 
to human dermal fibroblasts. The low toxicity of MNPs may be attributed to the fact that 
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these MNPs are hydrophilic, and their coating reduces the surface interactions with cells or 
proteins (Gupta & Wells 2004).  
7.5.2 Nanoparticles uptake with and without LPS 
It was previously hypothesised that PEG-MNPs may be ‘invisible’ to microglia, 
and so uptake of PEG-MNPs would be substantially lower than that of non-stealth MNPs 
(specifically, CMX-MNPs) (Jenkins et al. 2016). When tested, this effect was not as 
dramatic as predicted, although the levels of MNPs uptake per cell were lower for PEGylated 
MNPs. This study has attempted to build on this work. This study results showed that the 
uptake of CMX-MNPs was significantly higher than that of PEG-MNPs, which is in line 
with the previous report (Jenkins et al. 2016). This effect, now replicated here, may be due 
to PEGs ability to improve the biocompatibility of the MNPs by resisting protein adsorption 
(Zhang et al. 2002) (Figure 7-13), which may play a role in the recognition of MNPs by 
microglia cells (Zhang et al. 2002). Therefore, there may be clinical value in developing this 
strategy further, for example modifying the PEG coating (Jia et al. 2016; Pitek et al. 2016), 
or testing alternative stealth coatings such as derivatives of poly sulfobetaine, poly 
carboxybetaine and poly acrylic acid. 
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Figure 7-13: PEGylated coating inhibited protein adsorption. (A) CMX-PEG rapidly cleared by immune cell in the 
body. (B) PEG-MNP, PEGylating coating increase the circulation time by reducing the protein adsorption. Images 
created by Humphrey Yiu (Edinburgh University) (Jenkins et al. 2016). 
This study showed that pre-treatment of microglial cells with LPS has no effect on 
MNPs uptake. That is, introducing these MNPs to pro-inflammatory microglia did not lead 
to altered uptake dynamics, compared to inactivated microglia. Therefore, predicted levels 
of MNP uptake by microglia may be unaffected by cellular activation status, in line with 
data generated here. Pickard and Chari (2010) have reported that LPS treated microglia in 
culture do not exhibit increased MNP uptake activity. In contrast, another study has reported 
that LPS treatment of microglial cell lines can induce increased uptake of ultra-small 
dextran-coated NPs both in 6 and 24 h (Cengelli et al. 2006). However, cell lines typically 
show greater levels of uptake than primary cells. 
7.5.3 Nanoparticles effect on gene expression  
The original study comparing PEG- and CMX-MNPs looked at levels of uptake, 
but failed to assess cellular responses. The central hypothesis underpinning this research, 
was that althogh both MNP types are taken up by microglia, internalisation of PEG-MNPs 
may generate lower inflammatory responses than other MNPs. LPS-treatment was used to 
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generate a clear M1-response, as a positive control. MNPs treated microglia were then 
compared to this, and an untreated control. This study showed that none of the different 
MNPs (PEG-coated, and two control MNPs) caused inflammatory responses in microglia.  
In line with this study result, Wang et al. (2011) treated BV-2 cell lines with non 
coated iron oxide NPs for 6 h, the result showed no increase in Il-1β, Il-6 and Tnf-α protein 
production using ELISA. In contrast, a previous study using primary microglia to assess the 
effects of SiNPs, showed a significant increase in Cox-2 (3 fold change) only at the highest 
concentration of NPs, and the same study reported a significant decrease in Tnf-α gene 
expression. However, SiNPs are chemically different from the NPs used in this study, 
therefore it is not surprising that the immune response to them differs from the results 
generated here. Furthermore, Choi et al. (2010) study did not state the amount of this 
decrease, and also their qPCR data depends completely on a single unvalidated reference 
gene (ACTB). Wu et al. (2013) study aimed to understand the effect of carboxydextran-
coated iron oxide NPs on LPS-activated microglia by using ELISA assay to measure both 
Tnf-α and Il-1β protein production in BV-2 cell line. The results showed a decrease in Il-1β 
at higher NP concentrations (10 and 50 µg iron oxide NPs/ml) but not at the lowest 
concentration (1 µg). Wu et al. (2016) study showed no change in Tnf-α protein production 
at any concentration. Although the main aim of the Wu et al. study was to assess the effect 
of NPs on activated microglia, their experimental design involved treating the cells with 
different concentrations of NPs for 30 min, then with a high dose of LPS (100 ng/ml) for 24 
h. Furthermore, Il-1β production in BV-2 cell line is known to be problematic issue as has 
been shown in Table 3-1. 
In in vivo studies, chronic administration of aluminium oxide NPs to rats (1 mg/kg 
or 50 mg/kg) has been reported to cause microglial activation in cortex and hippocampus in 
the long exposure period (60 days) but not in the shorter exposure time (30 days) (Li et al. 
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2009). Aluminium oxide is unlikely to have clinical applications and this study was to assess 
the risk of exposure to these particles. Hutter et al. (2010) study found that intranasal 
administeration of sphero gold NPs for 24 h caused a small activation of microglia. However 
in the same study the results showed that PEGylated gold NPs did not lead to microglial 
activation.  
As described above, various NPs formulations have been shown to induce 
neuroinflammation, or specifically to cause microglial pro-inflammatory responses. 
However, none of the three MNPs formulations tested here generated M1 microglial 
response. These results are promising in terms of iron oxide particles, with carboxyl, dextran 
or PEG surface chemistries, having possible clinical utility. Nonetheless, more work should 
be carried to test different incubation time effect and the response of other genes and 
proteins, for these, and other NP designs. 
7.5.4 Nanoparticles effect on morphology with and without LPS 
The hypothesis is that if MNPs activate microglia, then microglia morphology will 
be more amoeboid in shape. To test the MNPs effect on microglia morphology, microglia 
have been treated with three different types of MNPs (CMX-MNP, PEG-MNP and Sphero), 
LPS (as a positive control). This study results showed no difference between any of the 
treatments in comparison to the control and, perhaps surprisingly, even with the positive 
control (LPS). Incubation of microglia with CMX-MNP, PEG-MNP or Sphero MNPs did 
not alter the morphology of microglia; a similar observation has been made previously by 
Zhang et al. (2002) when they treat macrophages cells with a different PEGylated MNP to 
these used in this study. Although in Zhang et al. (2002) N-hydroxysuccinimide PEG has 
been used while in this study diphosphate PEG have been used but the lack of changes in 
the morphology in both studies prove the biocompatiblity of the PEG coating. And in line 
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with this study, Pickard & Chari (2010) suggested that short-term exposure to Sphero MNPs 
(similar to one type of the MNPs used in this study) did not lead to microglial activation, as 
judged by morphological criteria. The same study suggested the pretreated microglia with 
LPS lead to morphological changes. However, ImageJ has been used in this study to assess 
microglia morphology while the previous study was evaluated by non-quantitative visual 
inspection. 
7.5.5 Nanoparticles effect on iNos protein expression and RNS with and 
without LPS 
The hypothesis is that if MNPs activate microglia, then microglia expression of 
iNos protein and nitrite will be higher then that of the control. To test the MNPs effect on 
iNos protein and nitrite production, microglia were treated with three different types of 
MNPs (CMX-MNP, PEG-MNP and Sphero) and LPS (as a positive control) was used. The 
results showed that none of the MNPs lead to pro-inflammatory activation of microglia, in 
terms of expression of iNos or presence of nitrite, which is consistent with qPCR result 
generated here (unaltered iNos gene expression). LPS was used as a positive control to assess 
maximum microglial response, and to confirm that elevated levels would be expected at this 
time point. In contrast to this study, Wang et al. (2011) showed that exposure of the BV-2 
microglial cell line to iron oxide NPs induced significant increase in nitrite (as assess by 
using similar technique to that used here: Griess assay). Similarly Choi et al. (2010) showed, 
that exposure of primary microglial culture to SiNPs induced the production of nitrite. Kim 
et al. (2009) study showed that treating microglia cells with methylprednisolone-NPs (24, 
48 or 72 h) does induce significant increase in the production of nitrite (as assess by using 
similar technique to that used here: Griess assay). However, the same study showed that their 
control NP as they called it (saline-NP) did not induce any increase in nitrite at any time 
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point which could suggest the the nitrite production is in response to the methylprednisolone 
coating not to the NPs itself. 
The result of iNos is consistent with that of nitrite production in the experiment 
where naïve microglia were treated with MNPs, and showed that MNPs have a comparable 
expression to that of untreated cells (control), while LPS treated cells (the positive control) 
show significant increase. At the same time, nitrite production from activated microglia 
treated with MNPs supports the hypothesis that MNPs do not induce activation respose in 
microglia, however, the result from iNos protein production was of high variablilty which 
unfortuntally could not support this hypothesis. Therefore, more replications are needed 
using the same assay to increase the strength of the data generated here.   
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7.6 Summary 
Experiments in this study have provided data largely consistent with the hypothesis 
that microglial uptake of MNPs (CMX-MNP, PEG-MNP) does not cause inflammatory 
responses in microglia. Furthermore, the data generated here suggest that microglial 
activation state does not change the extent of NP uptake or alter microglia inflammatory 
response. Therefore, the results generated here considered as a promising findings for using 
MNPs in drug delivery or diagnoses. 
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Chapter 8 : General discussion  
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8.1 Summary of key research findings 
An understanding of neurodegenerative diseases will be greatly enhanced by full 
recognition of microglial phenotype switching (as discussed in Chapter one). It has been 
widely speculated that events such as inappropriate M1 activation, loss of phagocytic 
function or microglial priming are key to disease onset or progression (Gao & Hong 2008). 
If this is true, then understanding microglia behaviour could offer a valuable insight into 
currently incurable and devastating diseases. Such insights could inform the development of 
effective therapies, based on neuroimmunomodulatory drugs, harnessing the 
protective/regenerative abilities of microglia.  
To date, researches on microglia phenotypes often lack full characterisation of the 
phenotypes of the microglial model. Thus, researchers often depend on a single 
concentration of stimulus, a single time point or both. Such limitations in these studies make 
their models inappropriate to study microglial phenotypes switching in neurodegenerative 
diseases and for testing different treatments for these diseases. Therefore, more knowledge 
in these areas would need more suitable models to fully characterise microglial phenotypes. 
This thesis has addressed the need to develop and characterise in vitro microglial 
culture systems suitable for assessing phenotypic changes. Such systems would be of high 
value for simulating diseases and developing novel immunotherapies. An attempt to 
characterise microglia phenotypes using gene expression is described in Chapter Five and 
Six. In this thesis, qPCR was used to measure the differences in microglial gene expressions 
in response to different stimuli.  
qPCR is a robust, highly reproducible and sensitive method to quantitatively study 
gene changes across varying environmental or experimental conditions (Wong & Medrano 
2005). Robust qPCR data analysis depends on using multiple reliable reference genes 
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(Bustin et al. 2013). However, a review of the literature shows that there is a notable lack of 
validation of microglial reference genes and a high reliance on using only a single reference 
gene (section 3.1.3). One of the aims of this study was to identify and validate rat microglia 
reference genes which could be used later by other researchers to study microglial gene 
expression (Chapter Three). In this study, three reference genes have been validated: Gapdh, 
Rpl32 and Usp14, all of which were stable across different treatments, time points and 
compositions of culture media. Gapdh has been widely used as a reference gene, however, 
most researchers have routinely used it as a solo reference gene (Aires et al. 2019; Li et al. 
2019; Stojiljkovic et al. 2019; Tröscher et al. 2019). Furthermore, Rpl32 has been also used 
as reference gene with or without microglia (Vecil et al. 2000; Sebastiani et al. 2006). These 
three validated reference genes were used in all subsequent experiments (in this thesis) to 
normalise the expression of “genes-of-interest”. 
In Chapter Four, there was an investigation into the possibility that supplementing 
the culture medium with serum could affect microglial behaviour, possibly confounding 
experimental conditions. Molecules in the serum might influence microglia, in ways that 
produce changes in gene expression. Also, it may be expected that small quantities of LPS 
or other TLR4 agonists in the serum would mean that for serum-supplemented medium, 
actual TLR4 activation could be greater than expected for the amount of LPS added (i.e. 
treatment group described as 1 ng/ml LPS, it could actually be ~1.2 ng/ml; see section 4.1.2.2 
for discussion of LPS levels in FBS). If this was an influence, then an increase in pEC50 
might be predicted in serum-supplemented media. Section 4.1.2 discussed the possibility 
that serum exposure does influence microglia. 
It was demonstrated in this chapter that using serum-supplemented media had no 
effect on the baseline gene expression (i.e. without LPS), and no effect on pEC50 or 
maximum dose response (for LPS) for any of the M1 markers tested (Il-1β, Il-6 and Tnf-α), 
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at least when used for a short period (24 h). In contrast, Colton et al. (1992) have reported 
that microglia cultures treated with 1-1000 U/ml Ifn-α/β for 24 or 48 h in serum free media 
produce 1l-1β protein level lower than that obtained of serum-supplemented media. The 
difference in the results between Colton et al. (1992) study and this study might be due to 
the slightly different activation mechanism between Ifn-α/β and LPS in microglia 
(Subramaniam & Federoff 2017). Furthermore, the non-effect of serum found in my study 
might be due to the prior exposure to serum during mixed glial culture (before isolation of 
microglia) which made changes that are not lost later, during the serum-free period. As there 
was no indication of any influence of serum on microglial activation, these data suggest that 
each of these two serum-free media could be used for short-term studies, providing more 
defined and reproducible experimental conditions. However, SFM failed to support 
microglia survival in longer-term culture (6 d) (Figure 4-14). Therefore, the conventional 
serum-supplemented medium was used for all subsequent experiments.  
In Chapter Five, gene expression of M1 microglia markers (Il-1β, Il-6 and Tnf-α) 
and some M2 microglia markers (Tgf-β and Il-10) have been characterised in detail. In 
Chapter Four, the LPS dose response effect was studied at one time point only (2 h) and 
across six LPS concentrations, while in Chapter Five, the dose response effect was studied 
in three time points (2, 6 and 24 h) and across nine LPS concentrations to increase the 
confidence in calculated pEC50. 
It was demonstrated in this chapter that there is a dose response at 2, 6 and 24 h for 
all M1 markers. LPS showed less potency at 24 h for Il-β (Figure 5-5A) and the maximum 
dose response was lower at 24 h for both Il-1β and Tnf-α (Figure 5-5B; Figure 5-9B) but not 
Il-6 (Figure 5-7B). The decrease in maximum response might be due to the shift in EC50 
value. Or, LPS high concentration might lead to the risk of cytotoxicity, which could give a 
"bell shaped" dose response curve. There is a suggestion of this, for example, when we 
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examine the dose-responsive increase in Tnf-a expression after 24 h LPS exposure. Here, 
expression at the highest LPS concentrations is lower than the maximal effect seen with 
slightly lower concentration, suggestive of an interaction between the concentration and 
duration of LPS exposure, potentially leading to cell death. This could have been explored 
using direct measurements of cell number at the end of the experiment, or indirect measures 
of cell viability such as the MTT assay (Gerlier & Thomasset 1986) or the LDH assay 
(Korzeniewski & Callewaert 1983). In agreement with this assumption, Woodroofe et al. 
(1991) have reported that Il-1β protein production decreased by 21% when LPS 
concentration was increased from 1 to 5 µg/ml. Tgf-β showed no dose response at any time 
point, as expected. Il-10 showed a dose response at 6 and 24 h but not at 2 h. This possibly 
delayed response (compared to Il-1β, Il-6 and Tnf-α) may indicate a secondary response to 
M1 activation (and so cytokine secretion) as LPS induces the production the pro-
inflammatory cytokine Il-6, which induces the (delayed) expression of the Il-10 gene (Lynch 
et al. 2004). 
The early steps in the development of an in vitro model to study M0’ (primed 
microglia) gene expression was carried out in this study (Chapter Five). The first part of this 
chapter showed that 10 ng/ml LPS for 6 h induced a robust microglia response. Therefore, 
this concentration and time point were chosen to study the effect of a repeated dose of LPS. 
The recovery period (4 days between doses) was sufficient for microglia to lose M1 
phenotype, with all M1 genes returning to baseline levels by this time point (Figure 5-15). 
In this study, a repeated dose of LPS had no effect on microglia behaviour (Figure 5-16). 
However, contradictory observations have been reported by other researchers (Deng et al. 
2013; Schaafsma et al. 2015). In line with this study, Deng et al. (2013) have reported that 
stimulating macrophages with 10 ng/ml LPS resulted in comparable expression of Il-6 and 
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Tnf-α upon secondary challenge. In contrast, Schaafsma et al. (2015) reported that multiple 
doses of LPS led to a decrease in the pro-inflammatory gene expression.  
In Chapter Six, there was an attempt to fully characterise M2 microglia (in the same 
way as was used with M1 in Chapter Five) using Il-4 as a stimulus. However, none of the 
M2-associated genes that might be predicted to be up-regulated were found to be affected 
by Il-4. Several approaches at troubleshooting were performed to understand why this 
system did not replicate the literature, but without clear conclusions. Although, literature 
have not reported that M2 microglia responses were hard to evoke, M1 microglia response 
were more studied and described in literature than M2.  
In Chapter Seven, the in vitro model of M1 activation developed earlier was 
challenged using NPs, a potential vector for drug delivery to the brain. NPs represent a 
promising tool to treat neurodegenerative disease with immunomodulatory drugs targeting 
microglia phenotype switching. Therefore, understanding the effects of drug delivery 
techniques such as NPs on microglial inflammatory responses would be relevant.  
This study showed that NPs used here did not induced an immune-response from 
microglia in vitro, which is an important finding since they could provide a safe carrier for 
many neurodegenerative drugs. In line with this study’s results, Wang et al. (2011) study 
showed that treating microglia with iron oxide NPs for 6 h resulted no increase in M1 marker 
(Il-1β, Il-6 and Tnf-α) protein production. In contrast, Choi et al. (2010) study showed that 
treated microglia with SiNPs (silica-based) resulted in an increase in Cox-2 and a decrease 
in Tnf-α gene expression. However, SiNPs are chemically different from the NPs used in 
this study, and it is likely that the chemical composition of these particles will be more 
important than their size in terms of effects on the phenotype of the microglia, therefore it is 
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difficult to read too much into this particular observation in terms of the interpretation of our 
results. 
In summary, an in vitro model of microglial switching has been refined and 
validated for M1 responses. Further refinement is necessary to study M2 switching. The NPs 
data suggested that NPs could be used without unintended inflammatory responses, and 
further testing is warranted in this regard. 
8.2 Microglial phenotype model challenging 
There are several challenges were associated with validation of in vitro microglia 
models using qPCR technique 
8.2.1 Technical challenges 
8.2.1.1 Aged versus neonatal microglia challenge 
In this thesis, a model to study microglia was developed using neonatal microglia 
culture. There are some reports of developmental differences between neonatal and 
adult/aged microglia, including possible differences in inflammatory responses. Given these 
reports, studying aged microglia could be advantageous, especially since many 
neurodegenerative diseases develop with aging (Beal 1995). However, a model to study aged 
microglia would require large numbers of cells for qPCR (larger than typically yielded per 
animal). Adult microglia are not cultured as easily as early postnatal, and it was not 
considered viable to expand their numbers in vitro through growth factor drive. Therefore, 
it would require large number of adult animals to be euthanised and dissected to generate 
enough microglia for all of the time points and concentrations (treatments) necessary for the 
detailed studies described in this thesis. This would involve considerable expenditure of 
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resources, limited the throughput of the experiments, and would be more difficult to justify 
ethically. 
Alternative methods were investigated to generate large numbers of adult microglia, 
including pilot studies involving seeding dissociated adult cortex on neonatal astrocyte 
cultures, a similar strategy was investigated by Masuch et al. (2016) using slice cultures. 
While this was successful in generating large numbers of microglia, it was not 
straightforward to demonstrate that these were of adult origin, rather than neonatal. 
Therefore, without a validated protocol for deriving large numbers of adult microglia, this 
particular research area was not pursued in this thesis. In future, a robust experimental 
strategy might be to use the neonatal model to generate experimental hypotheses, which 
could then be further tested in more “realistic”, but technically challenging models, such as 
primary microglia derived from adult or diseased animals; organotypic culture; and/or in in 
vivo models including models of neurodegenerative diseases. 
8.2.1.2 Pure microglia culture versus mixed glia or tissue culture challenge 
One important purpose of studying microglial behaviour in a high purity in vitro 
system was to explore microglial phenotype/function without the presence of other CNS 
cells. However, such culture has limitations in comparison to the in vivo system, for example 
microglia responses can be influenced through communication with other cells. Microglia 
express receptors to communicate with neuronal cells, such as fractalkine–CX3CR1, 
CD200–CD200R and CD47–CD172 (Loane & Kumar 2016). Hence, it was expected that 
when microglia are cultured in the absence of such signals their phenotype profile might be 
different from that present in vivo, where cell-cell signalling occurs between cell types. To 
obtain high value microglial gene expression profiles for each phenotype, high purity 
microglial cultures are essential (for high confidence that changes are microglia-specific). 
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Co-culture work could be done in future, to assess whether similar changes are detected. Or, 
using high purity microglia culture with conditioned media from neuronal and mixed glia 
culture, could bring the effect of secreted factors of other brain cells on microglia, without 
cell-cell physical communication (Dai et al. 2015).  
Using organotypic brain slice cultures to study microglia phenotype have 
advantages including providing all the CNS cell types and the 3D structure. Organotypic 
slices could be prepared from different CNS regions by slicing techniques with a usual 
thickness of 350 – 400 μm (Humpel 2015). Organotypic brain slice cultures can be 
maintained in vitro for several months; these slice cultures could bridge the gap between 
primary cell culture and pre-clinical animal experimentation (Jenkins 2013). Mertsch et al. 
(2001) reported that treated organotypic retina culture with LPS (100 ng/ml for 24h) have 
led to microglial activation, as authors assumed that higher levels of Tnf-α, Il-6 and MCP-1 
were realised from activated microglia in the culture medium. Furthermore, studies that 
attempted to characterise microglial activation in organotypic slice culture have used 
immunohistochemistry (Hailer et al. 1996; Czapiga & Colton 1999; Lari & Kitchener 2014).  
The slice ‘wound’ (tissue damaged during the procedure) might induce microgliosis 
due to the presence of cell debris. These activated microglia may confound investigations 
into inflammatory responses (Carson et al. 2008). Although using such system has many 
advantages over in vitro systems (realistic ECM, 3D) and the in vivo culture (the absence of 
infiltrating peripheral macrophages and blood-derived products leaking into the CNS), but 
the effects of slice ‘wounding’ on microglial activation state still need more characterisation. 
8.2.1.3 Microglia low RNA yield challenge 
One of the issues with studying microglia behaviours using qPCR technique was 
the small quantity of RNA extracted. This thesis showed that a high density of microglia 
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should be plated (compared to other cell types) in order to improve RNA yield and purity 
(Figure 3-11). The fact that microglia cells have low yield per cell limited the number of 
conditions/experiments that could be tested simultaneously. In line with these results, Mizee 
et al. (2017) reported a significant correlation between the number of human microglia cells 
used and the RNA yield obtained. The RNA yield was increased from 50 to 200 ng when 
the microglia cells numbers increased four times (Mizee et al. 2017). 
8.2.1.4 Statistical analysis challenge 
This study aimed to establish an in vitro model to study microglia phenotype, 
mainly using qPCR. In the early stages, several validatory procedures were carried out to 
ensure accurate qPCR results, such as validation of the reference genes, determining the 
specificity and efficiency of primers for genes of interest (Chapter three). There are no 
universally-agreed methods to statistically analyse qPCR results in the literature, which 
presented a challenge after the data were collected. Advice has been sought from 
statisticians, with respect to analytical methods.  
8.2.2 The effect of different stimuli on M1 microglia challenge 
In this thesis, the M1 microglia phenotype was well characterised in three different 
time points (2, 6 and 24 h) using LPS (Chapter Five). However, none of the other treatments 
investigated in this study had any obvious effect on M1 microglia behaviour. For example, 
using serum free media in Chapter four did not significantly change the baseline expression, 
pEC50 or maximum response of any of M1 markers (Il-1β, Il-6 and Tnf-α). However, LPS 
was significantly more potent for inducing Il-1β expression when microglia were incubated 
for 6 days in D10 compared to Xvivo (Figure 4-17). None of the other M1 markers (Il-6 and 
Tnf-α) showed a difference. In Chapter Five, microglia treated with repeated doses of LPS 
did not altered gene expression levels for M1 markers (Figure 5-16). Finally, in Chapter 
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Seven, microglia pre-treated with LPS (to induce M1), then challenged with different NPs, 
showed no difference in expression of iNos protein or nitric oxide, compared to LPS alone.  
In line with the results of Chapter Seven, Papa et al. (2014) reported that LPS did 
not affect microglia response to NPs. Mouse microglia were cultured with 1000 ng/ml LPS 
for 18 h, inducing an M1 phenotype, then LPS was removed and replaced with poly (methyl 
methacrylate) NPs for 24 h. This resulted no change in Il-6 protein production (both LPS 
treated cells and LPS-NPs treated cells were significantly higher than non-treated cells; 
however, there was no difference between LPS and LPS-NPs) (Papa et al. 2014). 
Furthermore, in line with Chapter Five results, Nguyen et al. (2004) showed that repeated in 
vivo challenges with LPS (1 mg/kg every 2 weeks for a 3‐month period) did not lead to 
microglial priming, although LPS clearly exacerbated the chronic inflammation associated 
with M1 microglia phenotype.  
Although different stimuli (excepting LPS) used in this study did not produce 
obvious changes in microglia phenotype, the literature suggested that M1 activation status 
can be altered by similar treatments. For example, Markoutsa & Xu (2017) reported that pre-
treating BV-2 (microglia cell line) with N-acetyl cysteine -NPs for 3 h, inhibited the 
subsequent activation by 100 ng/ml LPS, as detected by decreased production of ROS, RNS, 
Tnf-α, and Il-1β. Furthermore, several studies reported that pre-treated microglia with LPS 
strongly reduced pro-inflammatory cytokines Il-1β, Il-6 and Tnf-α, as compared with single 
stimulation (Ajmone-Cat et al. 2003; Cacci et al. 2008; Wuchert et al. 2008). 
8.3 Future directions  
The findings of this research have been discussed extensively within each relevant 
chapter, and therefore will not be elucidated further here. However, based on these findings, 
there are a number of areas in which these approaches could be developed. 
  
254 
 
1. Further validation could be performed using the shortlist of candidate qPCR 
reference genes, identified here (section 3.3.3.1). Validation should involve different 
stimuli (pro-M1, pro-M2 and pro-M0), to determine whether any of these genes may 
be truly universal reference genes, reliably unaltered by any stimuli. This would 
include Aβ, α-synuclein and any other disease-associated molecules. Genes that pass 
these tests could be recommended to the scientific community and would be of high 
value for cross-laboratory comparisons of qPCR data. 
2. It is of great value to work towards serum-free microglial culture, to provide more 
tightly-controlled experimental conditions over longer time-periods, and possibly 
facilitate future clinical applications, requiring xeno-free (no animal-derived 
component) culture conditions. Further research will be required to determine 
whether serum is affecting microglial responses in other conditions (i.e. besides LPS 
treatment), or due to previous exposure to serum, before switching to serum-free 
conditions. That is, if microglia encounter serum during preparation, or earlier 
culture, the serum could affect the cells, in ways that are not reversed by then 
switching to serum-free media. This could be investigated by establishing mixed glial 
cultures in serum free media from the beginning, with one treatment group then being 
switched to serum, to study the effects. Also, serum may affect different genes to the 
ones being analysed here. Other techniques could also be used, such as microarray 
analysis, to evaluate a wide screen of different genes, possibly identifying serum-
induced responses that were not identified here. 
3. Future work to study M0’ should consider/be aware of the ‘sub-threshold’ theory, 
that the first stimuli could be not strong enough to induce full M1 activation, but it 
could prime microglia that would be hyperactive in response to the second stimulus. 
This could be done by treating microglia with low LPS concentration (e.g., 0.01 
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ng/ml) known to be insufficient to activate microglia (no increase in M1 markers; as 
shown in Chapter Five), then after the (4 d) recovery period treat them with second 
dose of LPS (e.g., 10 ng/ml). Comparisons should focus on whether naïve microglia 
(no pre-treatment) respond differently to pre-treated (primed) microglia (Figure 8-1). 
 
Figure 8-1: Scheme to explain the ‘sub-threshold’ priming theory. The blue lines indicate the predicted microglial 
responses if microglia do not alter with ‘priming’ effects and return to standard M0 states after activation. Treating 
M0 microglia with low dose of LPS does not induces M1 activation. Second high dose of LPS produces M1 response. 
However, if priming is simulated in this system, it could be predicted that the low dose of LPS will leave microglia 
‘primed’ (neither M0 nor M1), and these primed microglia may show a greater M1 response on later LPS challenge 
(red line).  
4. More detailed investigations could be performed to study the lack of clear M2 
presentation in this system, such as studying the presence of Il-4R at rat microglia 
surface, and intracellular pathways related to Il-4R. This could be achieved using 
Western blotting to test the production of STAT6 (Il-4R downstream) (Nguyen & 
Benveniste 2000). It may be possible that these cells are reacting to Il-4 in this model, 
but somehow failing to produce the gene expression changes that were anticipated, 
and so the M2 phenotype is not being detected. Further assays could be done such as 
measuring the secretion of M2 markers by ELISA. Also, functional assay could be 
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performed to check if microglia change in ways that are neuroprotective (e.g., 
transferring microglia-conditioned medium to a neuronal culture, or co-culturing 
microglia with neurons). 
5. Although there is no indication of M1 activation by nanoparticles at the level of gene 
expression or morphology, it is possible that other subtle changes may be occurring. 
Therefore, other assays could be used such as microarray which gives more general 
look at all the other genes. Furthermore, the bacterial endotoxin contamination of 
NPs should be fully studied before using these NPs in pre-clinical study. Traditional 
methods to study endotoxin contamination include Limulus amoebocyte lysate 
(LAL) assay which is a widely used test to quantify the endotoxin in pharmaceutical 
products and medical devices (Dobrovolskaia 2015). Demonstrating that 
biomaterials are endotoxin-free is a standard requirement prior to clinical approval. 
Also, assays should be conducted relating to toxicity outside the brain: e.g., clotting 
or accumulation of the NPs in other parts of the body such as liver or kidney. Long-
term studies will be needed to assess NP fate, and whether NP breakdown products 
affect microglia, or other neural cells. Therefore, future work should include multiple 
CNS primary cell culture to estimate NPs cytotoxicity and its effect on the mixed 
glia culture.  
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8.4 Summary  
This thesis has demonstrated the importance of refinement and validation of in vitro 
models to study microglia phenotype profile using gene expression. Three reference genes 
have been validated to study rat microglia for the first time which provide an important tool 
for other researchers for cross-laboratory comparisons of qPCR data. The present of serum 
in the culture media effect on microglia was studied both in short and long incubation periods 
(1 and 6 days, respectively), the results showed no evidence of serum influence the M1 
activation state, at last over a short incubation period. An in vitro model of microglial 
switching has been refined and validated for M1 responses. Further refinement is necessary 
to study M2 switching. Additionally, the response of microglia to NPs has been tested, 
particularly their effect on inflammation state. This study showed that NPs did not induce 
inflammatory response in microglia, which is a promising finding when considering using 
these NPs in neuromodulatory therapies targeting microglia. 
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Appendix 1 
Supplementary video files  
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Legends for supplementary videos 
Video 1 
Time-lapse phase contrast microscopy of mixed glial culture. Microglia are far 
more active than other cell types, with sweeping membrane all around the cell. Microglia, 
astrocytes and oligodendrocyte precursor cells (OPCs; generate oligodendrocytes, which 
myelinate nerve fibres) are all present. Examples of each are labelled. Culture has stratified, 
with astrocytes dominating the layer adherent to the culture plastic. Microglia and OPCs are 
largely on top of this layer. Note that a microglial cell to the right of the image appears to be 
moving within the astrocyte bed layer, and then emerges. The other microglial cells are 
highly active, but not travelling. They appear to remain within a 'territory', and extend 
membrane/processes in all directions, surveilling their immediate environment. A microglial 
cell in the upper-middle region extends a process down the image, and appears to identify a 
damaged cell, which it then phagocytoses.  
 
Video 2 
Microglia, brain immune cells (Macrophages), in culture. Filmed immediately post-
treatment with lipopolysaccharide (LPS, 50 ng/ml; bacterial fragments, simulating 
infection). 2D, in vitro, glass coverslip, poly-D-lysine (PDL) coating / substrate. Note the 
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morphologies / shapes of the cells, and rates of membrane remodelling. Cells regularly leave 
a 'tail', a trailing membrane process. Sometimes cells return to the tail's anchorage point; 
sometimes the tail is retracted. Microglia are highly active, with sweeping membrane all 
around the cell. Often adopting a 'fried egg' morphology, with a prominent nucleus ('yolk') 
and surrounding membrane resembling the white of a fried egg. Some processes / branches 
form, but they are broader, flatter, not as fine, as processes in vivo (3D environment). Also 
note complex interior of microglia: many endosomes, lysosomes etc, containing acids, 
enzymes for degradation. Time-lapse microscopy; dynamic imaging. In vitro brain cells. Ref 
to filename: Micro TL 50ngml LPS 20fps labelled 
 
Video 3 
Microglia, brain immune cells (Macrophages), in culture. Prior to treatment with 
lipopolysaccharide (LPS; bacterial fragments, simulating infection). 2D, in vitro, glass 
coverslip, poly-D-lysine (PDL) coating / substrate. Note the morphologies / shapes of the 
cells, and rates of membrane remodelling. Cells regularly leave a 'tail', a trailing membrane 
process. Sometimes cells return to the tail's anchorage point; sometimes the tail is retracted. 
Microglia are highly active, with sweeping membrane all around the cell. Often adopting a 
'fried egg' morphology, with a prominent nucleus ('yolk') and surrounding membrane 
resembling the white of a fried egg. Some processes / branches form, but they are broader, 
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flatter, not as fine, as processes in vivo (3D environment). Also note complex interior of 
microglia: many endosomes, lysosomes etc, containing acids, enzymes for degradation. 
Time-lapse microscopy; dynamic imaging. In vitro brain cells. Ref to filename: Micro TL 
preLPS 20fps labelled 
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